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Summary
Background The Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) includes a 
comprehensive assessment of incidence, prevalence, and years lived with disability (YLDs) for 354 causes in 
195 countries and territories from 1990 to 2017. Previous GBD studies have shown how the decline of mortality rates 
from 1990 to 2016 has led to an increase in life expectancy, an ageing global population, and an expansion of the 
non-fatal burden of disease and injury. These studies have also shown how a substantial portion of the world’s 
population experiences non-fatal health loss with considerable heterogeneity among different causes, locations, 
ages, and sexes. Ongoing objectives of the GBD study include increasing the level of estimation detail, improving 
analytical strategies, and increasing the amount of high-quality data.
Methods We estimated incidence and prevalence for 354 diseases and injuries and 3484 sequelae. We used an updated 
and extensive body of literature studies, survey data, surveillance data, inpatient admission records, outpatient visit 
records, and health insurance claims, and additionally used results from cause of death models to inform estimates 
using a total of 68 781 data sources. Newly available clinical data from India, Iran, Japan, Jordan, Nepal, China, Brazil, 
Norway, and Italy were incorporated, as well as updated claims data from the USA and new claims data from Taiwan 
(province of China) and Singapore. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of 
estimation, ensuring consistency between rates of incidence, prevalence, remission, and cause of death for each 
condition. YLDs were estimated as the product of a prevalence estimate and a disability weight for health states of 
each mutually exclusive sequela, adjusted for comorbidity. We updated the Socio-demographic Index (SDI), 
a summary development indicator of income per capita, years of schooling, and total fertility rate. Additionally, we 
calculated differences between male and female YLDs to identify divergent trends across sexes. GBD 2017 complies 
with the Guidelines for Accurate and Transparent Health Estimates Reporting.
Findings Globally, for females, the causes with the greatest age-standardised prevalence were oral disorders, headache 
disorders, and haemoglobinopathies and haemolytic anaemias in both 1990 and 2017. For males, the causes with the 
greatest age-standardised prevalence were oral disorders, headache disorders, and tuberculosis including latent 
tuberculosis infection in both 1990 and 2017. In terms of YLDs, low back pain, headache disorders, and dietary iron 
deficiency were the leading Level 3 causes of YLD counts in 1990, whereas low back pain, headache disorders, and 
depressive disorders were the leading causes in 2017 for both sexes combined. All-cause age-standardised YLD rates 
decreased by 3·9% (95% uncertainty interval [UI] 3·1–4·6) from 1990 to 2017; however, the all-age YLD rate increased 
by 7·2% (6·0–8·4) while the total sum of global YLDs increased from 562 million (421–723) to 853 million (642–1100). 
The increases for males and females were similar, with increases in all-age YLD rates of 7·9% (6·6–9·2) for males and 
6·5% (5·4–7·7) for females. We found significant differences between males and females in terms of age-standardised 
prevalence estimates for multiple causes. The causes with the greatest relative differences between sexes in 2017 
included substance use disorders (3018 cases [95% UI 2782–3252] per 100 000 in males vs 1400 [1279–1524] per 
100 000 in females), transport injuries (3322 [3082–3583] vs 2336 [2154–2535]), and self-harm and interpersonal 
violence (3265 [2943–3630] vs 5643 [5057–6302]).
Interpretation Global all-cause age-standardised YLD rates have improved only slightly over a period spanning nearly 
three decades. However, the magnitude of the non-fatal disease burden has expanded globally, with increasing 
numbers of people who have a wide spectrum of conditions. A subset of conditions has remained globally pervasive 
since 1990, whereas other conditions have displayed more dynamic trends, with different ages, sexes, and geographies 
across the globe experiencing varying burdens and trends of health loss. This study emphasises how global 
improvements in premature mortality for select conditions have led to older populations with complex and potentially 
expensive diseases, yet also highlights global achievements in certain domains of disease and injury.
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Introduction
Measuring non-fatal health loss is one of the most 
complex endeavours in population health research. 
The evolution of modern health-care systems has led 
to an increasing number of diseases and injuries 
being diagnosed and treated in individual patients, 
and developments such as antihypertensive and statin 
medications, percutaneous coronary intervention, and 
antiretroviral therapies have led to averted deaths and 
longer lives. In parallel with the increasing complexity of 
clinical medicine in the past century, measuring non-
fatal health loss has necessitated continuous refinement 
as diagnostic classification systems expand, new diseases 
emerge, and metrics of disability improve. Across the 
global landscape, increased non-fatal health loss para-
doxically reflects both success in terms of diminishing 
rates of premature death but also failure in terms of 
maintaining health care for diseased and injured 
individuals. It is increasingly evident that differential 
access to care, economic inequality, and imbalanced risk 
factor profiles can and do challenge the ability of health 
systems to achieve equitable health outcomes in the face 
of complex and resource-draining diseases and injuries. 
Addressing such lapses in health equity can pose a 
burden to under-resourced health care systems and 
economies.
Global progress in improving the burden of non-fatal 
health outcomes has been limited, in part by a 
predominant focus on mortality rates as a common 
metric of tracking global health progress.1–3 In the latter 
part of the 20th century, the global community focused 
on communicable diseases such as tuberculosis, HIV, 
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Research in context
Evidence before this study
The Global Burden of Diseases, Injuries, and Risk Factors (GBD) 
study is a comprehensive study of health loss designed to 
capture complex patterns of disease and injury burden; for 
non-fatal health outcomes, these are measured in terms of 
incidence, prevalence, and years lived with disability (YLDs). 
Previous versions of the study have increased the estimation 
detail for conditions, locations, ages, and years. This study is a 
reassessment of the incidence, prevalence, and YLDs of diseases 
and injuries from 1990 to 2017 and updates results from 
previous GBD studies. There are no alternative measurements 
of non-fatal health loss that include the level of detail provided 
in the GBD study.
Added value of this study
This study adds new knowledge on non-fatal burden globally 
and improves upon previous iterations of the GBD study in the 
following ways. We expanded our database of non-fatal health 
outcomes by adding 2842 collaborator-provided data sources 
and incorporating new clinical data representing an additional 
149 million admissions and 3·7 billion outpatient visits for use in 
GBD modelling. This resulted in a total of 68 781 sources being 
used in the estimation process for GBD 2017. We improved 
estimation methods including updating the calculation of the 
Socio-demographic Index (SDI), adding the ability to report the 
statistical differences in non-fatal health outcomes for males and 
females, using internally consistent GBD estimates of population 
and fertility, and adopting several cause-specific modelling 
improvements. Cause-specific improvements included the 
following; for diarrhoea, we added additional literature 
informing aetiological attribution; for HIV/AIDS, we updated 
absolute neutrophil count bias adjustments, antiretroviral 
therapy coverage data, and sex-specific survey estimates. For 
hepatitis, we added case fatality rates and hepatitis B vaccine 
coverage to viral hepatitis incidence models. For maternal, 
neonatal, and child health causes, we added in-facility delivery 
rates to the inpatient admission per-capita estimates to more 
accurately measure the denominator for incident cases and 
expanded the age range affected by protein-energy malnutrition. 
For cancer, we applied mortality-incidence ratios directly to 
cause-specific mortality rates to estimate incidence, and then 
calculated prevalence on the basis of incidence and survival 
estimates. For mental and substance abuse disorders, 
we adopted new covariates for opioid use and updated autism 
spectrum disorder designations to be consistent with the most 
recent Diagnostic and Statistical Manual of Mental Disorders. 
We also added 19 new causes to our cause hierarchy, including 
type 1 and type 2 diabetes, chronic kidney disease due 
to type 1 diabetes, and chronic kidney disease due to 
type 2 diabetes; cirrhosis due to non-alcoholic steatohepatitis 
(NASH); liver cancer due to NASH; invasive non-typhoidal 
salmonella; myelodysplastic, myeloproliferative, and other 
haemopoietic neoplasms; subarachnoid haemorrhage; 
non-rheumatic valvular heart disease including calcific aortic and 
degenerative mitral subtypes; aggregates of vision disorders and 
hearing loss; poisoning by carbon monoxide; poisoning by other 
means; and estimates for natures of injury (eg, fractures).
Implications of all the available evidence
Global non-fatal burden is continuing to increase despite minor 
improvements in age-standardised rates. Three causes 
(low back pain, headache disorders, and depressive disorders) 
have prevailed as leading causes of non-fatal health loss for 
nearly three decades, while diabetes has emerged as the fourth 
leading cause of disability globally. The increase in YLDs reflects 
an ageing global population commensurate with declines in 
premature mortality across the development spectrum. 
Globally, patterns of non-fatal health loss vary dynamically by 
sex, age, location, SDI, and cause. The increasing burden of 
non-fatal diseases, injuries, and impairments could pose 
considerable challenges to health systems and economies not 
equipped to care for complex and expensive conditions.
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malaria, and other conditions that cause premature 
mortality. In the past decade, it has become evident 
that measuring non-fatal health loss is important for 
tracking progress as the disease burden, in terms of 
disability-adjusted life-years (DALYs), evolves toward 
being dominated by years lived with disability (YLDs). 
Transitions in ageing populations and reduced mortality 
in many areas of the world have created dynamic 
temporal patterns, particularly within the past decade, 
and measuring such time patterns is important because 
advents such as developing a cure for hepatitis C, 
discovering new therapies for cancer, and improving 
treatments for HIV can rapidly transform the burden in 
populations with access to these developments, and as 
conditions such as diabetes and non-alcoholic fatty liver 
disease become increasingly prevalent in lower-income 
countries.4
Estimates reported in recent iterations of the Global 
Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) have also illustrated differential health outcomes in 
males and females in certain locations and conditions. 
This topic has received attention in terms of mortality 
rates for sex-specific conditions such as maternal causes,5–9 
gynaecological and breast malignancies,10–13 and long-term 
complications of obstructed labour, such as obstetric 
fistula.14–18 GBD 2016 also highlighted how global, age-
standardised, all-cause YLD rates are approximately 
10% higher in females than males, emphasising how 
there may be sex-specific characteristics of the non-fatal 
burden that have not been explored in detail, particularly 
with respect to the differences in sex-specific health 
outcomes.2 It is increasingly of interest to measure 
differences in male and female non-fatal health loss.
This year’s GBD study represents the continued effort 
of quantifying non-fatal health outcomes in terms of 
incidence, prevalence, and YLDs for a list of 354 GBD 
causes for the years 1990–2017. Because the study is 
remeasured and published on an annual basis, new 
estimates are provided not only for new estimation years 
but also for all previous estimation years and supersede 
any previous results. This year’s study on non-fatal 
burden incorporates improvements in study design, 
estimation strategy, and data availability, and focuses on 
areas of non-fatal burden that are emerging as topical 
issues in measuring and improving health outcomes. We 
also explore the patterns of non-fatal health loss over 
time and estimate the statistical differences in non-fatal 
health loss for males and females.
Methods
Overview
The GBD study provides a standardised approach for 
estimating incidence, prevalence, and YLDs by cause, 
age, sex, year, and location. The study aims to use all 
accessible information on disease occurrence, natural 
history, and severity that passes a set of inclusion criteria. 
Our objective is to maximise the comparability of data, 
despite different collection methods or case definitions; 
to find a consistent set of estimates between data on 
prevalence, incidence, and causes of death; and to predict 
estimates for locations and causes with sparse or absent 
data by borrowing information from other locations and 
covariates.
The study conducts annual updates to incorporate 
new causes and data (including published literature, 
surveillance data, survey data, hospital and clinical data, 
and other types of data) and to improve demographic and 
statistical methods. In this study, we apply different 
methods to utilise available data and to measure specific 
epidemiological patterns of each cause of non-fatal 
burden. Our standard approach uses the Bayesian meta-
regression tool DisMod-MR 2.1. Subsequently, we use 
data for severity and the occurrence of particular con-
sequences of diseases, or sequelae, to establish the 
proportion of prevalent cases experiencing each sequela. 
There are several classes of alternative approaches for 
estimating non-fatal health outcomes, including for 
injuries, cancers, HIV/AIDS, other infectious diseases, 
and neonatal disorders. Presented below is a high-level 
description of our study methods; the supplementary 
methods (appendix 1 section 4) provide further detail on 
inputs, analytical processes, and outputs and methods 
specific to each cause in GBD 2017.
Analyses were completed using Python version 2.7, 
Stata version 13.1, or R version 3.3. Statistical code 
used for GBD estimation is publicly available online. All 
rates are expressed as age-standardised based on the 
GBD reference population19 unless otherwise specified. 
This study complies with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER)20 
recommendations (appendix 1).
Geographical units, time periods, and demographics
GBD 2017 is based on a geographical hierarchy that 
includes 195 countries and territories grouped into 
21 regions and seven GBD super-regions (appendix 1). 
Each year, GBD includes sub national analyses for a few 
new countries and continues to provide subnational 
estimates for countries that were added in previous cycles. 
Subnational estimation in GBD 2017 includes five new 
countries (Ethiopia, Iran, New Zealand, Norway, Russia) 
and countries previously estimated at subnational levels 
(GBD 2013: China, Mexico, and the UK [regional level]; 
GBD 2015: Brazil, India, Japan, Kenya, South Africa, 
Sweden, and the USA; GBD 2016: Indonesia and the UK 
[local government authority level]). All analyses are at the 
first level of administrative organisation within each 
country except for New Zealand (by Māori ethnicity), 
Sweden (by Stockholm and non-Stockholm), and the UK 
(by local government authorities). All subnational 
estimates for these countries were incorporated into 
model development and evaluation as part of GBD 2017. 
To meet data use requirements, in this publication we 
present all subnational estimates excluding those pending 
See Online for appendix 1
For the statistical code see 
https://github.com/ihmeuw/
ihme-modeling
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publication (Brazil, India, Japan, Kenya, Mexico, Sweden, 
the UK, and the USA); given space constraints these 
results are presented in appendix tables and figures 
instead of in the main text (appendix 2). Subnational 
estimates for countries with populations larger than 
200 million people (measured using our most recent 
year of published estimates) that have not yet been 
published elsewhere are presented wherever estimates 
are illustrated with maps but are not included in data 
tables. Cause-specific results for non-fatal estimates for 
GBD 2017 cover the years 1990–2017. A subset of areas in 
this analysis focuses on 1990, 2007, and 2017 to show 
changes over time to better inform policy assessments.
GBD 2017 is the first time that estimation of fertility 
and population has been done within the GBD frame-
work. Previously, the GBD study used external 
sources21,22 for fertility and population estimates, which 
affect estimates throughout the GBD study, particularly 
estimates expressed in terms of population rates. The 
purpose of using internally derived demographic 
estimates is to ensure internal consistency across all 
GBD estimates. That is, mortality rates and fertility 
rates have to match population rate change such that 
there should be no births, deaths, or migrations that are 
not accounted for in our population estimates.
GBD cause list
In GBD 2017, we further refined the existing cause list, 
and added 19 new causes, increasing the number of 
estimated causes in GBD to 359 with 282 causes of death 
estimated and 354 causes of non-fatal health loss 
estimated. In the GBD study, causes and their sequelae 
are organised into hierarchical levels. Level 1 contains 
three broad cause groups: communicable, maternal, 
neonatal, and nutritional diseases (CMNN); non-
communicable diseases (NCDs); and injuries. For non-
fatal health estimates, there are 22 Level 2 causes, 
167 Level 3 causes, and 288 Level 4 causes. We also report 
estimates for 3484 sequelae, nine impairments, and 
seven nature of injury aggregates.
New for GBD 2017
In GBD 2017, we report on 381 Level 5 sequelae. We have 
opted to include aggregate sequelae for GBD 2017 to 
foster more nuanced interpretations of groups of health 
outcomes that are relevant to policy makers and clinical 
users of the GBD. In addition, this reporting list allows 
for more detailed evaluation of aetiologies and outcomes 
from GBD causes.
For the first time in the GBD study, we present the 
burden of injuries in terms of nature of injury as well as 
external cause of injury. Previously, we reported the 
incidence, prevalence, and YLDs of injuries expressed 
only in terms of what caused the injury—eg, those 
caused by falls. However, the burden that results from 
falls is experienced in terms of the bodily harm that the 
fall itself causes—eg, spinal injury or skeletal fracture. 
We have grouped the 47 nature of injury sequelae into 
seven combined categories that represent 1410 sequelae. 
The supplementary methods (appendix 1) includes the 
full GBD 2017 non-fatal reporting hierarchy from 
Level 1 to Level 6.
Data sources
The process for non-fatal estimation begins with the 
compilation of data sources from a diverse set of possible 
sources, which include 21 possible Global Health Data 
Exchange (GHDx) data types ranging from scientific 
literature to survey data to epidemiological surveillance 
data. Our collaborator network provided 2842 data 
sources for GBD 2017. We analysed 21 100 sources of 
epidemiological surveillance data (country-years of 
disease reporting) for GBD 2017 and 4734 sources of 
disease registry data. For non-fatal estimation, we did 
systematic data and literature searches for 82 non-fatal 
causes and one impairment, which were updated to 
Feb 11, 2018. Search terms used for cause-specific 
systematic reviews, inclusion and exclusion criteria, 
preferred and alternative case definitions, and study 
methods detailed by cause are available in the 
supplementary methods (appendix 1 section 4). This 
search process contributed to the use of 15 449 scientific 
literature sources and 3126 survey sources used in 
non-fatal estimation, reflecting our updated counting 
criteria for GBD 2017. Household survey data archived 
in the GHDx were systematically screened together 
with sources suggested by country-level experts, surveys 
located in multinational survey data catalogues, and 
Ministry of Health and Central Statistical Office websites. 
Primary data sources containing disease prevalence, 
incidence, mortality risk, duration, remission, or severity 
were then combined in the estimation process. The 
supplementary methods section provides further details 
on gold standard data sources, adjustments, correction 
factors, and standardisations employed when incorpo-
rating these different types of non-fatal data (appendix 1 
section 4).
In addition to data sources based on primary literature, 
surveys, and surveillance, the GBD study has used an 
increasing number of hospital discharge records, out-
patient visit records, and health insurance claims to 
inform various steps of the non-fatal modelling process. 
This year, we received hospital discharge records for an 
additional 30 country-years, specifically discharge records 
from India (3 country-years), Iran (10), Japan (6), Jordan 
(1), Nepal (1), Brazil (2), China (1), and Italy (6); inpatient 
and outpatient claims from Taiwan (province of China); 
additional years of inpatient and outpatient claims 
from the USA; and inpatient claims from Singapore, 
representing an additional 148 842 107 hospital admis-
sions globally and bringing the total number of 
admissions that inform GBD estimation to more than 
2·6 billion. Additionally, we received 10 years of out-
patient visit records from Norway, representing a total of 
For the Global Health Data 
Exchange see http://ghdx.
healthdata.org
See Online for appendix 2
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153 351 282 outpatient visits over a 10-year period. Overall, 
the study now uses hospital data from 335 country-years, 
outpatient visit data from 45 country-years, and health 
insurance claims data from 33 country-years between 
the USA, Taiwan (province of China), and Singapore. 
These data inform multiple cause models in various 
ways, mainly by providing incidence and prevalence 
estimates adjusted for read mission, non-primary diag-
nosis, outpatient utilisation, or a combination of the 
above, but also by estimating parameters such as case 
fatality rates, remission rates, procedure rates, and 
distribution of disease subtypes. The supplementary 
methods provide a more detailed description of how the 
clinical data adjustments are calculated and how 
admission and outpatient visit data are processed and 
utilised (appendix 1 section 2).
In the supplementary methods (appendix 1), we show 
the geographical coverage of non-fatal data, both 
incidence and prevalence, for GBD 2017. In addition, we 
illustrate the non-fatal data density and availability for 
GBD 2017 from 1990 to 2017 by GBD region and year for 
each of the three Level 1 GBD cause groups. The GHDx 
provides the metadata for all sources used for non-fatal 
estimation.
Non-fatal disease models
For GBD 2017, we modelled non-fatal disease burden 
using DisMod-MR 2.1, a meta-analysis tool that uses 
a compartmental model structure with a series of 
differential equations that synthesise sparse and hetero-
geneous epidemiological data for non-fatal disease and 
injury outcomes. Estimation occurred at the five levels of 
the GBD location hierarchy—global, super-regional, 
regional, national, and subnational—with results of each 
higher level providing guidance for the analysis at the 
lower geographical level. Important modelling strategy 
changes from GBD 2016 to GBD 2017 for specific causes, 
as well as further details on these causes and their 
respective models, can be found in the supplementary 
methods (appendix 1 section 4).
Custom models were created if DisMod-MR 2.1 did not 
capture the complexity of the disease or if incidence and 
prevalence needed to be calculated from other data, or 
both. Further details of these custom models can be 
found in the cause-specific methods sections of the 
supplementary methods (appendix 1 section 4).
Prevalence was estimated for nine impairments, 
defined as sequelae of multiple causes for which better 
data were available to estimate the overall occurrence 
than for each underlying cause: anaemia, intellec-
tual disability, epilepsy, hearing loss, vision loss, heart 
failure, infertility, pelvic inflammatory disease, and 
Guillain-Barré syndrome. Different methodological app-
roaches were used for each impairment estimation 
process; these details are described in the supplementary 
methods (appendix 1 section 4).
Severity distributions and disability weights
Severity splits apply a set of proportions that represent the 
distribution of cases of a given non-fatal cause by its 
underlying severities. Severity splits are typically cate-
gorised as asymptomatic, mild, moderate, and severe. This 
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Figure 1: Non-fatal data availability in terms of site-years by GBD region and year for Level 1 causes of burden, 1990–2017
This figure represents non-fatal data from 1990 to 2017, showing the number of site-years for each location-year combination for each Level 1 cause of burden by GBD region. 
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distinction is important for conditions such as asthma that 
have a broad spectrum of symptomatic severities. Severity 
splits for most conditions use the Medical Expenditure 
Panel Survey (MEPS) data or literature sources identified 
through systematic reviews. Further detail on the severity 
splits for each cause, including changes from GBD 2016, 
are available in the cause-specific modelling write-ups in 
the supplementary methods (appendix 1 section 4).
Disability weight estimation is described in more detail 
elsewhere in the literature,23 but in summary, these 
represent the severity of health loss associated with a 
single given health state. The supplementary methods 
(appendix 1) provide a complete listing of the lay 
descriptions of all 234 health states used in the estimation 
of non-fatal results for GBD 2017.
Comorbidity
A combined disability weight is required to account for 
individuals with more than one condition. To calculate a 
combined disability weight, the health loss associated 
with two disability weights are multiplied together and 
then a weighted average of each constituent disability 
weight is calculated. The adjusted disability weight is 
proportional to the magnitude of the original disability 
weight. A simulation of 40 000 distinct individuals is 
done that calculates the distribution of comorbid con-
ditions on the basis of the expected distribution of 
each condition’s sequelae in the population. Then, the 
resulting distributions of comorbidity-adjusted disability 
weights are used to calculate YLDs. This process did not 
change from GBD 2016.
YLD computation
YLDs were estimated as the product of prevalence 
estimate and a disability weight for health states of each 
mutually exclusive sequela, adjusted for comorbidity as 
described above. The GBD cause hierarchy also includes 
35 residual disease categories to capture YLDs from 
conditions that lack specific estimation models.
Uncertainty analysis
We apply the same technique for propagating uncertainty 
as used elsewhere in the GBD study design.19,24,25 The 
distribution of every step in the computation process is 
stored in 1000 draws that are used for every other step 
in the process. The distributions are determined from 
the sampling error of data inputs, the uncertainty of 
the model coefficients, and the uncertainty of severity 
distributions and disability weights. Final estimates are 
computed using the mean estimate across 1000 draws, 
and the 95% uncertainty intervals (UIs) are determined 
on the basis of the 25th and 975th ranked values across 
all 1000 draws.
The Socio-demographic Index
The Socio-demographic Index (SDI) is a summary 
measure that estimates a location’s position on a spectrum 
of development.26 The SDI was originally con structed for 
GBD 2015 using the Human Development Index (HDI) 
methodology, wherein a 0–1 index value was determined 
for each of the original three covariate inputs (total 
fertility rate in women aged 15–49 years, educational 
attainment over the age of 15 years, and lag-distributed 
income per capita) using the observed minima and 
maxima over the estimation period to set the scales. In 
response to feedback from collaborators, we have refined 
the indicator with each GBD cycle. For GBD 2017, we 
replaced the total fertility rate with the total fertility rate in 
women under the age of 25 years. The GBD 2017 
Population and Fertility24 analysis of age-specific fertility 
rates revealed that through the process of development, 
many countries exhibited a decline in age-specific fertility 
rates over the age of 30 years and then increased, creating 
a U-shaped pattern; however, age-specific fertility rates in 
ages 10–14 years, 15–19 years, 20–24 years, and total 
fertility under 25 years did not exhibit this pattern. Total 
fertility under 25 years remains highly correlated with 
mortality measures including under-5 mortality rates 
(Pearson’s correlation coefficient r=0·873), and results 
from this revised method for computing SDI and results 
from GBD 2016 are also correlated (r=0·992).24 We 
computed the composite SDI as the geometric mean of 
the three indices for each location-year. The cutoff values 
used to determine quintiles for analysis were then 
computed using country-level estimates of SDI for 2017, 
excluding countries with populations of less than 
1 million. These quintiles are used to categorise and 
present GBD 2017 results on the basis of sociodemographic 
status. The SDI values ranged from a low of 0·191 in 
Niger to a high of 0·918 in Denmark in 2017. Additional 
details on and results from the SDI calculation are 
available in the supplementary methods (appendix 1 
section 2).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing 
the report. All authors had full access to the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Global prevalence, incidence, and YLDs
Non-fatal estimates by cause for 354 causes and nine 
impairments for the years 1990, 2007, and 2017 are 
available by age and sex through the online results tool. 
Results and findings mentioned in the discussion can 
also be viewed interactively through an online data 
visualisation tool.
Figure 1 shows the data density in terms of site-years by 
GBD region, cause group, and year. The figure shows 
how data density generally improves over time and how 
certain regions, particularly higher income regions, are 
more data dense than others. Additionally, the figure 
For the online results tool see 
https://collab2017.healthdata.
org/gbd-search
For the online data visualisation 
tool see https://vizhub.
healthdata.org/gbd-compare
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highlights how injuries data are generally less available 
than for the other two cause groups.
Table 1 reports cause-specific global estimates of 
prevalence, incidence, and YLDs for causes at Levels 1–5 
of the GBD hierarchy for 2017, as well as the percentage 
change in YLDs and age-standardised YLD rates between 
1990, 2007, and 2017. Unless otherwise specified, all rates 
reported in this analysis are age standardised.
Prevalence
For all ages and both sexes combined, globally, in 2017, 
the three most common causes at Level 3 of the GBD 
cause hierarchy in terms of all-age prevalent cases were 
oral disorders (3·47 billion, 95% UI 3·27–3·68), headache 
disorders (3·07 billion, 2·90–3·27), and tuberculosis 
including latent tuberculosis infection (1·93 billion, 
1·71–2·20; table 1).
Global age-standardised prevalence rankings remained 
unchanged for the top two Level 3 causes in the GBD 
hierarchy from 1990 to 2017, with oral disorders and 
headache disorders remaining the two most common 
causes. Tuberculosis including latent tuberculosis infec-
tion was the third leading cause in 1990 and became the 
fourth leading cause in 2017, whereas haemoglobin-
opathies were the fourth leading cause in 1990 and 
became the third leading cause in 2017. Between 1990 
and 2017, the age-standardised prevalence decreased for 
oral disorders by 5·5% (95% UI 4·9 to 6·0) but increased 
for headache disorders by 0·3% (−0·2 to 0·9) and for 
haemoglobinopathies by 4·7% (4·3 to 5·1).
Incidence
Globally, in 2017, for all ages and both sexes combined, the 
three leading Level 3 causes in terms of incident cases 
were upper respiratory infections (17·1 billion, 95% UI 
15·3 to 19·2), diarrhoeal diseases (6·29 billion, 
5·81 to 6·82), and oral disorders (3·60 billion, 3·23 to 3·99; 
table 1). These case rankings remained unchanged for the 
top three causes between 1990 and 2017 despite a decrease 
in age-standardised incidence rates of upper respiratory 
infections of 2·6% (95% UI 2·0 to 3·1), from 232 815 new 
cases (95% UI 207 461 to 260 397) to 226 802 new cases 
(201 716 to 253 367) per 100 000, and in age-standardised 
incident rates of oral disorders of 0·3% (−1·1 to 0·6), from 
48 423 new cases (43 233 to 53 971) to 48 276 new cases 
(43 109 to 53 919) per 100 000, and an increase in the 
number of new cases per 100 000 of diar rhoeal diseases of 
11·7% (8·8 to 14·6), from 75 087 new cases (69 475 to 81 367) 
to 83 846 new cases (77 402 to 90 965) per 100 000.
YLDs
The global number of YLDs increased from 562 million 
(95% UI 421–723) to 853 million (642–1097) between 
1990 and 2017, representing a 51·8% (50·2–53·5) increase 
and a 7·2% (6·0–8·4) increase in the all-age YLD rate, 
while age-standardised YLD rates decreased from 
11 310 YLDs (8485–14 506) to 10 871 YLDs (8171–13 980) per 
100 000, representing a 3·9% (3·1–4·6) decrease. CMNN 
causes accounted for 13·8% (12·5–15·1) of total YLDs in 
2017, while NCDs accounted for 79·5% (77·8–81·1) and 
injuries for 6·7% (6·2–7·3), with a total of 118 million 
(86·7–154) YLDs for CMNN causes, 678 million (510–876) 
for NCDs, and 57·2 million (42·1–75·4) for injuries. The 
number of YLDs from CMNN causes increased from 
1990 to 2017 by 13·6% (9·15–19·2), and the YLD rates 
from CMNN causes decreased by 14·8% (10·7–18·0) 
from 1846 YLDs (1343–2472) to 1573 YLDs (1159–2067) per 
100 000 during the same period. The number of YLDs 
from NCD causes increased between 1990 and 2017 by 
61·1% (60·0–62·4), and the YLD rate from these causes 
decreased by 1·2% (0·66–1·8) from 8684 YLDs 
(6540–11 223) to 8579 YLDs (6454–11 084) per 100 000. The 
number of YLDs from injuries increased between 1990 
and 2017 by 52·7% (49·3–56·4), and the YLD rate from 
injuries decreased by 7·8% (6·27–9·28) from 779 
(577–1023) YLDs to 719 YLDs (529–948) per 100 000. In 
2017, the YLD rate for all causes ranged from 9120 YLDs 
(6877–11 622) per 100 000 in Columbia to 14 824 YLDs 
(11 080–19 203) per 100 000 in Yemen.
Globally, in 1990, for all ages and both sexes, the 
leading Level 3 causes of YLDs were low back pain 
(42·5 million YLDs, 95% UI 30·2 to 57·2), headache 
disorders (35·1 million, 22·8 to 49·7), and dietary iron 
deficiency (31·7 million, 21·6 to 45·5). Between 1990 and 
2007, the number of all-age YLDs attributed to low 
back pain increased by 30·0% (27·9 to 31·9) and 
those attributed to headache disorders increased 
by 34·0% (33·0 to 35·1), while the number of all-age 
YLDs for dietary iron deficiency decreased by 0·2% 
(−2·8 to 2·2). Between 1990 and 2007, the number of all-
age YLDs attributed to depressive disorders increased by 
33·4% (31·0 to 35·8), becoming the third leading cause 
of all-age YLDs in 2007, and shifting dietary iron 
deficiency to fourth; the rankings for low back pain and 
headache disorders did not change from 1990 to 2007. 
From 2007 to 2017, we observed further increases in the 
number of all-age YLDs attributable to the leading three 
causes: low back pain (17·5%, 95% UI 16·2–19·0), 
headache disorders (15·4%, 14·6–16·2), and depressive 
disorders (14·3%, 13·1–15·6).
Figure 2 illustrates the leading Level 3 causes of YLD 
rates by GBD country and select subnational locations in 
2017 for both sexes combined. The geographical variation 
in the leading Level 3 causes of YLD rates across 
countries is shown: low back pain was the leading cause 
in 126 of the 195 countries and territories whereas 
diabetes was the leading cause of YLD rates in Mexico, 
Equatorial Guinea, Congo (Brazzaville), Myanmar, 
Mauritius, and Gabon, as well as parts of the Caribbean 
and most of Oceania. Dietary iron deficiency was the 
leading cause of YLD rates in Yemen, India, Antigua and 
Barbuda, and in parts of western sub-Saharan Africa. 
Conflict and terrorism was the leading cause of YLDs in 
Afghanistan, Eritrea, Rwanda, and Burundi.
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Prevalence (thousands) 
2017 counts
Incidence (thousands) 
2017 counts 
YLDs (thousands)
2017 counts Percentage 
change in counts, 
1990–2007
Percentage 
change in counts, 
2007–17
Percentage change 
in age-standardised 
rates, 1990–2007
Percentage change 
in age-standardised 
rates, 2007–17
All causes 7 369 526·2 
(7 344 769·0 to 
7 392 430·8)
38 480 253·2 
(36 469 390·1 to 
40 567 963·0)
853 042·6 
(642 084·6 to 
1 097 347·2)
29·8% 
(28·8 to 30·8)*
17·0% 
(16·4 to 17·6)*
−3·0% 
(−3·5 to −2·5)*
−0·9% 
(−1·4 to −0·4)*
Communicable, maternal, 
neonatal, and nutritional 
diseases
4 767 056·2 
(4 646 620·9 to 
4 904 464·9)
27 145 980·3 
(25 247 991·1 to 
29 151 315·9)
117 573·7 
(86 670·4 to 
154 424·2)
10·6% 
(7·4 to 14·8)*
2·6% 
(0·5 to 5·5)*
−7·8% 
(−10·4 to −4·5)*
−7·6% 
(−9·6 to −5·0)*
HIV/AIDS and sexually 
transmitted infections
1 238 129·2 
(1 129 539·6 to 
1 359 466·0)
769 111·2 
(694 471·1 to 
850 896·0)
5369·7 
(3783·6 to 7272·2)
204·0% 
(136·7 to 302·7)*
−6·0% 
(−20·6 to 8·3)
130·4% 
(79·8 to 202·8)*
−17·6% 
(−30·5 to −4·7)*
HIV/AIDS 36 822·2 
(34 794·9 to 39 199·8)
1942·1 
(1632·1 to 2287·5)†
3949·0 
(2746·5 to 5419·1)
372·9% 
(299·6 to 489·2)*
−11·5% 
(−26·2 to 5·4)
257·8% 
(204·6 to 343·0)*
−22·6% 
(−35·7 to −7·8)*
HIV/AIDS and 
drug-susceptible tuberculosis 
co-infection
1049·5 
(956·6 to 1149·6)
1321·6 
(1203·1 to 1454·8)
404·7 
(272·3 to 546·5)
329·9% 
(316·0 to 345·1)*
−19·6% 
(−21·8 to −17·3)*
229·1% 
(219·0 to 240·1)*
−29·2% 
(−31·1 to −27·2)*
HIV/AIDS and 
multidrug-resistant 
tuberculosis without 
extensive drug resistance 
co-infection
37·6 
(25·2 to 54·5)
52·0 
(37·5 to 71·2)
15·3 
(9·0 to 24·4)
3509·4% 
(1734·6 to 
6384·8)*
−23·4% 
(−47·9 to 12·8)
2591·5% 
(1256·0 to 
4788·1)*
−32·9% 
(−54·5 to −1·1)*
HIV/AIDS and extensively 
drug-resistant tuberculosis 
co-infection
1·4 
(0·9 to 2·3)
1·7 
(1·2 to 2·3)
0·6 
(0·3 to 1·0)
·· 37·1% 
(−12·3 to 116·5)
·· 19·5% 
(−23·8 to 88·6)
HIV/AIDS resulting in other 
diseases
35 733·7 
(33 669·3 to 38 076·0)
1942·1 
(1632·1 to 2287·5)
3528·5 
(2439·7 to 4941·4)
376·9% 
(292·0 to 510·8)*
−10·4% 
(−26·9 to 9·3)
260·2% 
(199·6 to 357·9)*
−21·7% 
(−36·3 to −4·5)*
HIV/AIDS not on 
antiretroviral treatment 
without tuberculosis
14 763·0 
(13 278·6 to 16 643·9)
1942·1 
(1632·1 to 2287·5)
1911·1 
(1240·9 to 2928·7)
343·8% 
(257·7 to 481·8)*
−47·8% 
(−52·9 to −42·9)*
235·0% 
(172·5 to 332·7)*
−53·9% 
(−58·4 to −49·5)*
HIV/AIDS on 
antiretroviral treatment 
without tuberculosis
20 970·7 
(19 876·1 to 22 058·6)
·· 1617·4 
(1079·5 to 2267·1)
2 265 649·4% 
(1 200 289·1 to 
5 966 377·3)*
491·3% 
(420·4 to 581·8)*
1 847 617·4% 
(1 009 483·5 to 
4 566 992·3)*
404·7% 
(343·7 to 482·1)*
Sexually transmitted 
infections excluding HIV
1 216 425·2 
(1 107 618·8 to 1 337 882·9)
767 169·1 
(692 748·8 to 849 178·3)
1420·7 
(764·5 to 2552·2)
33·8% 
(32·1 to 35·3)*
13·4% 
(12·1 to 14·8)*
0·8% 
(−0·2 to 1·5)
0·8% 
(−0·3 to 1·8)
Syphilis 36 388·6 
(31 030·7 to 42 960·2)
10 263·8 
(8574·2 to 11 991·1)
72·9 
(50·9 to 98·3)
28·7% 
(25·1 to 33·0)*
18·5% 
(15·7 to 21·5)*
−10·8% 
(−13·8 to −7·4)*
−3·5% 
(−5·8 to −1·2)*
Early syphilis 36 018·0 
(30 662·1 to 42 602·0)
10 263·8 
(8574·2 to 11 991·1)
8·6 
(2·6 to 21·9)
36·6% 
(32·5 to 40·8)*
13·7% 
(10·1 to 17·1)*
5·0% 
(2·2 to 7·8)*
2·2% 
(−1·0 to 5·3)
Tertiary syphilis 370·6 
(319·8 to 420·3)
·· 64·3 
(43·9 to 88·2)
27·7% 
(23·9 to 32·2)*
19·2% 
(16·1 to 22·5)*
−12·5% 
(−15·3 to −9·4)*
−4·2% 
(−6·5 to −1·8)*
Chlamydial infection 109 822·0 
(93 827·4 to 128 829·4)
297 131·3 
(247 050·0 to 358 150·1)
314·6 
(179·4 to 565·4)
30·9% 
(28·5 to 33·7)*
10·1% 
(7·7 to 12·7)*
0·3% 
(−1·0 to 2·0)
−0·7% 
(−2·7 to 1·6)
Chlamydia episode 104 561·0 
(88 447·0 to 123 536·5)
297 131·3 
(247 050·0 to 358 150·1)
175·0 
(68·4 to 379·5)
29·0% 
(26·4 to 31·4)*
9·0% 
(7·7 to 10·3)*
−1·0% 
(−1·7 to −0·3)*
−1·7% 
(−2·4 to −1·0)*
Chlamydial infection 
complications
5261·1 
(4960·3 to 5607·8)
·· 139·6 
(92·2 to 195·6)
33·5% 
(28·8 to 38·4)*
11·6% 
(6·5 to 16·6)*
2·1% 
(−1·0 to 5·2)
0·7% 
(−3·8 to 5·2)
Gonococcal infection 47 269·2 
(36 099·9 to 61 106·1)
137 221·5 
(105 854·1 to 173 538·4)
190·3 
(102·2 to 356·6)
27·0% 
(24·1 to 30·5)*
10·2% 
(6·8 to 14·4)*
1·3% 
(−0·5 to 3·3)
1·9% 
(−1·3 to 5·6)
Gonococcal infection 
complications
1705·4 
(1596·2 to 1824·5)
·· 68·9 
(45·3 to 97·9)
31·9% 
(26·9 to 36·9)*
16·9% 
(9·7 to 24·5)*
2·6% 
(−1·1 to 6·4)
6·6% 
(0·1 to 13·5)*
Gonorrhoea episode 45 563·8 
(34 373·4 to 59 361·5)
137 221·5 
(105 854·1 to 173 538·4)
121·3 
(46·5 to 271·5)
24·7% 
(22·1 to 28·0)*
6·7% 
(2·9 to 9·9)*
0·7% 
(−0·9 to 2·6)
−0·5% 
(−4·2 to 2·7)
Trichomoniasis 142 114·5 
(118 989·2 to 170 489·8)
244 855·9 
(208 226·8 to 289 024·3)
242·8 
(97·6 to 523·8)
37·7% 
(35·4 to 40·1)*
16·0% 
(14·2 to 17·7)*
2·9% 
(1·9 to 3·8)*
2·2% 
(1·1 to 3·2)*
Genital herpes 955 894·8 
(847 327·5 to 1 087 446·6)
77 696·7 
(68 687·0 to 87 707·7)
247·4 
(79·8 to 593·7)
41·7% 
(39·0 to 43·3)*
19·8% 
(18·1 to 21·0)*
1·9% 
(1·1 to 2·8)*
1·5% 
(0·9 to 2·3)*
Other sexually transmitted 
infections
11 860·5 
(11 121·7 to 12 735·7)
·· 352·7 
(214·9 to 598·5)
33·9% 
(31·9 to 36·2)*
11·2% 
(9·6 to 13·1)*
1·8% 
(0·7 to 3·1)*
0·8% 
(−0·6 to 2·3)
(Table 1 continues on next page)
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Prevalence (thousands) 
2017 counts
Incidence (thousands) 
2017 counts
YLDs (thousands)
2017 counts Percentage 
change in counts, 
1990–2007
Percentage 
change in counts, 
2007–17
Percentage change 
in age-standardised 
rates, 1990–2007
Percentage change 
in age-standardised 
rates, 2007–17
(Continued from previous page)
Other sexually transmitted 
diseases residual
·· ·· 193·3 
(105·6 to 361·3)
27·2% 
(25·3 to 29·5)*
7·8% 
(5·7 to 10·4)*
−0·0% 
(−1·2 to 1·4)
−0·6% 
(−2·6 to 1·7)
Other sexually 
transmitted diseases
11 860·5 
(11 121·7 to 12 735·7)
·· 352·7 
(214·9 to 598·5)
33·9% 
(31·9 to 36·2)*
11·2% 
(9·6 to 13·1)*
1·8% 
(0·7 to 3·1)*
0·8% 
(−0·6 to 2·3)
Respiratory infections and 
tuberculosis
2 187 290·0 
(1 979 143·1 to 
2 449 760·7)
17 942 622·2 
(16 102 037·4 to 
20 038 445·4)
11 670·3 
(7845·9 to 
16 749·7)
16·2% 
(14·9 to 17·6)*
9·8% 
(8·9 to 10·7)*
−6·9% 
(−8·3 to −5·7)*
−2·6% 
(−3·6 to −1·7)*
Tuberculosis 1 929 208·6 
(1 710 952·7 to 2 199 199·9)
8965·8 
(8191·8 to 9820·8)
3120·4 
(2133·6 to 4230·6)
16·3% 
(14·6 to 18·0)*
9·4% 
(7·8 to 11·2)*
−13·9% 
(−15·1 to −12·7)*
−7·6% 
(−8·8 to −6·5)*
Latent tuberculosis 
infection
1 918 892·1 
(1 701 127·1 to 2 187 433·5)
·· ·· ·· ·· ·· ··
Drug-susceptible 
tuberculosis
9828·6 
(8860·7 to 10 773·9)
8508·6 
(7808·6 to 9371·0)
2969·7 
(2011·4 to 4077·3)
11·4% 
(9·4 to 13·5)*
9·6% 
(5·2 to 12·7)*
−17·5% 
(−18·9 to −16·1)*
−7·5% 
(−11·1 to −5·1)*
Multidrug-resistant 
tuberculosis without 
extensive drug resistance
464·1 
(229·1 to 863·3)
432·8 
(254·6 to 726·9)
142·8 
(66·6 to 281·1)
589·4% 
(189·9 to 
1708·7)*
4·8% 
(−45·2 to 76·4)
399·5% 
(110·5 to 1218·1)*
−11·8% 
(−53·5 to 48·1)
Extensively drug-resistant 
tuberculosis
23·7 
(13·9 to 44·1)
24·5 
(17·7 to 35·0)
7·9 
(4·1 to 15·1)
·· 44·8% 
(−11·7 to 157·8)
·· 20·9% 
(−26·3 to 115·5)
Lower respiratory infections 10 638·1 
(9729·1 to 11 559·4)
471 825·5 
(429 571·3 to 516 976·9)
648·9 
(432·6 to 927·7)
3·2% 
(0·3 to 6·3)*
15·8% 
(11·8 to 20·1)*
−11·1% 
(−13·0 to −9·3)*
4·4% 
(0·5 to 8·4)*
Guillain-Barré syndrome 
due to lower respiratory 
infections
12·3 
(6·9 to 19·9)
·· 3·6 
(1·7 to 6·6)
29·2% 
(25·3 to 33·5)*
17·9% 
(15·5 to 20·6)*
2·7% 
(1·1 to 4·3)*
3·1% 
(1·9 to 4·2)*
Lower respiratory infection 
episode
10 625·8 
(9719·1 to 11 547·2)
471 825·5 
(429 571·3 to 516 976·9)
645·3 
(429·9 to 925·0)
3·1% 
(0·1 to 6·1)*
15·8% 
(11·8 to 20·1)*
−11·2% 
(−13·1 to −9·3)*
4·5% 
(0·5 to 8·4)*
Upper respiratory infections 236 084·8 
(211 064·1 to 264 360·3)
17 144 182·9 
(15 334 493·4 to 
19 211 715·4)
5866·0 
(3422·5 to 9336·4)
19·6% 
(17·3 to 21·9)*
11·5% 
(10·3 to 12·8)*
−2·5% 
(−3·3 to −1·8)*
0·2% 
(−0·6 to 1·1)
Guillain-Barré syndrome 
due to upper respiratory 
infections
33·4 
(24·4 to 44·7)
·· 9·9 
(5·8 to 15·5)
29·2% 
(25·3 to 33·4)*
17·9% 
(15·5 to 20·6)*
2·7% 
(1·1 to 4·3)*
3·1% 
(1·9 to 4·2)*
Upper respiratory infection 
episode
236 051·4 
(211 015·2 to 264 325·0)
17 144 182·9 
(15 334 493·4 to 
19 211 715·4)
5856·2 
(3414·4 to 9325·9)
19·6% 
(17·3 to 21·8)*
11·4% 
(10·3 to 12·8)*
−2·5% 
(−3·3 to −1·8)*
0·2% 
(−0·6 to 1·1)
Otitis media 101 690·4 
(92 570·7 to 111 633·5)
317 648·0 
(254 458·5 to 397 736·6)
2034·8 
(1230·7 to 3227·8)
11·6% 
(8·9 to 14·5)*
4·3% 
(1·8 to 7·0)*
−5·8% 
(−8·0 to −3·7)*
−4·6% 
(−6·9 to −2·2)*
Acute otitis media 18 153·8 
(14 592·6 to 22 589·9)
317 625·1 
(254 441·2 to 397 715·6)
238·4 
(117·1 to 437·1)
10·7% 
(8·2 to 13·6)*
7·5% 
(5·2 to 9·7)*
4·6% 
(2·5 to 7·1)*
0·2% 
(−2·1 to 2·2)
Chronic otitis media 83 536·6 
(75 211·7 to 92 279·1)
22·8 
(0·8 to 81·8)
1796·4 
(1107·7 to 2821·4)
11·7% 
(8·7 to 14·9)*
3·9% 
(1·0 to 7·0)*
−7·1% 
(−9·4 to −4·6)*
−5·2% 
(−7·8 to −2·5)*
Enteric infections 93 304·4 
(86 780·5 to 99 732·5)
6 307 792·4 
(5 822 111·3 to 
6 830 241·4)
10 583·7 
(7283·3 to 
14 516·1)
16·4% 
(13·6 to 19·4)*
23·6% 
(20·6 to 26·9)*
−2·5% 
(−4·2 to −0·7)*
9·7% 
(6·8 to 12·7)*
Diarrhoeal diseases 93 472·8 
(86 857·2 to 99 961·1)
6 292 936·7 
(5 808 374·7 to 
6 816 675·4)
10 465·1 
(7203·1 to 14 386·3)
17·6% 
(14·8 to 20·7)*
24·5% 
(21·5 to 27·9)*
−1·6% 
(−3·4 to 0·3)
10·4% 
(7·6 to 13·4)*
Guillain-Barré syndrome 
due to diarrhoeal diseases
11·4 
(7·8 to 15·7)
·· 3·4 
(2·0 to 5·4)
29·2% 
(25·3 to 33·5)*
17·9% 
(15·5 to 20·6)*
2·7% 
(1·1 to 4·3)*
3·1% 
(2·0 to 4·2)*
Diarrhoeal disease episode 93 461·4 
(86 846·3 to 99 951·5)
6 292 936·7 
(5 808 374·7 to 
6 816 675·4)
10 461·7 
(7201·2 to 14 382·7)
17·6% 
(14·7 to 20·7)*
24·5% 
(21·5 to 27·9)*
−1·6% 
(−3·4 to 0·3)
10·4% 
(7·6 to 13·4)*
Typhoid and paratyphoid 387·5 
(312·6 to 467·9)
14 321·1 
(12 540·3 to 16 337·4)
114·9 
(77·7 to 164·2)
−26·3% 
(−32·0 to −20·7)*
−24·9% 
(−30·9 to −18·4)*
−35·2% 
(−39·8 to −30·4)*
−30·4% 
(−36·1 to −24·2)*
Typhoid fever 691·5 
(582·2 to 808·9)
10 924·3 
(9343·0 to 12 597·1)
105·5 
(70·3 to 151·0)
−26·4% 
(−32·5 to −20·4)*
−25·6% 
(−32·0 to −18·5)*
−35·2% 
(−40·2 to −29·8)*
−31·1% 
(−37·2 to −24·4)*
(Table 1 continues on next page)
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Typhoid fever 
complications
144·0 
(120·1 to 173·7)
1880·1 
(1605·0 to 2191·0)
45·9 
(29·9 to 66·3)
−26·0% 
(−35·3 to −15·4)*
−25·7% 
(−35·6 to −14·3)*
−34·9% 
(−43·0 to −25·5)*
−31·1% 
(−40·6 to −20·4)*
Typhoid fever episode 547·5 
(457·7 to 640·9)
9044·1 
(7759·9 to 10 439·8)
59·6 
(39·3 to 87·0)
−26·7% 
(−33·8 to −18·5)*
−25·6% 
(−33·2 to −16·9)*
−35·4% 
(−41·6 to −28·5)*
−31·0% 
(−38·4 to −22·7)*
Paratyphoid fever 149·0 
(117·0 to 185·1)
3396·9 
(2666·5 to 4184·1)
9·4 
(5·9 to 13·9)
−25·8% 
(−32·5 to −18·1)*
−15·8% 
(−23·8 to −7·1)*
−35·6% 
(−41·2 to −29·2)*
−22·0% 
(−29·5 to −13·6)*
Intestinal perforation due 
to paratyphoid
6·7 
(5·2 to 8·4)
173·9 
(135·4 to 215·9)
0·8 
(0·5 to 1·1)
−26·4% 
(−34·5 to −17·6)*
−16·0% 
(−23·8 to −6·2)*
−36·0% 
(−42·9 to −28·8)*
−22·1% 
(−29·7 to −12·6)*
Paratyphoid fever 
episode
142·3 
(111·5 to 176·8)
3222·9 
(2537·7 to 3976·5)
8·6 
(5·4 to 12·8)
−25·8% 
(−32·7 to −17·7)*
−15·8% 
(−24·2 to −6·5)*
−35·6% 
(−41·4 to −28·7)*
−21·9% 
(−29·8 to −13·2)*
Invasive non-typhoidal 
salmonella
20·5 
(14·5 to 28·6)
534·6 
(409·0 to 705·0)
2·7 
(1·6 to 4·3)
97·4% 
(71·1 to 127·3)*
−20·9% 
(−30·1 to −9·7)*
75·1% 
(52·6 to 101·3)*
−26·9% 
(−36·1 to −16·0)*
Other intestinal infectious 
diseases
·· ·· 1·0 
(0·6 to 1·4)
−40·9% 
(−47·2 to −33·9)*
−41·4% 
(−47·4 to −34·8)*
−45·3% 
(−50·8 to −39·2)*
−47·0% 
(−52·6 to −40·9)*
Neglected tropical diseases 
and malaria
1 278 896·5 
(1 223 506·1 to 
1 343 059·2)
357 652·1 
(301 519·2 to 
431 965·1)
13 622·9 
(9498·3 to 
18 673·3)
2·4% 
(−1·9 to 7·7)
−10·3% 
(−15·0 to −5·6)*
−19·2% 
(−22·5 to −15·4)*
−20·6% 
(−24·6 to −16·5)*
Malaria 136 085·1 
(126 471·7 to 145 009·3)
208 768·2 
(170 214·0 to 257 506·0)
1468·0 
(1034·0 to 2020·6)
14·1% 
(4·7 to 24·4)*
−22·6% 
(−28·0 to −15·7)*
0·3% 
(−8·0 to 9·1)
−28·4% 
(−33·4 to −22·0)*
Malaria complications 794·8 
(723·8 to 875·7)
·· 328·3 
(255·8 to 405·9)
43·2% 
(38·1 to 49·0)*
26·8% 
(22·2 to 31·8)*
17·3% 
(13·1 to 21·9)*
17·4% 
(13·1 to 22·1)*
Malaria episode 12 152·1 
(7883·1 to 17 229·6)
208 768·2 
(170 214·0 to 257 506·0)
423·2 
(217·3 to 710·8)
10·0% 
(−2·3 to 20·4)
−22·1% 
(−29·0 to −13·9)*
−0·4% 
(−11·4 to 9·4)
−27·5% 
(−34·2 to −19·6)*
Malaria parasitaemia 123 138·2 
(112 779·9 to 133 815·6)
·· 716·6 
(471·7 to 1056·9)
10·9% 
(0·3 to 23·5)*
−34·5% 
(−40·4 to −27·0)*
−2·5% 
(−11·9 to 8·4)
−39·3% 
(−44·8 to −32·4)*
Chagas disease 6197·0 
(5248·5 to 7243·9)
162·5 
(139·0 to 189·0)
57·3 
(38·3 to 82·5)
10·1% 
(6·9 to 13·2)*
2·0% 
(−1·4 to 5·7)
−24·0% 
(−26·1 to −21·8)*
−17·8% 
(−20·6 to −15·0)*
Acute Chagas disease 0·9 
(0·4 to 1·5)
162·5 
(139·0 to 189·0)
0·0 
(0·0 to 0·1)
−16·2% 
(−22·1 to −12·7)*
−11·8% 
(−14·4 to −8·9)*
−32·1% 
(−36·3 to −29·6)*
−20·8% 
(−23·1 to −18·5)*
Asymptomatic Chagas 
disease
5274·6 
(4437·8 to 6166·6)
·· ·· ·· ·· ·· ··
Symptomatic chronic 
Chagas infection
921·4 
(731·1 to 1128·3)
·· 57·2 
(38·3 to 82·4)
10·1% 
(7·0 to 13·3)*
2·0% 
(−1·4 to 5·7)
−24·0% 
(−26·1 to −21·8)*
−17·8% 
(−20·6 to −15·0)*
Leishmaniasis 4130·2 
(3515·7 to 4966·8)
669·1 
(506·6 to 874·3)
264·4 
(172·4 to 389·6)
7·6% 
(−8·7 to 29·4)
30·1% 
(20·2 to 42·3)*
−16·2% 
(−28·2 to 1·1)
14·1% 
(4·6 to 25·9)*
Visceral leishmaniasis 10·6 
(8·2 to 16·5)
42·4 
(32·9 to 66·1)
0·8 
(0·5 to 1·3)
−96·0% 
(−97·1 to −94·0)*
−72·4% 
(−79·4 to −58·3)*
−96·4% 
(−97·4 to −94·7)*
−74·5% 
(−81·0 to −61·3)*
Cutaneous and 
mucocutaneous 
leishmaniasis
4166·6 
(3560·7 to 4992·8)
626·6 
(460·0 to 834·2)
263·6 
(171·9 to 388·8)
65·8% 
(35·6 to 126·1)*
31·5% 
(21·2 to 44·2)*
21·9% 
(0·0 to 66·3)*
15·3% 
(5·2 to 27·4)*
African trypanosomiasis 4·9 
(1·3 to 19·8)
3·3 
(2·0 to 8·1)
1·3 
(0·3 to 5·3)
−60·9% 
(−69·0 to −47·0)*
−79·1% 
(−94·4 to −11·2)*
−68·9% 
(−75·4 to −58·4)*
−81·2% 
(−94·9 to −20·5)*
Trypanosomiasis 
Gambiense
4·8 
(1·3 to 19·6)
3·1 
(1·8 to 8·0)
1·3 
(0·3 to 5·3)
−60·3% 
(−69·1 to −44·4)*
−78·4% 
(−94·6 to −7·0)*
−68·5% 
(−75·6 to −56·3)*
−80·5% 
(−95·1 to −16·4)*
Trypanosomiasis 
Rhodesiense
0·1 
(0·0 to 0·3)
0·2 
(0·1 to 0·6)
0·0 
(0·0 to 0·1)
−67·7% 
(−81·9 to −46·6)*
−91·7% 
(−97·3 to −73·1)*
−74·2% 
(−85·6 to −57·6)*
−92·5% 
(−97·6 to −75·4)*
Schistosomiasis 142 788·5 
(131 656·9 to 155 480·2)
·· 1089·1 
(535·8 to 2082·0)
48·4% 
(44·0 to 51·5)*
−20·7% 
(−22·2 to −19·2)*
10·6% 
(7·3 to 13·0)*
−30·0% 
(−31·5 to −28·6)*
Mild schistosomiasis 114 409·2 
(106 010·4 to 124 045·9)
·· 642·0 
(259·2 to 1341·1)
53·2% 
(51·5 to 54·7)*
−21·8% 
(−23·3 to −20·4)*
13·1% 
(11·5 to 14·6)*
−31·5% 
(−32·9 to −30·1)*
Anaemia due to 
schistosomiasis
7618·2 
(6901·9 to 8321·6)
·· 180·6 
(119·1 to 268·6)
33·0% 
(24·1 to 42·6)*
−30·4% 
(−35·1 to −25·9)*
−1·3% 
(−7·6 to 5·6)
−38·6% 
(−42·8 to −34·6)*
Schistosomiasis 
complications
20 785·2 
(18 564·0 to 23 286·9)
·· 266·5 
(146·7 to 472·7)
50·9% 
(47·6 to 54·5)*
−9·0% 
(−11·9 to −4·3)*
15·7% 
(12·7 to 18·5)*
−17·9% 
(−20·4 to −14·4)*
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Cysticercosis 5417·9 
(4662·0 to 6190·3)
·· 1568·5 
(1015·3 to 2181·0)
13·5% 
(8·2 to 18·7)*
8·5% 
(3·7 to 12·8)*
−17·7% 
(−21·3 to −14·2)*
−9·1% 
(−13·1 to −5·6)*
Cystic echinococcosis 589·5 
(373·9 to 926·5)
139·6 
(90·2 to 213·9)
48·3 
(25·4 to 85·0)
33·5% 
(26·3 to 41·9)*
18·9% 
(12·4 to 25·5)*
−1·0% 
(−7·6 to 4·8)
3·4% 
(−1·1 to 6·9)
Lymphatic filariasis 64 623·4 
(59 178·2 to 70 866·1)
·· 1364·0 
(752·0 to 2157·6)
25·5% 
(4·6 to 37·4)*
−37·0% 
(−48·7 to −26·4)*
−6·4% 
(−22·0 to 2·3)
−44·8% 
(−54·7 to −35·5)*
Prevalence of detectable 
microfilaria due to 
lymphatic filariasis
52 285·4 
(48 689·8 to 55 843·9)
·· ·· ·· ·· ·· ··
Lymphatic filariasis 
complications
12 338·1 
(8403·3 to 17 434·1)
·· 1364·0 
(752·0 to 2157·6)
25·5% 
(4·6 to 37·4)*
−37·0% 
(−48·7 to −26·4)*
−6·4% 
(−22·0 to 2·3)
−44·8% 
(−54·7 to −35·5)*
Onchocerciasis 20 938·1 
(12 882·3 to 37 227·7)
·· 1342·9 
(639·1 to 2371·9)
−10·6% 
(−15·5 to −4·3)*
3·9% 
(−15·1 to 19·9)
−32·4% 
(−36·4 to −27·3)*
−8·0% 
(−25·8 to 6·7)
Asymptomatic 
onchocerciasis
5131·9 
(35·8 to 18 859·4)
·· ·· ·· ·· ·· ··
Skin disease due to 
onchocerciasis
14 654·2 
(10 690·5 to 19 713·6)
·· 1246·9 
(552·7 to 2254·6)
−8·6% 
(−14·3 to −0·6)*
3·7% 
(−18·4 to 20·3)
−30·0% 
(−34·7 to −23·6)*
−7·5% 
(−27·7 to 7·9)
Vision loss due to 
onchocerciasis
1152·1 
(829·0 to 1703·6)
·· 96·1 
(60·6 to 141·5)
−31·6% 
(−36·5 to −26·5)*
7·0% 
(−4·8 to 21·4)
−52·9% 
(−56·4 to −49·3)*
−15·0% 
(−24·3 to −3·8)*
Trachoma 3818·9 
(2842·6 to 5135·2)
·· 302·9 
(201·7 to 425·1)
−12·8% 
(−18·2 to −6·4)*
−5·5% 
(−13·1 to 2·0)
−41·8% 
(−45·6 to −37·6)*
−28·2% 
(−33·8 to −22·5)*
Dengue 6267·4 
(3416·1 to 10 611·9)
104 771·9 
(63 759·0 to 158 870·0)
1019·8 
(447·3 to 1909·6)
178·9% 
(68·9 to 8404·5)*
61·1% 
(41·3 to 148·0)*
128·0% 
(38·1 to 6804·6)*
45·2% 
(27·4 to 123·4)*
Post-dengue chronic 
fatigue syndrome
4418·2 
(2064·8 to 8078·2)
·· 911·1 
(380·7 to 1726·5)
179·0% 
(69·0 to 8459·3)*
61·1% 
(41·1 to 149·3)*
128·2% 
(38·2 to 6850·0)*
45·2% 
(27·3 to 124·6)*
Dengue episode 1849·2 
(1117·6 to 2774·7)
104 771·9 
(63 759·0 to 158 870·0)
108·7 
(56·0 to 189·7)
177·7% 
(68·1 to 8513·3)*
61·1% 
(42·2 to 140·9)*
126·7% 
(37·4 to 6942·1)*
45·0% 
(28·0 to 116·7)*
Yellow fever 2·6 
(0·8 to 7·1)
97·4 
(28·0 to 251·7)
0·1 
(0·0 to 0·2)
−53·3% 
(−57·7 to −47·9)*
−15·8% 
(−25·4 to −4·4)*
−61·1% 
(−64·7 to −56·7)*
−22·4% 
(−31·4 to −11·4)*
Asymptomatic yellow fever 1·5 
(0·4 to 4·2)
54·4 
(14·0 to 152·9)
·· ·· ·· ·· ··
Yellow fever episode 1·2 
(0·3 to 3·0)
43·0 
(12·5 to 115·1)
0·1 
(0·0 to 0·2)
−53·3% 
(−57·7 to −47·9)*
−15·8% 
(−25·4 to −4·4)*
−61·1% 
(−64·7 to −56·7)*
−22·4% 
(−31·4 to −11·4)*
Rabies 0·5 
(0·4 to 0·6)
13·4 
(10·9 to 16·2)
0·1 
(0·0 to 0·1)
−46·8% 
(−57·6 to −36·0)*
−35·4% 
(−45·7 to −23·8)*
−56·9% 
(−66·1 to −48·1)*
−43·3% 
(−52·3 to −32·9)*
Intestinal nematode 
infections
894 917·5 
(836 669·5 to 961 911·6)
·· 1661·4 
(960·3 to 2708·6)
−35·8% 
(−41·3 to −30·1)*
−30·1% 
(−33·9 to −26·1)*
−47·3% 
(−51·8 to −42·6)*
−36·3% 
(−39·8 to −32·7)*
Ascariasis 447 009·0 
(394 765·2 to 508 585·1)
·· 603·8 
(325·2 to 1037·6)
−38·3% 
(−47·2 to −28·7)*
−34·2% 
(−41·2 to −26·8)*
−48·3% 
(−55·9 to −40·2)*
−39·9% 
(−46·2 to −33·1)*
Asymptomatic ascariasis 414 347·5 
(365 611·9 to 472 277·1)
·· ·· ·· ·· ·· ··
Ascariasis complications 32 661·5 
(28 939·0 to 36 737·1)
·· 603·8 
(325·2 to 1037·6)
−38·3% 
(−47·2 to −28·7)*
−34·2% 
(−41·2 to −26·8)*
−48·3% 
(−55·9 to −40·2)*
−39·9% 
(−46·2 to −33·1)*
Trichuriasis 289 617·7 
(254 640·5 to 330 724·5)
·· 212·7 
(120·0 to 353·7)
−43·0% 
(−50·2 to −35·7)*
−23·1% 
(−29·3 to −15·8)*
−53·4% 
(−59·4 to −47·5)*
−29·3% 
(−35·0 to −22·5)*
Asymptomatic 
trichuriasis
278 887·2 
(244 650·6 to 318 878·2)
·· ·· ·· ·· ·· ··
Trichuriasis complications 10 730·6 
(9782·7 to 11 693·0)
·· 212·7 
(120·0 to 353·7)
−43·0% 
(−50·2 to −35·7)*
−23·1% 
(−29·3 to −15·8)*
−53·4% 
(−59·4 to −47·5)*
−29·3% 
(−35·0 to −22·5)*
Hookworm disease 229 217·1 
(212 538·1 to 246 731·6)
·· 845·0 
(510·0 to 1340·3)
−31·6% 
(−39·5 to −23·8)*
−28·5% 
(−34·0 to −22·7)*
−44·8% 
(−51·3 to −38·5)*
−35·2% 
(−40·2 to −30·0)*
Asymptomatic 
hookworm disease
190 730·4 
(176 950·0 to 205 624·5)
·· ·· ·· ·· ·· ··
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Anaemia due to 
hookworm disease
9536·1 
(8764·4 to 10 362·8)
·· 245·9 
(164·0 to 360·4)
−41·2% 
(−49·1 to −32·8)*
−35·4% 
(−41·8 to −28·5)*
−51·7% 
(−58·1 to −44·7)*
−41·3% 
(−47·1 to −34·9)*
Hookworm disease 
complications
28 950·6 
(26 952·9 to 31 087·4)
·· 599·1 
(334·2 to 993·7)
−25·8% 
(−33·7 to −17·7)*
−25·2% 
(−30·2 to −19·5)*
−40·8% 
(−47·2 to −34·4)*
−32·2% 
(−36·8 to −27·1)*
Food-borne trematodiases 82 532·4 
(74 596·1 to 91 774·9)
40 746·0 
(35 650·0 to 46 019·1)
1870·7 
(1070·9 to 3149·7)
9·4% 
(−9·4 to 31·8)
8·5% 
(4·8 to 12·0)*
−16·6% 
(−30·0 to −0·8)*
−6·2% 
(−9·1 to −3·5)*
Asymptomatic food-
borne trematodiases
65 832·6 
(56 442·3 to 75 378·7)
30 998·0 
(23 711·7 to 37 759·6)
·· ·· ·· ·· ··
Food-borne trematodiases 
complications
16 699·7 
(11 172·6 to 25 636·1)
9748·1 
(5025·4 to 16 377·4)
1870·7 
(1070·9 to 3149·7)
9·4% 
(−9·4 to 31·8)
8·5% 
(4·8 to 12·0)*
−16·6% 
(−30·0 to −0·8)*
−6·2% 
(−9·1 to −3·5)*
Leprosy 518·5 
(487·7 to 552·5)
48·5 
(45·8 to 51·4)
31·5 
(21·5 to 44·6)
35·0% 
(31·7 to 38·2)*
−1·3% 
(−3·7 to 1·1)
−5·5% 
(−7·8 to −3·4)*
−20·4% 
(−22·4 to −18·5)*
Ebola virus disease ·· ·· ·· ·· −96·8% 
(−97·5 to −94·7)*
·· −97·1% 
(−97·8 to −95·3)*
Ebola cases ·· ·· ·· ·· −97·8% 
(−97·9 to −97·7)*
·· −98·1% 
(−98·1 to −98·0)*
Post-Ebola chronic 
fatigue syndrome
·· ·· ·· ·· −96·7% 
(−97·5 to −94·6)*
·· −97·1% 
(−97·7 to −95·2)*
Zika virus disease 37·6 
(28·2 to 52·0)
2232·2 
(1659·6 to 3097·6)
1·2 
(0·8 to 1·8)
·· ·· ·· ··
Zika virus complications 0·9 
(0·7 to 1·5)
0·6 
(0·4 to 1·2)
0·5 
(0·3 to 0·8)
·· ·· ·· ··
Zika virus episode 36·7 
(27·3 to 50·9)
2231·6 
(1659·1 to 3097·0)
0·7 
(0·4 to 1·1)
·· ·· ·· ··
Guinea worm disease ·· ·· ·· −99·6% 
(−99·6 to 
−99·6)*
−99·5% 
(−99·6 to 
−99·3)*
−99·7% 
(−99·7 to −99·7)*
−99·5% 
(−99·7 to −99·3)*
Moderate pain and 
limited mobility due to 
guinea worm
·· ·· ·· −99·6% 
(−99·6 to 
−99·6)*
−99·5% 
(−99·6 to 
−99·3)*
−99·7% 
(−99·7 to −99·7)*
−99·5% 
(−99·7 to −99·4)*
Guinea worm disease 
complications
·· ·· ·· −99·6% 
(−99·7 to 
−99·6)*
−99·5% 
(−99·6 to 
−99·2)*
−99·7% 
(−99·7 to −99·7)*
−99·5% 
(−99·7 to −99·3)*
Other neglected tropical 
diseases
52 797·1 
(51 667·9 to 54 034·5)
·· 1531·2 
(1027·0 to 2201·6)
2·2% 
(−1·2 to 5·5)
−5·7% 
(−9·7 to −1·5)*
−10·9% 
(−13·7 to −8·0)*
−13·3% 
(−17·1 to −9·4)*
Acute infection due to 
other neglected tropical 
diseases
·· ·· 13·3 
(6·9 to 23·0)
164·3% 
(61·7 to 303·2)*
107·6% 
(83·3 to 199·8)*
135·1% 
(44·5 to 257·7)*
86·9% 
(64·7 to 169·5)*
Anaemia due to other 
neglected tropical diseases
52 797·1 
(51 667·9 to 54 034·5)
·· 1517·9 
(1018·7 to 2185·7)
1·9% 
(−1·4 to 5·3)
−6·2% 
(−10·2 to −2·0)*
−11·1% 
(−14·0 to −8·3)*
−13·7% 
(−17·6 to −9·8)*
Other infectious diseases 101 451·5 
(97 425·1 to 105 559·6)
478 720·6 
(450 498·3 to 
511 601·6)
4056·6 
(2835·5 to 5535·8)
5·0% 
(2·1 to 7·5)*
−0·5% 
(−2·9 to 1·6)
−13·3% 
(−15·3 to −11·5)*
−10·6% 
(−12·7 to −8·9)*
Meningitis 10 572·9 
(8836·7 to 12 552·2)
5045·4 
(4435·1 to 5877·8)
933·9 
(653·0 to 1255·1)
10·6% 
(8·4 to 13·2)*
−3·2% 
(−5·9 to −0·3)*
−10·3% 
(−12·2 to −8·1)*
−12·4% 
(−14·7 to −9·7)*
Pneumococcal meningitis 3557·0 
(2932·0 to 4337·6)
444·9 
(357·8 to 552·1)
325·0 
(219·2 to 440·0)
19·9% 
(16·6 to 23·3)*
−24·8% 
(−27·4 to −22·1)*
−3·7% 
(−6·3 to −1·0)*
−32·1% 
(−34·6 to −29·6)*
Acute pneumococcal 
meningitis
19·9 
(15·8 to 25·0)
444·9 
(357·8 to 552·1)
2·6 
(1·6 to 3·9)
9·7% 
(3·6 to 15·9)*
−28·4% 
(−34·2 to −22·4)*
−0·9% 
(−6·0 to 4·7)
−34·1% 
(−39·8 to −28·4)*
Pneumococcal meningitis 
complications
3537·1 
(2915·9 to 4314·0)
·· 322·4 
(217·6 to 436·2)
20·0% 
(16·7 to 23·4)*
−24·7% 
(−27·4 to −22·1)*
−3·7% 
(−6·4 to −1·0)*
−32·1% 
(−34·5 to −29·5)*
H influenzae type B 
meningitis
924·2 
(668·2 to 1229·3)
262·3 
(195·1 to 351·1)
84·3 
(57·6 to 115·4)
−2·7% 
(−5·7 to 0·5)
−48·1% 
(−50·4 to −45·8)*
−20·3% 
(−22·8 to −17·6)*
−52·5% 
(−54·6 to −50·3)*
Acute H influenzae type B 
meningitis
11·3 
(8·4 to 15·2)
262·3 
(195·1 to 351·1)
1·5 
(0·9 to 2·4)
−9·6% 
(−14·9 to −4·3)*
−48·4% 
(−54·2 to −42·2)*
−16·3% 
(−21·4 to −11·4)*
−51·7% 
(−57·2 to −45·6)*
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Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1801
Prevalence (thousands) 
2017 counts
Incidence (thousands) 
2017 counts
YLDs (thousands)
2017 counts Percentage 
change in counts, 
1990–2007
Percentage 
change in counts, 
2007–17
Percentage change 
in age-standardised 
rates, 1990–2007
Percentage change 
in age-standardised 
rates, 2007–17
(Continued from previous page)
H influenzae type B 
meningitis complications
912·9 
(657·9 to 1216·9)
·· 82·8 
(56·6 to 113·3)
−2·6% 
(−5·6 to 0·7)
−48·1% 
(−50·4 to −45·8)*
−20·4% 
(−23·0 to −17·6)*
−52·5% 
(−54·6 to −50·2)*
Meningococcal infection 1076·7 
(764·8 to 1424·7)
402·5 
(312·5 to 517·6)
99·0 
(67·5 to 135·4)
12·4% 
(9·4 to 15·4)*
−3·2% 
(−6·4 to −0·1)*
−9·8% 
(−12·3 to −7·3)*
−12·9% 
(−15·9 to −10·0)*
Acute meningococcal 
meningitis
18·0 
(13·9 to 23·1)
402·5 
(312·5 to 517·6)
2·4 
(1·4 to 3·7)
5·8% 
(−1·3 to 13·5)
−4·1% 
(−12·3 to 4·5)
−3·6% 
(−9·8 to 3·0)
−12·0% 
(−19·8 to −3·9)*
Meningococcal 
meningitis complications
1058·6 
(749·6 to 1404·6)
·· 96·6 
(65·7 to 132·1)
12·6% 
(9·6 to 15·6)*
−3·2% 
(−6·3 to −0·1)*
−10·0% 
(−12·5 to −7·4)*
−12·9% 
(−15·9 to −10·1)*
Other meningitis 5015·1 
(3735·5 to 6370·4)
3935·7 
(3466·6 to 4569·8)
425·7 
(292·3 to 570·1)
5·6% 
(2·9 to 8·6)*
58·6% 
(53·4 to 64·1)*
−13·3% 
(−15·7 to −10·7)*
43·4% 
(38·7 to 48·4)*
Other acute bacterial 
meningitis
64·0 
(54·6 to 76·8)
1519·8 
(1296·4 to 1836·4)
8·5 
(5·4 to 12·6)
−1·8% 
(−6·8 to 4·1)
54·1% 
(41·2 to 68·0)*
−8·3% 
(−13·1 to −3·2)*
42·9% 
(30·7 to 56·3)*
Acute viral meningitis 109·0 
(95·5 to 125·5)
2416·0 
(2142·8 to 2745·8)
14·5 
(9·3 to 20·8)
6·8% 
(3·0 to 10·6)*
5·8% 
(0·5 to 11·4)*
−9·2% 
(−12·4 to −5·9)*
−3·9% 
(−9·0 to 1·6)
Other bacterial 
meningitis complications
4842·0 
(3574·3 to 6179·3)
·· 402·7 
(275·3 to 539·5)
5·7% 
(2·8 to 9·0)*
61·6% 
(56·3 to 67·5)*
−13·6% 
(−16·2 to −10·8)*
46·1% 
(41·1 to 51·4)*
Encephalitis 6724·9 
(3731·2 to 10 760·4)
2220·5 
(2189·1 to 2255·2)
524·1 
(365·5 to 691·3)
9·0% 
(6·6 to 11·2)*
6·7% 
(4·6 to 8·9)*
−15·8% 
(−17·5 to −14·1)*
−6·2% 
(−8·1 to −4·3)*
Acute encephalitis 116·9 
(115·1 to 118·8)
2220·5 
(2189·1 to 2255·2)
15·5 
(10·4 to 22·2)
14·1% 
(13·3 to 14·8)*
13·9% 
(13·4 to 14·3)*
−5·2% 
(−5·8 to −4·7)*
1·2% 
(0·8 to 1·6)*
Encephalitis complications 6608·0 
(3613·0 to 10 644·0)
·· 508·6 
(355·4 to 672·4)
8·8% 
(6·4 to 11·1)*
6·5% 
(4·3 to 8·8)*
−16·1% 
(−17·8 to −14·3)*
−6·5% 
(−8·4 to −4·5)*
Diphtheria 1·1 
(0·7 to 1·7)
14·4 
(9·7 to 22·4)
0·1 
(0·0 to 0·1)
−76·4% 
(−81·7 to −69·1)*
−32·3% 
(−55·3 to 7·2)
−77·6% 
(−82·6 to −70·7)*
−36·7% 
(−58·7 to 1·1)
Whooping cough 1974·5 
(1525·2 to 2490·2)
14 413·5 
(11 134·0 to 18 178·7)
98·1 
(58·2 to 154·8)
−26·1% 
(−27·9 to −24·0)*
−8·2% 
(−10·3 to −6·3)*
−26·5% 
(−28·4 to −24·5)*
−12·9% 
(−14·8 to −11·0)*
Tetanus 59·6 
(56·7 to 62·6)
79·2 
(53·4 to 105·3)
1·7 
(1·1 to 2·5)
−59·8% 
(−66·6 to 
−51·9)*
−28·6% 
(−39·7 to −17·5)*
−64·3% 
(−70·0 to −57·5)*
−36·2% 
(−46·2 to −26·1)*
Severe tetanus 4·4 
(3·0 to 5·9)
79·2 
(53·4 to 105·3)
0·6 
(0·3 to 0·9)
−73·0% 
(−77·3 to −66·9)*
−57·0% 
(−67·1 to −42·6)*
−75·4% 
(−79·2 to −70·1)*
−61·3% 
(−70·2 to −48·0)*
Neonatal tetanus 
complications
55·2 
(52·9 to 57·6)
·· 1·1 
(0·6 to 1·8)
12·2% 
(9·5 to 14·1)*
8·6% 
(6·6 to 10·3)*
−7·3% 
(−9·0 to −6·1)*
−2·0% 
(−3·7 to −0·5)*
Measles 572·3 
(203·7 to 1267·9)
20 888·3 
(7433·5 to 46 276·7)
51·4 
(17·4 to 118·2)
−44·0% 
(−47·2 to −41·0)*
−46·7% 
(−51·4 to −41·5)*
−44·6% 
(−47·8 to −41·6)*
−49·7% 
(−54·1 to −44·8)*
Varicella and herpes zoster 6836·5 
(6151·0 to 7510·6)
95 660·6 
(91 657·3 to 99 992·6)
311·4 
(187·5 to 471·2)
38·1% 
(34·9 to 41·5)*
21·7% 
(19·1 to 24·3)*
1·8% 
(0·0 to 3·7)*
1·0% 
(−0·6 to 2·5)
Chickenpox 1236·7 
(1200·1 to 1273·0)
64 530·2 
(62 619·2 to 66 422·9)
7·1 
(2·8 to 15·0)
1·4% 
(−1·1 to 3·8)
5·8% 
(3·3 to 8·1)*
−0·9% 
(−3·1 to 1·4)
0·1% 
(−2·4 to 2·3)
Herpes zoster 5599·7 
(4913·3 to 6277·7)
31 130·4 
(27 271·7 to 35 058·2)
304·3 
(183·4 to 461·1)
39·5% 
(36·3 to 42·8)*
22·1% 
(19·5 to 24·8)*
1·9% 
(0·1 to 3·8)*
1·0% 
(−0·6 to 2·6)
Acute hepatitis 31 960·4 
(29 698·0 to 34 406·8)
340 398·7 
(319 758·5 to 362 492·1)
511·8 
(334·5 to 739·0)
32·1% 
(21·7 to 42·8)*
7·5% 
(−0·8 to 17·2)
4·9% 
(−3·5 to 13·5)
−3·8% 
(−11·0 to 4·7)
Acute hepatitis A 13 087·1 
(12 396·2 to 13 831·2)
170 132·3 
(161 150·2 to 179 805·9)
211·2 
(134·0 to 308·2)
24·2% 
(15·6 to 33·9)*
6·8% 
(0·2 to 13·5)*
5·6% 
(−1·7 to 13·6)
−0·4% 
(−6·9 to 6·3)
Acute hepatitis B 16 793·7 
(14 752·6 to 19 222·1)
145 731·0 
(128 012·1 to 166 802·5)
263·5 
(169·6 to 398·1)
42·1% 
(21·9 to 65·7)*
8·4% 
(−6·2 to 26·7)
5·5% 
(−9·4 to 22·7)
−6·7% 
(−18·9 to 8·6)
Acute hepatitis C 587·4 
(532·0 to 649·7)
5091·1 
(4610·8 to 5631·1)
8·2 
(4·0 to 15·8)
5·7% 
(0·7 to 10·9)*
3·1% 
(−1·3 to 7·5)
−8·6% 
(−12·4 to −4·9)*
−7·1% 
(−11·4 to −3·0)*
Acute hepatitis E 1492·1 
(1330·2 to 1674·3)
19 444·3 
(17 332·9 to 21 836·3)
28·9 
(17·9 to 43·5)
20·6% 
(10·1 to 32·1)*
6·5% 
(−1·8 to 15·7)
−0·4% 
(−8·6 to 8·9)
−1·9% 
(−9·6 to 6·2)
Other unspecified infectious 
diseases
53 643·7 
(52 688·5 to 54 671·1)
·· 1624·1 
(1084·1 to 2337·5)
−0·4% 
(−3·3 to 2·5)
−3·5% 
(−6·7 to −0·2)*
−16·0% 
(−18·3 to −13·8)*
−12·1% 
(−15·1 to −9·0)*
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Guillain-Barré syndrome due 
to other infectious diseases
7·4 
(5·0 to 10·7)
·· 2·2 
(1·2 to 3·6)
29·2% 
(25·3 to 33·5)*
18·0% 
(15·5 to 20·6)*
2·7% 
(1·1 to 4·3)*
3·1% 
(2·0 to 4·2)*
Other infectious diseases ·· ·· 187·2 
(114·4 to 291·1)
12·3% 
(8·1 to 15·9)*
18·0% 
(15·7 to 20·2)*
−11·2% 
(−14·3 to −8·6)*
6·0% 
(4·1 to 7·8)*
Anaemia due to other 
infectious diseases
53 636·3 
(52 678·9 to 54 662·5)
·· 1434·7 
(967·8 to 2073·7)
−1·6% 
(−4·7 to 1·4)
−5·7% 
(−9·1 to −2·2)*
−16·5% 
(−19·0 to −14·1)*
−13·9% 
(−17·2 to −10·6)*
Maternal and neonatal 
disorders
158 835·8 
(140 427·7 to 179 076·8)
101 962·6 
(94 726·5 to 109 284·9)
29 894·3 
(22 429·9 to 
38 381·6)
49·5% 
(44·8 to 54·4)*
22·6% 
(16·2 to 29·9)*
24·5% 
(20·8 to 28·3)*
11·3% 
(5·5 to 18·0)*
Maternal disorders 8532·0 
(7424·5 to 9856·9)
79 812·2 
(72 665·3 to 87 135·8)
805·6 
(570·1 to 1084·3)
0·7% 
(−8·3 to 10·5)
−3·3% 
(−12·0 to 7·1)
−21·9% 
(−28·6 to −14·6)*
−12·5% 
(−20·6 to −3·3)*
Maternal haemorrhage 1659·9 
(1538·9 to 1777·6)
6988·4 
(5611·4 to 8568·4)
60·9 
(40·9 to 87·1)
−16·6% 
(−28·5 to −3·5)*
−4·5% 
(−18·5 to 11·5)
−32·4% 
(−42·0 to −21·7)*
−12·6% 
(−25·1 to 2·2)
Maternal haemorrhage 
complications
1506·9 
(1412·6 to 1601·5)
·· 35·5 
(23·6 to 51·8)
−20·9% 
(−28·3 to −13·0)*
−6·7% 
(−14·7 to 1·1)
−35·8% 
(−41·7 to −29·6)*
−14·6% 
(−21·7 to −7·5)*
Maternal haemorrhage 
episode
153·0 
(100·5 to 227·6)
6988·4 
(5611·4 to 8568·4)
25·5 
(15·0 to 40·0)
−9·3% 
(−35·3 to 30·5)
−1·2% 
(−32·3 to 41·8)
−26·6% 
(−47·7 to 5·4)
−9·5% 
(−37·8 to 30·0)
Maternal sepsis and other 
pregnancy-related infections
2989·5 
(2502·7 to 3623·3)
12 060·9 
(9668·8 to 14 890·9)
57·0 
(29·3 to 101·3)
−1·7% 
(−39·7 to 68·6)
5·9% 
(−34·4 to 65·1)
−21·4% 
(−51·3 to 33·9)
−3·0% 
(−40·4 to 51·3)
Infertility due to 
puerperal sepsis
2073·0 
(1839·6 to 2335·1)
113·0 
(100·6 to 127·1)
10·4 
(3·9 to 21·8)
39·6% 
(36·9 to 42·7)*
21·8% 
(19·2 to 24·3)*
−0·3% 
(−2·2 to 1·7)
6·6% 
(4·3 to 8·8)*
Maternal sepsis and other 
maternal infection episode
916·5 
(511·3 to 1514·1)
11 947·9 
(9553·3 to 14 781·0)
46·6 
(22·8 to 85·5)
−6·9% 
(−46·6 to 75·8)
2·9% 
(−42·8 to 75·5)
−24·5% 
(−56·7 to 42·2)
−4·8% 
(−47·1 to 61·2)
Maternal hypertensive 
disorders
2849·8 
(1890·6 to 3972·4)
15 830·2 
(13 530·0 to 18 779·5)
143·1 
(80·7 to 231·8)
−6·3% 
(−35·5 to 40·3)
−0·9% 
(−34·3 to 41·0)
−24·7% 
(−48·6 to 12·5)
−9·1% 
(−39·6 to 29·3)
Maternal hypertensive 
disorder complications
102·0 
(97·7 to 107·0)
1600·2 
(1535·3 to 1675·1)
6·7 
(4·1 to 10·2)
38·4% 
(31·0 to 46·7)*
17·9% 
(10·7 to 24·7)*
9·7% 
(3·8 to 16·4)*
7·3% 
(0·7 to 13·4)*
Maternal hypertensive 
disorder episode
2747·7 
(1789·8 to 3869·6)
14 230·0 
(11 902·3 to 17 192·4)
136·4 
(75·7 to 220·6)
−7·5% 
(−37·4 to 40·2)
−1·7% 
(−36·0 to 41·7)
−25·7% 
(−49·9 to 12·4)
−9·8% 
(−41·1 to 30·4)
Maternal obstructed labour 
and uterine rupture
1232·6 
(1048·2 to 1449·1)
7915·2 
(6032·2 to 10 169·3)
397·6 
(260·5 to 551·0)
−0·9% 
(−6·0 to 5·2)
−10·7% 
(−15·8 to −5·0)*
−24·9% 
(−28·6 to −20·6)*
−20·0% 
(−24·5 to −14·9)*
Obstructed labour, acute 
event
105·1 
(64·7 to 163·8)
7694·5 
(5811·6 to 9959·4)
33·0 
(16·8 to 55·9)
−9·9% 
(−42·7 to 51·8)
0·8% 
(−40·1 to 61·4)
−26·4% 
(−53·6 to 23·6)
−7·0% 
(−44·2 to 48·6)
Maternal obstructed 
labour complications
1127·5 
(939·1 to 1338·2)
220·7 
(179·2 to 267·7)
364·6 
(238·5 to 506·1)
−0·1% 
(−4·2 to 4·3)
−11·6% 
(−15·7 to −7·2)*
−24·8% 
(−27·7 to −21·6)*
−21·1% 
(−24·7 to −17·3)*
Maternal abortive outcome 164·2 
(109·5 to 234·1)
20 052·1 
(16 262·0 to 25 281·8)
18·1 
(10·2 to 29·7)
2·5% 
(−32·1 to 54·5)
2·4% 
(−34·5 to 51·8)
−18·0% 
(−45·6 to 24·0)
−5·6% 
(−39·4 to 39·1)
Ectopic pregnancy 138·7 
(90·1 to 199·9)
16 965·4 
(13 647·7 to 20 936·5)
15·1 
(8·3 to 24·0)
35·5% 
(−10·4 to 115·0)
14·6% 
(−26·3 to 72·1)
6·5% 
(−29·1 to 68·3)
5·1% 
(−32·4 to 58·5)
Other maternal disorders ·· ·· 113·8 
(80·5 to 154·3)
45·4% 
(32·0 to 60·0)*
20·1% 
(8·9 to 33·5)*
12·9% 
(3·0 to 23·8)*
9·0% 
(−1·0 to 21·2)
Neonatal disorders 150 455·9 
(131 734·1 to 170 851·4)
22 150·4 
(20 975·1 to 23 700·8)
29 088·7 
(21 771·2 to 
37 499·1)
52·1% 
(47·2 to 57·4)*
23·5% 
(16·8 to 31·2)*
27·0% 
(22·9 to 31·3)*
12·1% 
(6·2 to 19·2)*
Neonatal preterm birth 92 585·6 
(81 049·6 to 106 597·3)
17 416·9 
(17 182·7 to 17 646·4)
13 156·9 
(9307·3 to 17 833·1)
46·0% 
(39·6 to 52·0)*
26·1% 
(10·6 to 41·4)*
22·2% 
(17·0 to 27·1)*
14·8% 
(0·7 to 28·6)*
Preterm birth 
complications
67 508·3 
(56 539·6 to 81 115·5)
·· 12 537·7 
(8824·7 to 17 161·8)
48·4% 
(41·1 to 55·5)*
27·3% 
(10·6 to 43·7)*
24·7% 
(18·7 to 30·8)*
16·0% 
(0·8 to 30·8)*
Retinopathy of 
prematurity
11 361·8 
(8979·6 to 13 871·7)
·· 619·2 
(415·3 to 861·4)
14·4% 
(10·0 to 18·7)*
6·1% 
(2·4 to 10·3)*
−8·6% 
(−12·3 to −5·0)*
−5·9% 
(−9·5 to −2·0)*
Uncomplicated preterm 
birth
13 715·6 
(12 775·0 to 14 383·3)
17 416·9 
(17 182·7 to 17 646·4)
·· ·· ·· ·· ··
Neonatal encephalopathy 
due to birth asphyxia and 
trauma
53 823·7 
(39 817·7 to 70 951·7)
2753·4 
(1840·4 to 4017·0)
9703·5 
(5872·1 to 15 081·3)
69·8% 
(57·8 to 84·9)*
23·0% 
(19·3 to 27·6)*
39·5% 
(30·0 to 51·5)*
11·1% 
(7·7 to 14·9)*
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Neonatal sepsis and other 
neonatal infections
14 268·5 
(8908·0 to 21 573·1)
1326·7 
(792·7 to 2284·9)
4171·9 
(2230·5 to 7009·0)
44·7% 
(39·1 to 50·6)*
19·5% 
(15·9 to 22·5)*
17·5% 
(13·0 to 22·1)*
7·5% 
(4·3 to 10·1)*
Neonatal sepsis and other 
neonatal infection 
complications
13 944·6 
(8561·4 to 21 248·8)
996·6 
(472·4 to 1951·3)
4171·9 
(2230·5 to 7009·0)
44·7% 
(39·1 to 50·6)*
19·5% 
(15·9 to 22·5)*
17·5% 
(13·0 to 22·1)*
7·5% 
(4·3 to 10·1)*
Neonatal sepsis and other 
neonatal infection 
episode
323·9 
(254·4 to 405·5)
330·1 
(259·0 to 413·2)
·· ·· ·· ·· ··
Haemolytic disease and 
other neonatal jaundice
2355·4 
(2032·4 to 2684·1)
653·3 
(269·5 to 1211·6)
877·7 
(679·2 to 1090·3)
37·1% 
(33·2 to 40·9)*
20·2% 
(16·6 to 23·3)*
14·8% 
(11·4 to 17·9)*
9·3% 
(6·0 to 12·2)*
Other neonatal disorders ·· ·· 1178·7 
(893·2 to 1519·2)
35·3% 
(31·1 to 39·6)*
16·0% 
(9·2 to 23·8)*
35·6% 
(31·4 to 39·9)*
9·7% 
(3·3 to 17·2)*
Nutritional deficiencies 1 862 030·8 
(1 806 258·9 to 
1 921 493·5)
1 186 745·8 
(1 089 728·9 to 
1 283 530·0)
42 376·2 
(28 774·0 to 
61 009·9)
−8·3% 
(−10·4 to −6·2)*
−7·8% 
(−10·6 to −4·9)*
−20·9% 
(−22·7 to −19·3)*
−16·1% 
(−18·5 to −13·4)*
Protein-energy malnutrition 96 454·6 
(93 495·9 to 99 611·1)
79 726·7 
(76 183·7 to 83 392·8)
1798·0 
(1167·7 to 2545·0)
−19·5% 
(−23·4 to −15·5)*
−3·4% 
(−6·3 to −0·7)*
−22·0% 
(−26·0 to −18·1)*
−10·1% 
(−12·8 to −7·6)*
Iodine deficiency 116 021·9 
(104 300·5 to 128 878·3)
3027·9 
(2734·2 to 3363·7)
2057·7 
(1247·3 to 3255·6)
−33·6% 
(−38·2 to −27·8)*
−6·9% 
(−10·1 to −4·3)*
−46·4% 
(−50·2 to −41·9)*
−17·4% 
(−20·1 to −14·9)*
Visible goitre without 
symptoms
113 393·1 
(101 868·1 to 126 335·9)
3027·9 
(2734·2 to 3363·7)
1208·8 
(590·5 to 2248·6)
−41·9% 
(−45·1 to −38·3)*
−6·1% 
(−8·2 to −4·4)*
−53·3% 
(−55·6 to −50·6)*
−17·4% 
(−19·2 to −15·9)*
Visible goitre with 
complications
2628·8 
(1500·7 to 3684·3)
·· 848·9 
(445·5 to 1286·3)
−17·0% 
(−22·5 to −11·1)*
−8·1% 
(−15·8 to −3·1)*
−32·7% 
(−37·2 to −27·6)*
−17·3% 
(−24·2 to −12·8)*
Vitamin A deficiency 818 420·2 
(748 849·9 to 892 688·1)
1 103 991·2 
(1 007 169·1 to 
1 199 987·2)
8313·0 
(5398·6 to 12 150·6)
−19·7% 
(−22·9 to −16·7)*
−17·3% 
(−20·8 to −13·6)*
−23·0% 
(−26·0 to −20·2)*
−22·3% 
(−25·7 to −18·8)*
Asymptomatic vitamin A 
deficiency
600 048·0 
(547 539·5 to 655 650·3)
1 103 991·2 
(1 007 169·1 to 
1 199 987·2)
·· ·· ·· ·· ··
Vitamin A deficiency 
complications
5403·4 
(4329·4 to 6754·9)
·· 304·0 
(195·6 to 442·0)
23·8% 
(19·4 to 28·3)*
13·4% 
(9·9 to 17·1)*
8·8% 
(5·3 to 12·1)*
3·7% 
(0·6 to 7·1)*
Vitamin A deficiency with 
anaemia
212 971·7 
(189 376·4 to 240 436·1)
·· 8009·0 
(5196·4 to 11 716·1)
−20·5% 
(−23·7 to −17·4)*
−18·1% 
(−21·8 to −14·3)*
−23·6% 
(−26·7 to −20·7)*
−23·0% 
(−26·5 to −19·5)*
Dietary iron deficiency 1 136 043·5 
(1 117 204·2 to 1 156 043·7)
·· 30 013·9 
(20 323·3 to 
43 628·0)
−0·2% 
(−2·8 to 2·2)
−5·2% 
(−8·3 to −1·9)*
−17·4% 
(−19·4 to −15·5)*
−14·3% 
(−17·2 to −11·4)*
Other nutritional deficiencies ·· ·· 193·6 
(125·3 to 272·6)
−13·7% 
(−20·8 to −7·2)*
2·2% 
(−2·6 to 6·2)
−25·8% 
(−32·2 to −19·9)*
−9·6% 
(−13·9 to −6·2)*
Non-communicable diseases 7 011 916·8 
(6 965 421·4 to 
7 057 358·0)
10 813 562·6 
(10 375 088·4 to 
11 286 148·0)
678 294·4 
(510 467·3 to 
875 605·3)
35·0% 
(34·4 to 35·7)*
19·3% 
(18·8 to 19·9)*
−1·3% 
(−1·7 to −0·9)*
0·1% 
(−0·3 to 0·5)
Neoplasms 100 482·9 
(98 189·8 to 102 850·5)
24 361·6 
(21 911·3 to 27 310·3)
7775·2 
(5747·9 to 
10 028·9)
59·3% 
(55·6 to 63·3)*
40·6% 
(38·3 to 43·2)*
8·5% 
(6·0 to 11·2)*
9·7% 
(7·6 to 12·0)*
Lip and oral cavity cancer 1631·9 
(1570·3 to 1691·6)
389·8 
(374·5 to 404·4)
163·3 
(120·3 to 212·3)
49·6% 
(44·6 to 54·6)*
39·8% 
(34·0 to 45·1)*
1·1% 
(−2·3 to 4·4)
9·2% 
(4·7 to 13·4)*
Diagnosis and primary 
therapy phase of mouth 
cancer
95·7 
(92·1 to 99·1)
389·8 
(374·5 to 404·4)
26·6 
(18·0 to 36·6)
50·8% 
(44·8 to 57·1)*
40·1% 
(34·2 to 46·3)*
2·2% 
(−1·8 to 6·4)
9·8% 
(5·2 to 14·5)*
Controlled phase of mouth 
cancer
1364·1 
(1312·8 to 1414·1)
·· 62·4 
(40·8 to 89·4)
51·8% 
(46·5 to 56·9)*
41·0% 
(35·3 to 46·7)*
3·6% 
(0·0 to 6·8)*
11·2% 
(6·7 to 15·6)*
Metastatic phase of mouth 
cancer
149·4 
(143·4 to 154·9)
·· 62·1 
(42·6 to 81·2)
47·5% 
(41·0 to 54·6)*
38·5% 
(31·9 to 45·2)*
−1·0% 
(−5·3 to 3·6)
7·4% 
(2·3 to 12·5)*
Terminal phase of mouth 
cancer
22·7 
(21·8 to 23·6)
·· 12·2 
(8·5 to 15·7)
47·4% 
(42·5 to 51·7)*
39·5% 
(33·9 to 44·5)*
−1·4% 
(−4·4 to 1·4)
7·8% 
(3·4 to 11·6)*
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Nasopharynx cancer 508·7 
(480·9 to 539·0)
109·8 
(104·4 to 115·6)
52·3 
(37·8 to 69·6)
6·6% 
(−1·2 to 14·3)
20·3% 
(13·7 to 28·1)*
−24·7% 
(−29·8 to −19·7)*
−1·6% 
(−7·0 to 4·5)
Diagnosis and primary 
therapy phase of 
nasopharynx cancer
29·1 
(27·5 to 30·9)
109·8 
(104·4 to 115·6)
8·3 
(5·6 to 11·7)
7·7% 
(−0·9 to 17·5)
20·3% 
(12·0 to 29·9)*
−23·4% 
(−29·4 to −16·9)*
−0·7% 
(−7·4 to 6·9)
Controlled phase of 
nasopharynx cancer
427·7 
(403·8 to 453·3)
·· 20·3 
(13·1 to 29·9)
6·7% 
(−1·8 to 15·3)
19·7% 
(12·1 to 28·1)*
−23·7% 
(−29·5 to −18·0)*
−0·7% 
(−6·9 to 6·0)
Metastatic phase of 
nasopharynx cancer
46·2 
(43·9 to 48·7)
·· 20·6 
(14·1 to 27·7)
6·5% 
(−1·3 to 14·9)
20·9% 
(13·3 to 29·5)*
−25·6% 
(−30·6 to −19·9)*
−2·6% 
(−8·6 to 4·2)
Terminal phase of 
nasopharynx cancer
5·7 
(5·4 to 5·9)
·· 3·1 
(2·1 to 4·0)
3·5% 
(−3·1 to 9·8)
20·7% 
(15·4 to 27·1)*
−27·8% 
(−32·2 to −23·8)*
−3·5% 
(−7·6 to 1·6)
Other pharynx cancer 440·8 
(399·7 to 462·4)
179·3 
(160·3 to 188·6)
59·2 
(42·3 to 77·6)
61·7% 
(54·3 to 70·4)*
44·3% 
(35·0 to 51·2)*
10·1% 
(5·1 to 15·8)*
11·7% 
(4·4 to 16·9)*
Diagnosis and primary 
therapy phase of other 
pharynx cancer
24·6 
(22·3 to 25·7)
179·3 
(160·3 to 188·6)
7·0 
(4·7 to 9·8)
69·9% 
(62·7 to 77·5)*
46·7% 
(38·2 to 53·0)*
15·7% 
(10·8 to 20·8)*
13·5% 
(7·0 to 18·4)*
Controlled phase of other 
pharynx cancer
334·1 
(304·3 to 350·1)
·· 15·5 
(10·0 to 22·9)
72·0% 
(63·3 to 81·8)*
46·5% 
(37·3 to 54·0)*
17·5% 
(11·7 to 24·1)*
13·8% 
(6·6 to 19·6)*
Metastatic phase of other 
pharynx cancer
69·6 
(62·2 to 73·2)
·· 29·9 
(20·4 to 39·7)
56·4% 
(48·1 to 66·2)*
42·7% 
(32·2 to 51·5)*
6·4% 
(0·6 to 12·8)*
10·3% 
(2·3 to 16·9)*
Terminal phase of other 
pharynx cancer
12·6 
(11·2 to 13·3)
·· 6·8 
(4·7 to 8·7)
56·7% 
(49·4 to 64·7)*
44·2% 
(34·9 to 51·0)*
6·6% 
(1·5 to 11·8)*
11·3% 
(4·1 to 16·6)*
Oesophageal cancer 806·3 
(782·1 to 829·8)
472·5 
(459·5 to 485·3)
130·3 
(94·5 to 166·4)
34·6% 
(29·1 to 40·2)*
19·0% 
(14·5 to 23·9)*
−9·1% 
(−12·7 to −5·3)*
−9·1% 
(−12·6 to −5·4)*
Diagnosis and primary 
therapy phase of 
oesophageal cancer
67·0 
(65·0 to 69·0)
472·5 
(459·5 to 485·3)
18·4 
(12·4 to 25·4)
45·2% 
(37·3 to 53·9)*
23·9% 
(17·5 to 31·3)*
−1·3% 
(−6·7 to 4·5)
−5·0% 
(−9·9 to 0·8)
Controlled phase of 
oesophageal cancer
535·4 
(518·8 to 552·0)
·· 24·6 
(16·0 to 35·8)
52·6% 
(45·9 to 58·7)*
26·1% 
(20·9 to 31·5)*
4·7% 
(0·1 to 8·8)*
−2·8% 
(−6·8 to 1·2)
Metastatic phase of 
oesophageal cancer
167·5 
(162·9 to 171·9)
·· 68·2 
(47·0 to 89·1)
28·6% 
(22·5 to 35·2)*
16·1% 
(10·5 to 21·8)*
−13·3% 
(−17·4 to −8·9)*
−11·6% 
(−15·8 to −7·3)*
Terminal phase of 
oesophageal cancer
36·4 
(35·4 to 37·4)
·· 19·0 
(13·4 to 24·3)
29·0% 
(21·9 to 36·6)*
16·7% 
(10·7 to 23·1)*
−13·1% 
(−17·9 to −8·2)*
−11·2% 
(−15·7 to −6·3)*
Stomach cancer 2823·2 
(2740·2 to 2914·9)
1220·7 
(1189·0 to 1254·6)
348·8 
(255·9 to 448·5)
17·6% 
(14·4 to 20·9)*
32·7% 
(28·1 to 37·7)*
−20·8% 
(−23·0 to −18·6)*
1·2% 
(−2·3 to 5·0)
Diagnosis and primary 
therapy phase of stomach 
cancer
268·1 
(260·2 to 276·6)
1220·7 
(1189·0 to 1254·6)
70·1 
(47·9 to 95·2)
22·1% 
(17·7 to 26·4)*
39·7% 
(34·3 to 45·6)*
−17·8% 
(−20·7 to −15·0)*
6·6% 
(2·5 to 11·1)*
Controlled phase of 
stomach cancer
2122·2 
(2057·1 to 2193·0)
·· 96·9 
(62·7 to 140·7)
31·4% 
(28·3 to 34·8)*
54·0% 
(48·8 to 59·4)*
−11·0% 
(−13·1 to −8·8)*
18·1% 
(14·2 to 22·2)*
Metastatic phase of 
stomach cancer
344·3 
(335·7 to 353·8)
·· 137·3 
(95·8 to 178·7)
11·2% 
(7·5 to 15·1)*
21·4% 
(16·9 to 26·2)*
−25·3% 
(−27·7 to −22·7)*
−7·4% 
(−10·8 to −3·9)*
Terminal phase of stomach 
cancer
88·7 
(86·5 to 91·2)
·· 44·6 
(31·3 to 56·9)
11·8% 
(7·7 to 15·9)*
21·1% 
(16·3 to 26·8)*
−24·8% 
(−27·6 to −22·0)*
−7·7% 
(−11·4 to −3·5)*
Colon and rectum cancer 9352·3 
(9143·0 to 9558·6)
1833·5 
(1791·9 to 1873·5)
877·6 
(650·2 to 1133·2)
70·2% 
(65·4 to 74·2)*
39·8% 
(35·9 to 43·6)*
12·3% 
(9·3 to 15·1)*
6·0% 
(3·1 to 9·0)*
Diagnosis and primary 
therapy phase of colon and 
rectum cancers
401·1 
(391·8 to 410·2)
1833·5 
(1791·9 to 1873·5)
103·1 
(70·4 to 139·0)
78·5% 
(72·3 to 84·4)*
43·5% 
(38·3 to 48·8)*
18·7% 
(14·7 to 22·5)*
9·4% 
(5·4 to 13·4)*
Controlled phase of colon 
and rectum cancers
7946·7 
(7764·5 to 8129·2)
·· 453·5 
(304·5 to 637·7)
83·2% 
(79·5 to 86·7)*
42·8% 
(38·9 to 47·0)*
22·9% 
(20·6 to 25·1)*
9·2% 
(6·3 to 12·3)*
Metastatic phase of colon 
and rectum cancers
653·8 
(639·1 to 667·7)
·· 253·1 
(176·5 to 327·7)
54·5% 
(49·5 to 59·3)*
35·5% 
(31·2 to 40·2)*
0·6% 
(−2·4 to 3·5)
1·8% 
(−1·4 to 5·2)
Terminal phase of colon 
and rectum cancers
92·9 
(90·8 to 94·9)
·· 45·9 
(32·6 to 57·9)
48·8% 
(42·5 to 54·6)*
33·5% 
(28·3 to 38·2)*
−2·9% 
(−6·8 to 0·7)
0·2% 
(−3·7 to 3·8)
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Stoma from colon and 
rectum cancers, beyond 
10 years
257·8 
(249·3 to 266·6)
·· 22·1 
(15·3 to 30·0)
52·3% 
(47·4 to 57·0)*
28·3% 
(25·1 to 31·6)*
−3·5% 
(−6·5 to −0·6)*
−5·2% 
(−7·6 to −2·9)*
Liver cancer 803·4 
(753·1 to 856·7)
953·1 
(916·5 to 997·0)
229·5 
(163·9 to 301·7)
52·2% 
(44·8 to 60·5)*
39·8% 
(34·2 to 47·3)*
4·4% 
(−0·6 to 9·9)
8·1% 
(3·8 to 13·7)*
Liver cancer due to 
hepatitis B
661·2 
(617·3 to 713·0)
404·0 
(378·3 to 434·1)
98·1 
(69·9 to 129·6)
42·1% 
(34·2 to 52·6)*
38·1% 
(30·2 to 48·7)*
−1·5% 
(−7·0 to 5·6)
8·6% 
(2·5 to 17·0)*
Diagnosis and primary 
therapy phase of liver 
cancer due to hepatitis B
97·9 
(91·6 to 105·1)
404·0 
(378·3 to 434·1)
26·6 
(18·0 to 37·2)
40·5% 
(29·7 to 53·4)*
35·2% 
(24·8 to 48·0)*
−2·5% 
(−9·9 to 6·5)
6·4% 
(−1·6 to 16·5)
Controlled phase of liver 
cancer due to hepatitis B
453·6 
(422·8 to 490·7)
·· 21·3 
(13·7 to 31·5)
61·5% 
(50·8 to 75·1)*
70·3% 
(58·3 to 84·7)*
12·0% 
(4·8 to 21·1)*
35·0% 
(25·4 to 46·4)*
Metastatic phase of liver 
cancer due to hepatitis B
78·5 
(73·5 to 84·4)
·· 33·5 
(22·9 to 44·7)
37·4% 
(27·3 to 50·4)*
29·1% 
(19·7 to 40·9)*
−4·7% 
(−11·8 to 4·0)
1·5% 
(−6·0 to 10·7)
Terminal phase of liver 
cancer due to hepatitis B
31·3 
(29·3 to 33·6)
·· 16·7 
(11·5 to 21·7)
37·9% 
(31·2 to 47·0)*
29·3% 
(22·3 to 39·6)*
−4·4% 
(−9·0 to 1·7)
1·5% 
(−4·0 to 9·5)
Liver cancer due to 
hepatitis C
366·5 
(341·7 to 391·6)
257·9 
(241·3 to 274·5)
60·6 
(43·0 to 79·7)
62·2% 
(54·8 to 68·9)*
38·8% 
(34·3 to 44·5)*
9·7% 
(4·6 to 14·2)*
4·9% 
(1·5 to 9·2)*
Diagnosis and primary 
therapy phase of liver 
cancer due to hepatitis C
60·8 
(56·9 to 64·7)
257·9 
(241·3 to 274·5)
16·8 
(11·3 to 23·4)
61·1% 
(53·2 to 68·2)*
37·3% 
(31·9 to 43·9)*
8·8% 
(3·5 to 13·5)*
3·7% 
(−0·3 to 8·7)
Controlled phase of liver 
cancer due to hepatitis C
234·4 
(217·9 to 250·9)
·· 10·9 
(6·9 to 15·9)
82·3% 
(72·8 to 92·3)*
56·4% 
(48·6 to 65·8)*
25·9% 
(19·4 to 32·6)*
19·6% 
(13·6 to 26·7)*
Metastatic phase of liver 
cancer due to hepatitis C
51·0 
(47·7 to 54·3)
·· 22·1 
(14·9 to 29·5)
57·6% 
(49·8 to 64·5)*
34·4% 
(29·1 to 40·1)*
6·2% 
(1·0 to 10·8)*
1·4% 
(−2·6 to 5·7)
Terminal phase of liver 
cancer due to hepatitis C
20·3 
(19·0 to 21·6)
·· 10·9 
(7·6 to 14·1)
58·4% 
(51·0 to 64·7)*
34·7% 
(30·9 to 39·7)*
6·7% 
(1·8 to 10·7)*
1·5% 
(−1·4 to 5·2)
Liver cancer due to alcohol 
use
206·3 
(180·7 to 239·9)
143·9 
(127·2 to 165·0)
34·7 
(24·8 to 47·1)
62·6% 
(52·2 to 70·8)*
39·4% 
(33·7 to 46·1)*
9·6% 
(2·7 to 15·0)*
7·2% 
(2·9 to 12·1)*
Diagnosis and primary 
therapy phase of liver 
cancer due to alcohol use
34·0 
(30·0 to 39·1)
143·9 
(127·2 to 165·0)
9·7 
(6·4 to 13·9)
61·1% 
(50·9 to 69·6)*
38·5% 
(32·0 to 45·2)*
8·5% 
(1·7 to 14·1)*
6·4% 
(1·7 to 11·4)*
Controlled phase of liver 
cancer due to alcohol use
132·6 
(115·1 to 155·3)
·· 6·2 
(3·8 to 9·2)
88·0% 
(74·5 to 101·3)*
55·3% 
(45·5 to 65·6)*
28·8% 
(19·5 to 37·8)*
20·5% 
(13·1 to 28·5)*
Metastatic phase of liver 
cancer due to alcohol use
28·4 
(25·2 to 32·6)
·· 12·7 
(8·6 to 17·4)
57·1% 
(47·4 to 65·0)*
35·4% 
(29·9 to 41·7)*
5·7% 
(−0·7 to 10·8)
3·9% 
(−0·2 to 8·5)
Terminal phase of liver 
cancer due to alcohol use
11·3 
(10·0 to 13·0)
·· 6·1 
(4·2 to 8·1)
57·4% 
(47·4 to 65·1)*
35·3% 
(30·3 to 41·2)*
5·9% 
(−0·8 to 10·8)
3·8% 
(0·2 to 8·2)*
Liver cancer due to NASH 97·4 
(86·8 to 108·0)
72·2 
(64·6 to 79·9)
17·5 
(12·3 to 23·1)
74·4% 
(63·9 to 83·0)*
52·5% 
(47·5 to 58·9)*
18·2% 
(11·2 to 23·6)*
16·1% 
(12·4 to 20·9)*
Diagnosis and primary 
therapy phase of liver 
cancer due to NASH
16·9 
(15·1 to 18·6)
72·2 
(64·6 to 79·9)
4·8 
(3·2 to 6·7)
73·3% 
(62·6 to 81·8)*
51·4% 
(46·5 to 57·5)*
17·3% 
(10·3 to 22·7)*
15·2% 
(11·6 to 19·8)*
Controlled phase of liver 
cancer due to NASH
60·5 
(53·5 to 67·4)
·· 2·9 
(1·8 to 4·4)
93·7% 
(82·0 to 103·9)*
75·6% 
(66·7 to 85·7)*
34·2% 
(26·1 to 40·9)*
35·6% 
(28·9 to 43·7)*
Metastatic phase of liver 
cancer due to NASH
14·3 
(12·8 to 15·9)
·· 6·5 
(4·4 to 8·7)
70·7% 
(60·0 to 79·0)*
47·3% 
(42·7 to 53·3)*
15·3% 
(8·4 to 20·6)*
11·9% 
(8·4 to 16·3)*
Terminal phase of liver 
cancer due to NASH
5·7 
(5·1 to 6·3)
·· 3·2 
(2·2 to 4·2)
70·7% 
(60·0 to 79·0)*
47·3% 
(42·6 to 53·3)*
15·3% 
(8·3 to 20·6)*
11·9% 
(8·4 to 16·3)*
Liver cancer due to other 
causes
114·8 
(102·2 to 128·7)
75·1 
(67·5 to 83·3)
18·6 
(13·2 to 25·1)
43·9% 
(36·4 to 52·0)*
42·3% 
(36·1 to 50·4)*
−0·3% 
(−5·4 to 5·0)
11·0% 
(6·5 to 17·2)*
Diagnosis and primary 
therapy phase of liver 
cancer due to other causes
18·0 
(16·1 to 20·0)
75·1 
(67·5 to 83·3)
5·2 
(3·5 to 7·3)
42·7% 
(35·2 to 50·5)*
40·6% 
(34·9 to 47·9)*
−1·1% 
(−6·0 to 4·0)
9·7% 
(5·4 to 15·3)*
Controlled phase of liver 
cancer due to other causes
76·3 
(67·5 to 85·8)
·· 3·7 
(2·3 to 5·5)
61·3% 
(51·7 to 72·7)*
68·1% 
(56·9 to 81·0)*
12·3% 
(5·8 to 20·1)*
32·7% 
(23·7 to 42·5)*
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Metastatic phase of liver 
cancer due to other causes
14·7 
(13·2 to 16·3)
·· 6·6 
(4·5 to 9·0)
40·0% 
(32·7 to 47·7)*
35·3% 
(30·0 to 42·2)*
−3·1% 
(−7·8 to 2·0)
5·4% 
(1·4 to 10·6)*
Terminal phase of liver 
cancer due to other causes
5·8 
(5·3 to 6·5)
·· 3·2 
(2·2 to 4·1)
40·0% 
(32·7 to 47·7)*
35·3% 
(30·0 to 42·2)*
−3·1% 
(−7·8 to 2·0)
5·4% 
(1·4 to 10·6)*
Gallbladder and biliary tract 
cancer
235·9 
(209·6 to 252·6)
210·9 
(186·1 to 225·4)
49·1 
(34·4 to 64·3)
33·4% 
(23·2 to 38·9)*
34·6% 
(28·1 to 41·4)*
−12·1% 
(−18·8 to −8·5)*
1·4% 
(−3·7 to 6·8)
Diagnosis and primary 
therapy phase of gallbladder 
and biliary tract cancer
33·7 
(29·9 to 35·9)
210·9 
(186·1 to 225·4)
9·3 
(6·2 to 12·9)
34·1% 
(24·3 to 39·7)*
35·5% 
(28·5 to 42·6)*
−11·7% 
(−18·1 to −7·9)*
2·1% 
(−3·3 to 7·8)
Controlled phase of 
gallbladder and biliary tract 
cancer
126·7 
(113·2 to 136·4)
·· 5·8 
(3·7 to 8·5)
36·9% 
(28·6 to 44·3)*
53·1% 
(42·0 to 64·3)*
−8·1% 
(−13·8 to −3·1)*
17·5% 
(8·9 to 26·4)*
Metastatic phase of 
gallbladder and biliary tract 
cancer
58·6 
(51·7 to 62·7)
·· 25·0 
(16·8 to 33·4)
32·9% 
(21·7 to 39·8)*
31·7% 
(25·3 to 38·3)*
−12·6% 
(−20·0 to −8·0)*
−1·0% 
(−6·1 to 4·3)
Terminal phase of 
gallbladder and biliary tract 
cancer
16·9 
(14·9 to 18·1)
·· 8·9 
(6·2 to 11·6)
32·3% 
(21·9 to 37·2)*
31·4% 
(25·4 to 37·6)*
−13·3% 
(−20·0 to −9·8)*
−1·4% 
(−6·0 to 3·6)
Pancreatic cancer 380·6 
(372·7 to 388·4)
447·7 
(438·6 to 456·3)
91·9 
(64·7 to 119·3)
65·8% 
(62·2 to 69·6)*
38·5% 
(34·8 to 42·2)*
9·8% 
(7·3 to 12·4)*
4·7% 
(1·8 to 7·6)*
Diagnosis and primary 
therapy phase of pancreatic 
cancer
99·0 
(97·0 to 101·0)
447·7 
(438·6 to 456·3)
26·5 
(18·1 to 36·2)
65·4% 
(60·1 to 70·8)*
38·7% 
(33·2 to 43·5)*
9·6% 
(6·0 to 13·2)*
4·8% 
(0·6 to 8·4)*
Controlled phase of 
pancreatic cancer
151·7 
(148·4 to 155·0)
·· 7·1 
(4·6 to 10·3)
102·1% 
(96·0 to 109·5)*
35·1% 
(30·2 to 40·4)*
37·5% 
(33·3 to 42·6)*
5·1% 
(1·4 to 9·2)*
Metastatic phase of 
pancreatic cancer
93·2 
(91·3 to 95·0)
·· 38·9 
(26·7 to 51·3)
62·5% 
(57·6 to 67·8)*
39·1% 
(34·2 to 44·0)*
7·7% 
(4·3 to 11·2)*
4·8% 
(1·0 to 8·6)*
Terminal phase of 
pancreatic cancer
36·7 
(35·9 to 37·4)
·· 19·4 
(13·6 to 24·8)
62·1% 
(59·3 to 65·0)*
38·6% 
(34·9 to 41·9)*
6·6% 
(4·6 to 8·6)*
4·4% 
(1·6 to 7·0)*
Larynx cancer 1094·9 
(1074·7 to 1118·4)
210·6 
(206·4 to 215·5)
109·4 
(79·7 to 142·5)
25·1% 
(21·7 to 28·5)*
34·2% 
(30·6 to 37·9)*
−14·9% 
(−17·2 to −12·6)*
2·8% 
(0·0 to 5·6)*
Diagnosis and primary 
therapy phase of larynx 
cancer
65·3 
(64·1 to 66·8)
210·6 
(206·4 to 215·5)
18·1 
(12·3 to 24·9)
27·6% 
(22·0 to 33·4)*
38·1% 
(32·8 to 43·5)*
−13·1% 
(−17·0 to −9·1)*
5·8% 
(1·7 to 9·9)*
Controlled phase of larynx 
cancer
882·3 
(864·9 to 902·3)
·· 48·7 
(32·0 to 70·1)
28·2% 
(24·5 to 31·8)*
36·5% 
(32·5 to 40·5)*
−12·3% 
(−14·7 to −9·8)*
4·9% 
(1·9 to 8·0)*
Metastatic phase of larynx 
cancer
79·7 
(78·1 to 81·6)
·· 33·8 
(23·2 to 44·7)
19·9% 
(14·9 to 24·9)*
30·8% 
(25·3 to 36·1)*
−18·8% 
(−22·2 to −15·5)*
−0·1% 
(−4·3 to 4·0)
Terminal phase of larynx 
cancer
11·3 
(11·0 to 11·6)
·· 6·1 
(4·2 to 7·8)
16·3% 
(13·9 to 19·0)*
28·2% 
(25·1 to 31·3)*
−21·3% 
(−22·9 to −19·6)*
−2·2% 
(−4·5 to 0·2)
Laryngectomy from larynx 
cancer, beyond 10 years
56·3 
(54·4 to 58·2)
·· 2·7 
(1·7 to 4·1)
48·5% 
(43·6 to 53·7)*
25·6% 
(21·0 to 30·3)*
−0·8% 
(−4·3 to 2·7)
−4·5% 
(−8·0 to −0·9)*
Tracheal, bronchus, and lung 
cancer
3343·1 
(3267·9 to 3422·5)
2163·1 
(2117·0 to 2212·9)
537·1 
(393·6 to 677·2)
51·6% 
(47·5 to 55·5)*
41·0% 
(36·8 to 45·4)*
2·9% 
(0·1 to 5·5)*
7·2% 
(3·9 to 10·4)*
Diagnosis and primary 
therapy phase of tracheal, 
bronchus, and lung cancer
219·5 
(214·6 to 224·8)
2163·1 
(2117·0 to 2212·9)
57·0 
(39·1 to 77·4)
64·3% 
(58·4 to 69·9)*
51·1% 
(45·1 to 57·5)*
11·4% 
(7·3 to 15·2)*
14·9% 
(10·3 to 19·7)*
Controlled phase of 
tracheal, bronchus, and 
lung cancer
2188·1 
(2137·3 to 2241·4)
·· 99·3 
(64·4 to 144·3)
87·5% 
(83·3 to 91·7)*
65·8% 
(61·2 to 70·5)*
28·0% 
(25·1 to 30·7)*
26·4% 
(22·9 to 30·0)*
Metastatic phase of 
tracheal, bronchus, and 
lung cancer
765·7 
(749·5 to 783·3)
·· 299·0 
(208·3 to 387·8)
44·3% 
(40·1 to 48·2)*
34·5% 
(30·1 to 38·7)*
−2·0% 
(−4·8 to 0·5)
2·2% 
(−1·1 to 5·3)
Terminal phase of tracheal, 
bronchus, and lung cancer
169·8 
(166·2 to 173·7)
·· 81·8 
(58·1 to 103·2)
44·3% 
(38·9 to 49·6)*
34·0% 
(28·8 to 39·6)*
−2·2% 
(−5·7 to 1·3)
1·8% 
(−2·1 to 6·0)
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Malignant skin melanoma 2324·4 
(1794·8 to 2796·2)
308·7 
(237·6 to 365·9)
140·9 
(90·8 to 201·6)
104·3% 
(82·1 to 111·6)*
32·3% 
(27·0 to 36·9)*
41·3% 
(24·4 to 46·9)*
4·9% 
(0·9 to 8·6)*
Diagnosis and primary 
therapy phase of malignant 
skin melanoma
64·1 
(49·0 to 76·8)
308·7 
(237·6 to 365·9)
17·5 
(11·0 to 25·2)
110·3% 
(89·4 to 118·3)*
32·4% 
(26·1 to 38·8)*
46·4% 
(30·5 to 52·6)*
5·4% 
(0·5 to 10·6)*
Controlled phase of 
malignant skin melanoma
2208·7 
(1709·0 to 2662·4)
·· 101·2 
(59·9 to 154·2)
113·8% 
(93·9 to 121·4)*
32·9% 
(27·7 to 37·9)*
50·2% 
(34·9 to 55·4)*
6·4% 
(2·3 to 10·7)*
Metastatic phase of 
malignant skin melanoma
44·3 
(32·7 to 49·6)
·· 18·4 
(11·3 to 25·1)
68·4% 
(40·0 to 80·0)*
29·5% 
(22·6 to 35·5)*
12·5% 
(−7·3 to 20·9)
−1·6% 
(−6·9 to 3·2)
Terminal phase of 
malignant skin melanoma
7·3 
(5·4 to 8·2)
·· 3·9 
(2·4 to 5·2)
64·2% 
(37·2 to 73·7)*
28·7% 
(21·6 to 33·9)*
9·0% 
(−9·7 to 15·6)
−2·6% 
(−7·8 to 1·3)
Non-melanoma skin cancer 2537·1 
(1666·4 to 3696·8)
7663·6 
(5251·1 to 10 570·3)
90·2 
(49·5 to 149·0)
211·2% 
(142·3 to 305·0)*
32·7% 
(25·3 to 40·0)*
96·8% 
(46·7 to 162·7)*
−2·0% 
(−7·7 to 3·9)
Non-melanoma skin cancer 
(squamous-cell carcinoma)
2158·9 
(1294·8 to 3255·8)
1778·8 
(1068·8 to 2620·9)
87·7 
(46·9 to 146·3)
221·7% 
(148·5 to 334·5)*
32·8% 
(25·0 to 40·0)*
102·5% 
(47·3 to 180·3)*
−2·0% 
(−7·8 to 4·0)
Non-melanoma skin cancer 
(basal-cell carcinoma)
596·8 
(325·9 to 947·0)
5884·8 
(3702·9 to 8742·9)
2·5 
(0·9 to 5·2)
44·5% 
(20·3 to 76·5)*
30·8% 
(23·1 to 37·0)*
−3·8% 
(−21·1 to 18·1)
−1·0% 
(−6·4 to 3·2)
Breast cancer 16 697·3 
(16 178·9 to 17 171·7)
1960·7 
(1891·4 to 2023·2)
1307·9 
(932·0 to 1769·3)
67·7% 
(60·6 to 72·7)*
33·8% 
(29·0 to 37·7)*
11·7% 
(7·1 to 15·0)*
4·5% 
(0·7 to 7·5)*
Diagnosis and primary 
therapy phase of breast 
cancer
416·5 
(401·4 to 430·2)
1960·7 
(1891·4 to 2023·2)
107·8 
(75·1 to 146·7)
71·1% 
(61·6 to 79·5)*
36·1% 
(29·4 to 42·2)*
15·1% 
(9·0 to 20·4)*
7·3% 
(2·2 to 11·9)*
Controlled phase of breast 
cancer
13 532·2 
(13 027·8 to 13 977·4)
·· 843·4 
(538·9 to 1218·3)
74·5% 
(66·8 to 79·7)*
34·4% 
(29·3 to 38·7)*
17·7% 
(12·9 to 21·0)*
6·0% 
(2·1 to 9·3)*
Metastatic phase of breast 
cancer
676·3 
(654·5 to 697·0)
·· 263·8 
(183·5 to 341·1)
57·5% 
(49·2 to 64·5)*
33·4% 
(28·0 to 38·2)*
2·8% 
(−2·1 to 7·0)
2·3% 
(−1·8 to 5·8)
Terminal phase of breast 
cancer
52·0 
(50·4 to 54·0)
·· 26·9 
(18·8 to 34·2)
49·6% 
(40·4 to 57·4)*
31·4% 
(25·7 to 36·4)*
−2·1% 
(−7·7 to 2·8)
0·5% 
(−3·9 to 4·4)
Mastectomy from breast 
cancer, beyond 10 years
2020·3 
(1957·2 to 2080·1)
·· 66·0 
(38·5 to 102·5)
38·5% 
(35·8 to 41·3)*
25·8% 
(23·9 to 27·7)*
−9·5% 
(−11·2 to −7·8)*
−6·2% 
(−7·5 to −4·7)*
Cervical cancer 3657·9 
(3364·6 to 3803·1)
601·2 
(554·5 to 625·4)
288·1 
(205·6 to 381·5)
24·2% 
(12·3 to 32·3)*
18·9% 
(12·6 to 23·2)*
−14·2% 
(−22·3 to −8·7)*
−1·7% 
(−6·8 to 1·8)
Diagnosis and primary 
therapy phase of cervical 
cancer
187·6 
(172·7 to 195·1)
601·2 
(554·5 to 625·4)
51·4 
(34·5 to 70·5)
26·3% 
(13·6 to 35·9)*
19·2% 
(12·2 to 25·5)*
−12·2% 
(−21·1 to −6·0)*
−0·8% 
(−6·7 to 4·2)
Controlled phase of cervical 
cancer
3275·4 
(3011·5 to 3405·2)
·· 151·8 
(96·7 to 222·6)
25·7% 
(13·5 to 34·1)*
19·7% 
(13·5 to 24·1)*
−12·4% 
(−20·8 to −6·8)*
0·1% 
(−5·2 to 3·7)
Metastatic phase of cervical 
cancer
171·3 
(158·6 to 178·3)
·· 72·2 
(48·9 to 95·3)
20·9% 
(10·1 to 29·0)*
17·4% 
(10·9 to 22·9)*
−17·6% 
(−24·7 to −12·4)*
−5·1% 
(−10·3 to −0·6)*
Terminal phase of cervical 
cancer
23·6 
(21·9 to 24·6)
·· 12·8 
(8·8 to 16·4)
17·5% 
(7·5 to 24·9)*
17·4% 
(11·7 to 21·6)*
−20·4% 
(−27·0 to −15·7)*
−6·4% 
(−10·9 to −3·0)*
Uterine cancer 3084·6 
(3005·7 to 3171·3)
406·8 
(396·7 to 418·0)
210·9 
(151·5 to 279·7)
65·8% 
(60·6 to 71·6)*
36·5% 
(32·7 to 41·1)*
11·0% 
(7·5 to 14·9)*
4·9% 
(1·9 to 8·2)*
Diagnosis and primary 
therapy phase of uterine 
cancer
141·8 
(138·2 to 145·8)
406·8 
(396·7 to 418·0)
37·5 
(25·9 to 51·1)
69·1% 
(60·6 to 78·2)*
37·4% 
(30·9 to 44·1)*
13·5% 
(7·8 to 19·7)*
5·9% 
(1·0 to 10·9)*
Controlled phase of uterine 
cancer
2838·0 
(2765·2 to 2918·0)
·· 129·3 
(84·2 to 188·0)
72·5% 
(67·5 to 78·1)*
38·3% 
(34·6 to 43·0)*
16·6% 
(13·3 to 20·2)*
6·9% 
(4·1 to 10·5)*
Metastatic phase of uterine 
cancer
94·9 
(92·6 to 97·4)
·· 38·8 
(26·7 to 50·7)
48·4% 
(40·9 to 56·2)*
31·1% 
(25·7 to 37·3)*
−2·3% 
(−7·2 to 2·9)
−1·0% 
(−5·2 to 3·8)
Terminal phase of uterine 
cancer
9·9 
(9·7 to 10·2)
·· 5·3 
(3·7 to 6·8)
42·2% 
(38·7 to 46·5)*
29·0% 
(25·9 to 33·0)*
−6·6% 
(−8·8 to −3·9)*
−3·1% 
(−5·4 to −0·1)*
Ovarian cancer 1353·0 
(1313·7 to 1401·1)
286·1 
(278·1 to 295·3)
176·1 
(127·9 to 224·2)
48·9% 
(42·2 to 56·6)*
27·7% 
(22·9 to 32·9)*
1·6% 
(−2·6 to 6·5)
2·2% 
(−1·6 to 6·4)
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Diagnosis and primary 
therapy phase of ovarian 
cancer
48·1 
(46·7 to 49·8)
286·1 
(278·1 to 295·3)
13·8 
(9·3 to 19·2)
51·7% 
(45·6 to 58·8)*
28·4% 
(23·9 to 33·0)*
4·4% 
(0·5 to 8·9)*
3·7% 
(0·1 to 7·4)*
Controlled phase of ovarian 
cancer
1027·2 
(997·4 to 1064·3)
·· 47·3 
(30·3 to 69·3)
52·7% 
(45·2 to 60·7)*
28·6% 
(23·2 to 33·9)*
5·8% 
(0·9 to 11·0)*
4·5% 
(0·2 to 8·9)*
Metastatic phase of ovarian 
cancer
261·4 
(253·9 to 270·1)
·· 106·2 
(72·2 to 139·2)
47·4% 
(40·1 to 55·7)*
27·2% 
(21·3 to 33·5)*
0·1% 
(−4·7 to 5·5)
1·2% 
(−3·5 to 6·3)
Terminal phase of ovarian 
cancer
16·3 
(15·8 to 16·8)
·· 8·8 
(6·1 to 11·2)
42·6% 
(37·6 to 48·5)*
29·0% 
(25·2 to 32·9)*
−4·6% 
(−7·6 to −1·0)*
−0·1% 
(−2·9 to 3·1)
Prostate cancer 9901·9 
(8810·8 to 12 762·0)
1334·3 
(1170·9 to 1697·9)
843·2 
(614·4 to 1146·4)
97·5% 
(87·3 to 125·6)*
41·0% 
(36·3 to 50·9)*
27·7% 
(20·5 to 46·5)*
5·6% 
(2·1 to 13·2)*
Diagnosis and primary 
therapy phase of prostate 
cancer
342·9 
(303·1 to 446·1)
1334·3 
(1170·9 to 1697·9)
86·1 
(57·9 to 121·6)
115·8% 
(103·5 to 149·5)*
44·0% 
(37·3 to 56·3)*
42·5% 
(34·4 to 65·2)*
8·6% 
(3·6 to 17·9)*
Controlled phase of 
prostate cancer
8443·6 
(7481·1 to 11 011·9)
·· 476·0 
(309·6 to 698·6)
123·7% 
(113·6 to 156·9)*
43·3% 
(38·4 to 54·7)*
49·5% 
(42·7 to 72·3)*
8·3% 
(4·5 to 17·1)*
Metastatic phase of 
prostate cancer
653·8 
(568·1 to 817·9)
·· 244·6 
(168·2 to 321·2)
63·3% 
(56·2 to 86·0)*
36·4% 
(31·6 to 44·7)*
2·9% 
(−1·5 to 17·2)
1·1% 
(−2·4 to 7·5)
Terminal phase of prostate 
cancer
39·7 
(34·2 to 48·1)
·· 18·5 
(13·0 to 23·8)
57·9% 
(47·9 to 75·1)*
35·1% 
(28·7 to 43·8)*
−0·7% 
(−6·9 to 10·3)
−0·5% 
(−5·1 to 6·2)
Impotence and incontinence 
after 10-year survival from 
prostate cancer
421·9 
(411·4 to 432·6)
·· 18·1 
(12·6 to 25·0)
61·8% 
(57·7 to 66·2)*
35·0% 
(31·2 to 38·9)*
0·5% 
(−1·9 to 3·1)
−1·6% 
(−4·2 to 1·1)
Testicular cancer 578·0 
(556·4 to 603·6)
71·3 
(68·8 to 74·4)
36·2 
(24·8 to 49·6)
51·2% 
(44·3 to 58·7)*
23·8% 
(18·3 to 29·5)*
14·7% 
(9·4 to 20·4)*
9·0% 
(4·1 to 14·1)*
Diagnosis and primary 
therapy phase of testicular 
cancer
18·9 
(18·2 to 19·7)
71·3 
(68·8 to 74·4)
5·4 
(3·6 to 7·5)
55·1% 
(48·5 to 62·3)*
24·9% 
(19·2 to 30·8)*
18·2% 
(13·3 to 23·5)*
10·4% 
(5·4 to 15·6)*
Controlled phase of 
testicular cancer
549·1 
(528·5 to 573·5)
·· 26·1 
(16·8 to 38·7)
55·3% 
(47·5 to 64·2)*
25·0% 
(19·0 to 31·4)*
18·7% 
(12·7 to 25·4)*
10·7% 
(5·2 to 16·2)*
Metastatic phase of 
testicular cancer
9·0 
(8·7 to 9·4)
·· 4·1 
(2·8 to 5·4)
31·0% 
(26·1 to 35·8)*
16·9% 
(13·1 to 21·2)*
−3·8% 
(−7·2 to −0·3)*
−0·3% 
(−3·5 to 3·4)
Terminal phase of testicular 
cancer
1·0 
(1·0 to 1·1)
·· 0·6 
(0·4 to 0·7)
22·7% 
(17·7 to 27·7)*
9·9% 
(6·2 to 14·3)*
−8·8% 
(−12·4 to −5·2)*
−5·7% 
(−8·8 to −1·8)*
Kidney cancer 2184·1 
(2081·8 to 2249·0)
393·0 
(371·2 to 404·6)
141·0 
(101·2 to 190·1)
50·2% 
(44·0 to 58·6)*
24·1% 
(18·8 to 28·9)*
7·2% 
(3·5 to 12·3)*
−2·2% 
(−6·3 to 1·6)
Diagnosis and primary 
therapy phase of kidney 
cancer
·· 393·0 
(371·2 to 404·6)
·· ·· ·· ·· ··
Controlled phase of kidney 
cancer
2080·7 
(1985·3 to 2143·1)
·· 95·6 
(62·2 to 139·5)
47·6% 
(39·9 to 57·7)*
22·6% 
(16·8 to 27·7)*
8·2% 
(3·8 to 14·7)*
−2·0% 
(−6·7 to 2·0)
Metastatic phase of kidney 
cancer
86·7 
(81·4 to 89·3)
·· 36·4 
(24·6 to 48·3)
55·9% 
(49·4 to 63·7)*
27·2% 
(21·8 to 33·1)*
5·1% 
(0·6 to 10·3)*
−2·6% 
(−6·7 to 1·9)
Terminal phase of kidney 
cancer
16·7 
(15·7 to 17·2)
·· 9·0 
(6·3 to 11·6)
57·3% 
(52·5 to 62·9)*
27·0% 
(23·3 to 31·5)*
5·8% 
(2·7 to 9·3)*
−3·0% 
(−5·8 to 0·4)
Bladder cancer 2632·4 
(2566·9 to 2717·2)
473·8 
(462·2 to 491·8)
247·0 
(179·4 to 322·8)
47·3% 
(43·4 to 53·6)*
33·0% 
(29·9 to 36·2)*
−1·9% 
(−4·6 to 2·2)
0·9% 
(−1·4 to 3·3)
Diagnosis and primary 
therapy phase of bladder 
cancer
141·8 
(138·1 to 146·6)
473·8 
(462·2 to 491·8)
37·4 
(25·4 to 50·8)
47·4% 
(41·0 to 56·0)*
34·2% 
(29·3 to 39·3)*
−1·3% 
(−5·4 to 4·2)
2·2% 
(−1·5 to 6·0)
Controlled phase of bladder 
cancer
2269·1 
(2209·3 to 2343·1)
·· 139·9 
(95·0 to 195·4)
50·9% 
(46·7 to 58·3)*
34·1% 
(30·8 to 37·6)*
2·0% 
(−0·8 to 6·6)
2·7% 
(0·1 to 5·3)*
Metastatic phase of bladder 
cancer
121·5 
(118·5 to 126·6)
·· 48·2 
(33·4 to 63·1)
37·7% 
(31·9 to 44·9)*
29·9% 
(25·5 to 34·6)*
−10·3% 
(−14·0 to −5·9)*
−3·1% 
(−6·4 to 0·3)
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Terminal phase of bladder 
cancer
22·6 
(22·0 to 23·5)
·· 11·6 
(8·1 to 14·8)
38·0% 
(32·5 to 45·2)*
29·5% 
(25·2 to 34·1)*
−10·4% 
(−14·0 to −5·8)*
−3·5% 
(−6·8 to 0·0)
Incontinence from bladder 
cancer, beyond 10 years
77·5 
(74·8 to 80·5)
·· 10·0 
(6·8 to 14·1)
63·5% 
(57·7 to 69·4)*
32·3% 
(27·9 to 37·3)*
5·2% 
(1·6 to 9·2)*
−0·8% 
(−4·1 to 2·9)
Brain and nervous system 
cancer
1705·7 
(1471·0 to 1894·8)
405·2 
(351·0 to 442·6)
166·9 
(117·5 to 223·0)
56·9% 
(34·3 to 85·1)*
49·9% 
(41·3 to 58·9)*
19·1% 
(2·2 to 37·8)*
24·8% 
(17·7 to 32·8)*
Diagnosis and primary 
therapy phase of brain and 
nervous system cancers
100·0 
(86·4 to 110·7)
405·2 
(351·0 to 442·6)
28·6 
(19·0 to 40·4)
76·5% 
(51·1 to 107·8)*
61·2% 
(51·3 to 71·1)*
34·8% 
(15·7 to 55·6)*
35·4% 
(27·5 to 44·1)*
Controlled phase of brain 
and nervous system cancers
1453·1 
(1251·8 to 1625·0)
·· 68·5 
(43·3 to 102·1)
72·1% 
(45·5 to 109·1)*
61·9% 
(50·1 to 74·9)*
35·8% 
(16·1 to 61·4)*
38·0% 
(28·0 to 49·2)*
Metastatic phase of brain 
and nervous system cancers
130·1 
(112·7 to 139·8)
·· 57·7 
(38·4 to 78·2)
41·8% 
(22·1 to 62·1)*
36·5% 
(30·0 to 42·0)*
4·9% 
(−9·4 to 17·6)
10·9% 
(5·6 to 15·2)*
Terminal phase of brain and 
nervous system cancers
22·6 
(19·6 to 24·3)
·· 12·2 
(8·4 to 15·9)
38·7% 
(18·9 to 59·0)*
34·3% 
(27·8 to 39·3)*
3·0% 
(−10·8 to 15·6)
8·8% 
(3·7 to 12·9)*
Thyroid cancer 2144·9 
(2059·5 to 2287·8)
255·5 
(245·7 to 272·5)
132·0 
(91·7 to 180·8)
95·1% 
(87·1 to 104·5)*
37·7% 
(32·4 to 44·0)*
33·4% 
(27·9 to 39·2)*
11·4% 
(7·1 to 16·5)*
Diagnosis and primary 
therapy phase of thyroid 
cancer
57·8 
(55·5 to 61·6)
255·5 
(245·7 to 272·5)
16·6 
(11·1 to 23·1)
99·5% 
(91·6 to 109·7)*
38·5% 
(32·3 to 45·3)*
37·5% 
(32·6 to 43·9)*
12·7% 
(7·6 to 18·1)*
Controlled phase of thyroid 
cancer
2040·7 
(1958·4 to 2176·9)
·· 94·5 
(61·6 to 138·2)
101·9% 
(93·0 to 113·0)*
38·1% 
(32·4 to 45·2)*
40·1% 
(34·3 to 46·8)*
12·9% 
(8·2 to 18·7)*
Metastatic phase of thyroid 
cancer
42·9 
(41·6 to 45·4)
·· 19·0 
(12·9 to 25·3)
67·5% 
(60·9 to 73·2)*
35·7% 
(31·4 to 40·1)*
9·9% 
(5·2 to 13·3)*
4·3% 
(1·1 to 7·7)*
Terminal phase of thyroid 
cancer
3·5 
(3·4 to 3·8)
·· 1·9 
(1·3 to 2·5)
63·9% 
(57·0 to 70·0)*
34·7% 
(30·4 to 39·1)*
8·6% 
(4·2 to 12·1)*
3·9% 
(0·6 to 7·3)*
Mesothelioma 78·6 
(76·1 to 81·1)
34·6 
(33·5 to 35·7)
14·9 
(10·6 to 19·7)
33·7% 
(17·7 to 56·9)*
23·9% 
(16·2 to 30·9)*
−10·0% 
(−20·4 to 5·2)
−4·6% 
(−10·3 to 0·7)
Diagnosis and primary 
therapy phase of 
mesothelioma
9·1 
(8·8 to 9·4)
34·6 
(33·5 to 35·7)
2·6 
(1·7 to 3·6)
35·5% 
(20·0 to 58·2)*
24·6% 
(17·0 to 31·2)*
−8·7% 
(−19·0 to 6·2)
−4·1% 
(−9·8 to 1·0)
Controlled phase of 
mesothelioma
46·8 
(45·3 to 48·3)
·· 2·2 
(1·4 to 3·2)
34·9% 
(18·0 to 58·3)*
23·6% 
(14·8 to 32·4)*
−8·6% 
(−19·8 to 7·0)
−4·3% 
(−11·0 to 2·3)
Metastatic phase of 
mesothelioma
20·0 
(19·3 to 20·6)
·· 8·7 
(5·9 to 11·6)
33·3% 
(17·0 to 56·9)*
23·7% 
(15·3 to 32·1)*
−10·4% 
(−20·9 to 4·9)
−4·8% 
(−11·1 to 1·4)
Terminal phase of 
mesothelioma
2·8 
(2·7 to 2·9)
·· 1·5 
(1·0 to 1·9)
31·6% 
(16·2 to 53·5)*
24·1% 
(17·1 to 30·2)*
−11·7% 
(−21·7 to 2·5)
−4·6% 
(−9·8 to −0·2)*
Hodgkin lymphoma 657·1 
(568·9 to 780·8)
101·1 
(88·0 to 118·7)
50·5 
(35·1 to 69·3)
31·2% 
(18·9 to 59·3)*
19·1% 
(13·8 to 23·7)*
−1·0% 
(−10·3 to 19·8)
2·5% 
(−2·2 to 6·5)
Diagnosis and primary 
therapy phase of Hodgkin 
lymphoma
21·7 
(18·8 to 25·9)
101·1 
(88·0 to 118·7)
6·2 
(4·1 to 9·0)
44·2% 
(30·3 to 77·5)*
22·8% 
(17·3 to 27·3)*
10·8% 
(0·9 to 35·5)*
6·6% 
(2·0 to 10·6)*
Controlled phase of 
Hodgkin lymphoma
601·2 
(520·5 to 716·2)
·· 28·6 
(17·5 to 43·0)
43·8% 
(29·2 to 77·6)*
22·4% 
(16·1 to 27·8)*
11·1% 
(0·4 to 36·7)*
6·7% 
(1·4 to 11·3)*
Metastatic phase of 
Hodgkin lymphoma
31·0 
(26·7 to 36·1)
·· 14·0 
(9·1 to 19·0)
13·5% 
(4·6 to 33·3)*
13·3% 
(8·3 to 17·3)*
−16·9% 
(−23·0 to −3·0)*
−5·0% 
(−9·1 to −1·6)*
Terminal phase of Hodgkin 
lymphoma
3·2 
(2·7 to 3·7)
·· 1·7 
(1·1 to 2·2)
−2·7% 
(−10·9 to 13·0)
4·6% 
(0·8 to 8·2)*
−28·0% 
(−33·5 to −17·1)*
−12·1% 
(−15·3 to −9·1)*
Non-Hodgkin lymphoma 2371·9 
(2325·0 to 2418·1)
488·0 
(478·9 to 496·9)
193·1 
(140·2 to 254·2)
77·8% 
(70·5 to 84·3)*
41·4% 
(37·7 to 45·0)*
26·1% 
(21·4 to 30·3)*
11·3% 
(8·2 to 14·2)*
Diagnosis and primary 
therapy phase of 
non-Hodgkin lymphoma
87·8 
(86·0 to 89·4)
488·0 
(478·9 to 496·9)
24·2 
(16·4 to 33·1)
90·1% 
(82·5 to 97·4)*
45·3% 
(40·5 to 49·9)*
35·2% 
(30·7 to 39·7)*
14·7% 
(10·8 to 18·3)*
Controlled phase of 
non-Hodgkin lymphoma
2119·9 
(2077·3 to 2161·3)
·· 97·3 
(62·9 to 140·5)
91·9% 
(83·9 to 99·1)*
45·4% 
(41·4 to 49·4)*
38·6% 
(33·9 to 42·8)*
15·6% 
(12·3 to 18·9)*
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Metastatic phase of 
non-Hodgkin lymphoma
140·1 
(137·6 to 142·6)
·· 58·8 
(40·5 to 77·5)
60·4% 
(53·7 to 66·4)*
35·4% 
(31·3 to 39·6)*
12·0% 
(7·9 to 15·8)*
5·1% 
(1·9 to 8·4)*
Terminal phase of 
non-Hodgkin lymphoma
24·1 
(23·7 to 24·6)
·· 12·9 
(9·0 to 16·5)
57·3% 
(51·5 to 62·0)*
34·0% 
(30·5 to 37·2)*
9·4% 
(6·2 to 11·9)*
3·8% 
(1·2 to 6·2)*
Multiple myeloma 449·3 
(414·6 to 520·9)
152·7 
(140·6 to 172·7)
90·8 
(64·2 to 118·4)
93·4% 
(85·2 to 102·7)*
44·3% 
(38·6 to 50·3)*
29·7% 
(24·3 to 35·4)*
10·3% 
(5·9 to 14·7)*
Diagnosis and primary 
therapy phase of multiple 
myeloma
28·1 
(26·0 to 32·7)
152·7 
(140·6 to 172·7)
8·0 
(5·3 to 11·2)
116·1% 
(110·1 to 130·1)*
48·6% 
(43·2 to 54·8)*
47·0% 
(43·2 to 55·9)*
14·4% 
(10·2 to 19·0)*
Controlled phase of 
multiple myeloma
252·3 
(233·7 to 294·6)
·· 11·7 
(7·5 to 17·3)
118·2% 
(107·1 to 135·2)*
48·9% 
(42·0 to 56·3)*
48·8% 
(41·5 to 60·1)*
15·0% 
(9·7 to 20·7)*
Metastatic phase of 
multiple myeloma
157·9 
(145·3 to 181·5)
·· 65·1 
(44·2 to 85·7)
90·5% 
(80·8 to 100·4)*
43·8% 
(37·3 to 50·4)*
27·7% 
(21·3 to 34·0)*
9·8% 
(4·8 to 14·8)*
Terminal phase of multiple 
myeloma
10·9 
(10·1 to 12·3)
·· 5·9 
(4·1 to 7·6)
63·8% 
(53·4 to 68·1)*
35·8% 
(31·5 to 39·8)*
8·5% 
(0·7 to 11·3)*
2·4% 
(−0·9 to 5·5)
Leukaemia 2432·4 
(2190·3 to 2591·6)
518·5 
(472·2 to 548·0)
263·3 
(191·2 to 342·0)
27·8% 
(13·5 to 38·0)*
25·1% 
(19·7 to 29·5)*
−3·6% 
(−12·7 to 2·1)
2·3% 
(−2·3 to 6·5)
Acute lymphoid leukaemia 521·1 
(433·1 to 579·5)
64·2 
(56·4 to 70·4)
43·0 
(30·6 to 58·6)
29·9% 
(3·6 to 46·7)*
31·6% 
(11·9 to 47·7)*
11·1% 
(−9·4 to 24·0)
18·6% 
(0·3 to 33·7)*
Diagnosis and primary 
therapy phase of acute 
lymphoid leukaemia
32·0 
(28·1 to 35·1)
64·2 
(56·4 to 70·4)
9·2 
(6·1 to 13·0)
18·6% 
(−6·0 to 33·6)
11·8% 
(−3·0 to 21·9)
0·6% 
(−18·0 to 11·8)
−1·0% 
(−14·5 to 8·0)
Controlled phase of acute 
lymphoid leukaemia
465·2 
(383·8 to 521·0)
·· 22·6 
(14·0 to 34·1)
39·6% 
(10·2 to 59·8)*
48·4% 
(20·2 to 69·2)*
24·4% 
(−0·3 to 41·3)
36·8% 
(10·2 to 56·6)*
Metastatic phase of acute 
lymphoid leukaemia
20·1 
(17·3 to 21·7)
·· 9·1 
(6·0 to 12·4)
26·3% 
(3·9 to 42·1)*
21·6% 
(10·0 to 31·5)*
2·4% 
(−13·6 to 13·8)
5·8% 
(−4·5 to 14·3)
Terminal phase of acute 
lymphoid leukaemia
3·7 
(3·2 to 4·0)
·· 2·0 
(1·4 to 2·6)
25·4% 
(2·9 to 41·5)*
20·8% 
(9·0 to 30·9)*
2·0% 
(−14·1 to 13·7)
5·2% 
(−5·2 to 13·9)
Chronic lymphoid 
leukaemia
567·7 
(534·1 to 600·4)
90·6 
(85·6 to 95·6)
74·6 
(54·8 to 96·5)
72·3% 
(65·5 to 80·3)*
42·7% 
(36·5 to 49·1)*
12·5% 
(7·8 to 17·7)*
7·3% 
(2·5 to 12·3)*
Diagnosis and primary 
therapy phase of chronic 
lymphoid leukaemia
30·4 
(28·6 to 32·1)
90·6 
(85·6 to 95·6)
8·6 
(5·8 to 11·9)
78·0% 
(71·6 to 84·8)*
45·4% 
(39·0 to 52·0)*
18·1% 
(13·6 to 22·7)*
10·6% 
(5·5 to 15·7)*
Controlled phase of 
chronic lymphoid 
leukaemia
424·3 
(399·1 to 449·4)
·· 19·5 
(12·7 to 28·2)
83·4% 
(75·4 to 91·3)*
46·6% 
(39·4 to 54·0)*
23·1% 
(18·0 to 28·5)*
12·2% 
(6·9 to 17·9)*
Metastatic phase of 
chronic lymphoid 
leukaemia
108·9 
(103·0 to 114·8)
·· 44·4 
(31·2 to 58·5)
67·8% 
(59·1 to 77·9)*
40·8% 
(33·9 to 48·3)*
8·5% 
(2·8 to 14·8)*
5·1% 
(0·0 to 10·7)*
Terminal phase of chronic 
lymphoid leukaemia
4·0 
(3·8 to 4·2)
·· 2·2 
(1·5 to 2·8)
58·4% 
(52·4 to 64·5)*
35·9% 
(30·4 to 41·8)*
1·6% 
(−2·4 to 5·5)
0·5% 
(−3·6 to 5·0)
Acute myeloid leukaemia 150·9 
(137·0 to 160·0)
119·6 
(108·4 to 125·9)
28·8 
(20·2 to 37·7)
52·6% 
(24·2 to 72·6)*
22·9% 
(12·9 to 30·0)*
13·5% 
(−4·6 to 25·4)
1·0% 
(−7·1 to 6·7)
Diagnosis and primary 
therapy phase of acute 
myeloid leukaemia
·· 119·6 
(108·4 to 125·9)
·· ·· ·· ·· ··
Controlled phase of acute 
myeloid leukaemia
99·2 
(90·5 to 105·8)
·· 4·8 
(3·0 to 7·2)
63·3% 
(25·1 to 91·8)*
18·7% 
(7·4 to 27·0)*
26·4% 
(1·9 to 44·0)*
0·0% 
(−9·5 to 7·1)
Metastatic phase of acute 
myeloid leukaemia
42·5 
(38·5 to 44·7)
·· 19·0 
(12·5 to 25·5)
50·4% 
(23·7 to 69·1)*
23·8% 
(14·0 to 30·8)*
11·1% 
(−6·0 to 22·1)
1·1% 
(−6·4 to 6·8)
Terminal phase of acute 
myeloid leukaemia
9·2 
(8·4 to 9·7)
·· 5·0 
(3·4 to 6·5)
51·0% 
(24·2 to 69·8)*
24·0% 
(14·2 to 30·8)*
11·6% 
(−5·6 to 22·6)
1·2% 
(−6·2 to 6·8)
Chronic myeloid leukaemia 95·8 
(88·3 to 103·2)
34·2 
(31·5 to 36·7)
11·7 
(8·4 to 15·4)
6·5% 
(1·3 to 11·2)*
6·6% 
(3·0 to 10·0)*
−28·1% 
(−31·5 to −24·8)*
−15·0% 
(−17·9 to −12·1)*
(Table 1 continues on next page)
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1811
Prevalence (thousands) 
2017 counts
Incidence (thousands) 
2017 counts
YLDs (thousands)
2017 counts Percentage 
change in counts, 
1990–2007
Percentage 
change in counts, 
2007–17
Percentage change 
in age-standardised 
rates, 1990–2007
Percentage change 
in age-standardised 
rates, 2007–17
(Continued from previous page)
Diagnosis and primary 
therapy phase of chronic 
myeloid leukaemia
6·9 
(6·4 to 7·4)
34·2 
(31·5 to 36·7)
2·0 
(1·3 to 2·8)
13·6% 
(8·5 to 18·5)*
7·5% 
(3·9 to 11·0)*
−23·4% 
(−26·6 to −20·3)*
−13·7% 
(−16·6 to −10·8)*
Controlled phase of 
chronic myeloid leukaemia
76·1 
(70·1 to 82·0)
·· 3·7 
(2·4 to 5·6)
17·9% 
(12·1 to 23·7)*
7·8% 
(3·9 to 11·5)*
−19·3% 
(−23·2 to −15·2)*
−12·6% 
(−15·8 to −9·5)*
Metastatic phase of 
chronic myeloid 
leukaemia
10·6 
(9·7 to 11·3)
·· 4·8 
(3·2 to 6·4)
−1·3% 
(−6·1 to 2·9)
5·5% 
(2·0 to 9·1)*
−33·5% 
(−36·6 to −30·5)*
−16·7% 
(−19·7 to −13·8)*
Terminal phase of chronic 
myeloid leukaemia
2·3 
(2·1 to 2·5)
·· 1·2 
(0·9 to 1·6)
−1·7% 
(−6·3 to 2·6)
5·5% 
(1·9 to 9·1)*
−33·9% 
(−36·7 to −31·1)*
−16·8% 
(−19·6 to −13·9)*
Other leukaemia 1096·8 
(930·7 to 1204·2)
209·9 
(180·8 to 227·5)
105·3 
(74·7 to 137·1)
9·1% 
(−6·7 to 25·2)
15·4% 
(8·5 to 22·4)*
−14·8% 
(−25·1 to −5·3)*
−4·0% 
(−9·7 to 1·9)
Diagnosis and primary 
therapy phase of other 
leukaemia
·· 209·9 
(180·8 to 227·5)
·· ·· ·· ·· ··
Controlled phase of other 
leukaemia
957·9 
(808·7 to 1058·8)
·· 45·4 
(28·5 to 67·6)
7·6% 
(−13·7 to 33·7)
13·1% 
(1·7 to 25·4)*
−8·8% 
(−24·9 to 9·7)
−1·1% 
(−11·7 to 10·0)
Metastatic phase of other 
leukaemia
130·2 
(114·4 to 139·3)
·· 55·1 
(37·6 to 72·8)
10·8% 
(−0·2 to 20·4)
17·4% 
(13·1 to 23·7)*
−18·7% 
(−25·8 to −13·5)*
−6·0% 
(−9·4 to −1·3)*
Terminal phase of other 
leukaemia
8·8 
(7·7 to 9·4)
·· 4·7 
(3·3 to 6·1)
6·4% 
(−4·0 to 17·1)
15·2% 
(11·1 to 20·7)*
−20·7% 
(−27·2 to −15·4)*
−7·6% 
(−10·9 to −3·4)*
Other malignant cancers 9176·2 
(8080·3 to 10 439·8)
715·5 
(656·3 to 740·0)
678·1 
(481·1 to 910·4)
99·7% 
(84·8 to 118·8)*
149·2% 
(122·1 to 179·0)*
46·4% 
(35·6 to 60·0)*
107·7% 
(84·2 to 133·3)*
Diagnosis and primary 
therapy phase of other 
malignant neoplasms
205·1 
(181·3 to 231·1)
715·5 
(656·3 to 740·0)
56·6 
(38·0 to 80·5)
126·8% 
(107·3 to 150·6)*
177·7% 
(146·5 to 210·3)*
67·9% 
(55·4 to 83·7)*
133·3% 
(107·0 to 161·9)*
Controlled phase of other 
malignant neoplasms
8451·7 
(7437·1 to 9683·5)
·· 397·1 
(252·9 to 592·8)
140·6% 
(114·5 to 174·5)*
204·9% 
(166·8 to 245·8)*
86·8% 
(68·6 to 109·9)*
161·4% 
(127·6 to 198·8)*
Metastatic phase of other 
malignant neoplasms
460·4 
(413·4 to 501·3)
·· 188·6 
(128·3 to 248·2)
67·0% 
(58·2 to 80·1)*
86·3% 
(71·8 to 101·9)*
18·3% 
(12·2 to 27·4)*
49·1% 
(37·2 to 61·1)*
Terminal phase of other 
malignant neoplasms
68·0 
(61·1 to 73·8)
·· 35·8 
(24·8 to 46·0)
62·1% 
(54·1 to 73·7)*
77·1% 
(65·3 to 90·1)*
14·2% 
(8·8 to 22·0)*
40·7% 
(31·0 to 51·3)*
Other neoplasms 25 223·0 
(24 682·1 to 25 725·3)
11 159·5 
(10 928·2 to 11 416·2)
55·1 
(35·2 to 80·9)
47·4% 
(42·6 to 52·3)*
34·5% 
(31·6 to 37·3)*
4·7% 
(1·8 to 7·7)*
6·0% 
(4·0 to 7·9)*
Myelodysplastic, 
myeloproliferative, and 
other haemopoietic 
neoplasms
1212·2 
(1098·1 to 1332·1)
134·3 
(118·4 to 148·9)
55·1 
(35·2 to 80·9)
47·4% 
(42·6 to 52·3)*
34·5% 
(31·6 to 37·3)*
4·7% 
(1·8 to 7·7)*
6·0% 
(4·0 to 7·9)*
Benign and in-situ 
intestinal neoplasms
3966·3 
(3840·7 to 4110·3)
1010·9 
(980·1 to 1049·4)
·· ·· ·· ·· ··
Benign and in-situ cervical 
and uterine neoplasms
1180·0 
(1138·1 to 1223·0)
299·4 
(287·6 to 312·8)
·· ·· ·· ·· ··
Other benign and in-situ 
neoplasms
19 417·1 
(18 926·5 to 19 882·6)
9715·0 
(9488·7 to 9966·6)
·· ·· ·· ·· ··
Cardiovascular diseases 485 620·9 
(468 031·7 to 504 964·4)
72 721·2 
(70 388·1 to 75 264·1)
35 697·3 
(26 428·2 to 
45 510·3)
39·8% 
(38·8 to 40·8)*
34·3% 
(32·0 to 37·0)*
−5·5% 
(−6·2 to −4·8)*
4·5% 
(2·9 to 6·4)*
Rheumatic heart disease 39 345·4 
(37 960·8 to 40 828·7)
1311·3 
(1269·4 to 1354·9)
1901·0 
(1232·8 to 2766·0)
40·9% 
(40·0 to 41·8)*
16·0% 
(15·3 to 16·7)*
7·3% 
(6·7 to 7·9)*
2·4% 
(1·9 to 3·1)*
Rheumatic heart disease 
without heart failure
38 145·4 
(36 705·9 to 39 639·2)
1311·3 
(1269·4 to 1354·9)
1797·9 
(1160·7 to 2619·0)
40·0% 
(39·2 to 40·9)*
15·4% 
(14·8 to 16·1)*
7·3% 
(6·7 to 7·9)*
2·6% 
(2·0 to 3·2)*
Heart failure due to 
rheumatic heart disease
1199·9 
(1006·1 to 1403·8)
·· 103·1 
(69·7 to 145·1)
58·9% 
(54·7 to 62·6)*
27·2% 
(24·4 to 30·2)*
7·9% 
(5·3 to 10·3)*
−0·1% 
(−2·2 to 1·9)
Ischaemic heart disease 126 451·5 
(118 587·5 to 134 706·5)
10 636·5 
(9573·2 to 11 794·5)
5291·9 
(3657·3 to 7238·9)
35·8% 
(34·5 to 37·0)*
23·5% 
(22·9 to 24·2)*
−10·9% 
(−11·9 to −10·0)*
−5·2% 
(−5·7 to −4·7)*
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Asymptomatic ischaemic 
heart disease following 
myocardial infarction
37 908·6 
(31 907·4 to 44 225·6)
·· ·· ·· ·· ·· ··
Angina due to ischaemic 
heart disease
70 969·3 
(66 224·1 to 75 830·1)
·· 3850·4 
(2615·6 to 5381·2)
35·1% 
(34·3 to 35·9)*
22·9% 
(22·2 to 23·5)*
−10·0% 
(−10·4 to −9·5)*
−4·6% 
(−5·0 to −4·2)*
Heart failure due to 
ischaemic heart disease
17 007·2 
(14 512·0 to 19 849·5)
·· 1388·9 
(951·7 to 1947·2)
37·2% 
(33·2 to 41·7)*
25·9% 
(24·3 to 27·5)*
−13·5% 
(−16·2 to −10·7)*
−6·4% 
(−7·6 to −5·1)*
Myocardial infarction due 
to ischaemic heart disease
566·4 
(505·5 to 634·4)
10 636·5 
(9573·2 to 11 794·5)
52·7 
(36·6 to 72·9)
48·9% 
(46·1 to 51·7)*
13·6% 
(10·5 to 16·6)*
−4·2% 
(−5·9 to −2·5)*
−14·6% 
(−17·0 to −12·3)*
Stroke 104 178·7 
(98 454·0 to 110 125·0)
11 931·1 
(11 118·4 to 12 825·8)‡
18 695·4 
(13 574·3 to 
23 686·9)
40·0% 
(38·4 to 41·4)*
43·6% 
(39·6 to 47·8)*
−4·7% 
(−5·8 to −3·7)*
11·2% 
(8·1 to 14·3)*
Ischaemic stroke 82 417·3 
(76 967·8 to 88 516·9)
7737·5 
(6951·1 to 8677·6)‡
14 304·4 
(10 297·5 to 
18 176·0)
42·8% 
(40·6 to 44·9)*
54·3% 
(49·1 to 59·4)*
−4·1% 
(−5·5 to −2·7)*
18·1% 
(14·1 to 22·0)*
Acute ischaemic stroke 587·5 
(529·1 to 655·7)
7737·5 
(6951·1 to 8677·6)‡
144·3 
(100·1 to 188·1)
40·1% 
(37·4 to 42·9)*
43·0% 
(37·0 to 49·4)*
−6·9% 
(−8·5 to −5·2)*
8·8% 
(4·3 to 13·6)*
Chronic ischaemic stroke 81 829·7 
(76 384·9 to 87 926·6)
·· 14 160·1 
(10 204·3 to 
17 970·9)
42·8% 
(40·6 to 45·0)*
54·4% 
(49·2 to 59·6)*
−4·1% 
(−5·4 to −2·7)*
18·2% 
(14·1 to 22·2)*
Intracerebral haemorrhage 17 914·9 
(16 190·6 to 19 666·6)
3128·6 
(2874·6 to 3418·0)‡
2946·9 
(2121·6 to 3794·1)
32·1% 
(29·9 to 34·3)*
13·9% 
(8·0 to 20·3)*
−6·8% 
(−8·2 to −5·4)*
−9·5% 
(−14·2 to −4·8)*
Acute intracerebral 
haemorrhage
168·7 
(154·2 to 184·6)
3128·6 
(2874·6 to 3418·0)‡
44·3 
(31·0 to 57·8)
39·4% 
(36·8 to 42·4)*
−1·9% 
(−6·8 to 3·2)
−5·5% 
(−7·3 to −3·7)*
−24·4% 
(−28·1 to −20·6)*
Chronic intracerebral 
haemorrhage
17 746·2 
(16 029·3 to 19 493·5)
·· 2902·6 
(2090·3 to 3738·5)
32·0% 
(29·8 to 34·1)*
14·2% 
(8·1 to 20·6)*
−6·8% 
(−8·3 to −5·4)*
−9·3% 
(−14·0 to −4·4)*
Subarachnoid haemorrhage 9321·9 
(8523·7 to 10 242·4)
1064·9 
(953·3 to 1182·6)‡
1444·2 
(1031·6 to 1845·4)
36·8% 
(34·7 to 38·9)*
25·0% 
(21·3 to 28·6)*
−5·7% 
(−7·1 to −4·3)*
−1·6% 
(−4·4 to 1·2)
Acute subarachnoid 
haemorrhage
80·5 
(71·7 to 89·5)
1064·9 
(953·3 to 1182·6)‡
21·1 
(14·5 to 28·0)
40·2% 
(31·1 to 43·9)*
25·2% 
(19·8 to 27·2)*
−4·6% 
(−10·2 to −2·5)*
−1·6% 
(−5·5 to −0·2)*
Chronic subarachnoid 
haemorrhage
9241·4 
(8444·1 to 10 171·4)
·· 1423·1 
(1016·6 to 1817·9)
36·7% 
(34·6 to 38·8)*
25·0% 
(21·2 to 28·6)*
−5·7% 
(−7·1 to −4·3)*
−1·6% 
(−4·4 to 1·2)
Hypertensive heart disease 17 067·7 
(14 426·9 to 19 874·3)
·· 1408·0 
(966·6 to 1982·4)
63·8% 
(60·5 to 67·2)*
34·9% 
(33·2 to 36·6)*
6·0% 
(3·8 to 8·2)*
1·9% 
(0·7 to 2·9)*
Non-rheumatic valvular heart 
disease
29 729·1 
(28 505·4 to 31 022·5)
30 691·2 
(29 436·4 to 32 002·2)
360·8 
(207·1 to 559·6)
54·9% 
(49·0 to 61·0)*
35·8% 
(30·9 to 40·7)*
−4·5% 
(−7·7 to −1·7)*
−1·0% 
(−4·3 to 2·1)
Non-rheumatic calcific 
aortic valve disease
12 570·2 
(11 411·8 to 13 841·1)
12 570·2 
(11 411·8 to 13 841·1)
168·0 
(96·6 to 259·9)
64·8% 
(56·5 to 73·5)*
38·9% 
(30·9 to 46·2)*
−0·2% 
(−5·1 to 4·3)
0·2% 
(−5·9 to 5·3)
Heart failure due to calcific 
aortic valve disease
1386·0 
(896·6 to 2029·9)
·· 111·0 
(63·7 to 173·8)
42·3% 
(30·1 to 56·6)*
30·6% 
(13·2 to 47·6)*
−14·1% 
(−21·4 to −6·0)*
−6·0% 
(−19·0 to 6·2)
Non-rheumatic calcific 
aortic valve disease
11 184·2 
(9987·3 to 12 425·7)
12 570·2 
(11 411·8 to 13 841·1)
56·9 
(30·4 to 93·2)
163·9% 
(124·2 to 209·0)*
58·7% 
(36·3 to 84·3)*
62·6% 
(37·1 to 93·2)*
15·0% 
(−1·6 to 34·3)
Non-rheumatic 
degenerative mitral valve 
disease
18 121·0 
(17 682·3 to 18 586·4)
18 121·0 
(17 682·3 to 18 586·4)
190·3 
(109·2 to 295·3)
47·4% 
(41·5 to 52·7)*
33·2% 
(28·1 to 38·0)*
−8·1% 
(−11·5 to −5·4)*
−2·0% 
(−5·6 to 1·2)
Heart failure due to 
degenerative mitral valve 
disease
1723·6 
(1111·4 to 2494·0)
·· 139·9 
(81·5 to 217·1)
33·3% 
(25·0 to 43·1)*
26·7% 
(15·5 to 38·6)*
−17·1% 
(−22·2 to −11·4)*
−6·8% 
(−15·0 to 2·0)
Non-rheumatic 
degenerative mitral valve 
disease
16 397·4 
(15 574·9 to 17 179·2)
18 121·0 
(17 682·3 to 18 586·4)
50·5 
(26·7 to 84·0)
129·8% 
(95·6 to 171·4)*
55·2% 
(33·1 to 78·0)*
44·9% 
(22·1 to 72·2)*
14·0% 
(−2·5 to 30·9)
Other non-rheumatic valve 
diseases
26·9 
(22·1 to 32·2)
·· 2·5 
(1·6 to 3·6)
63·1% 
(58·9 to 67·2)*
37·7% 
(34·1 to 41·1)*
7·4% 
(5·1 to 9·4)*
6·1% 
(4·1 to 8·1)*
Mild heart failure due to 
other non-rheumatic 
valve disease
5·0 
(3·5 to 6·8)
·· 0·2 
(0·1 to 0·3)
63·6% 
(59·2 to 68·1)*
38·0% 
(34·5 to 41·4)*
7·7% 
(5·4 to 9·9)*
6·2% 
(4·2 to 8·1)*
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Moderate heart failure 
due to other non-
rheumatic valve disease
3·3 
(2·2 to 4·4)
·· 0·2 
(0·1 to 0·4)
63·6% 
(59·0 to 68·0)*
38·0% 
(34·5 to 41·6)*
7·7% 
(5·3 to 10·0)*
6·2% 
(4·0 to 8·2)*
Severe heart failure due 
to other non-rheumatic 
valve disease
8·8 
(6·9 to 10·9)
·· 1·5 
(1·0 to 2·3)
63·0% 
(58·7 to 67·4)*
37·7% 
(33·6 to 41·6)*
7·3% 
(4·8 to 9·8)*
6·1% 
(3·7 to 8·8)*
Controlled, medically 
managed heart failure due 
to other non-rheumatic 
valve disease
9·9 
(8·0 to 12·1)
·· 0·5 
(0·3 to 0·7)
63·2% 
(58·8 to 67·6)*
37·6% 
(33·5 to 41·6)*
7·4% 
(5·0 to 10·0)*
6·1% 
(3·3 to 8·7)*
Cardiomyopathy and 
myocarditis
5429·9 
(4694·4 to 6257·1)
3071·0 
(2745·0 to 3451·2)
623·8 
(424·7 to 859·3)
27·4% 
(24·5 to 30·9)*
21·2% 
(19·2 to 23·0)*
−12·6% 
(−14·9 to −10·3)*
−3·9% 
(−5·0 to −2·9)*
Myocarditis 1804·6 
(1635·3 to 1983·8)
3071·0 
(2745·0 to 3451·2)
131·4 
(90·1 to 183·0)
26·6% 
(23·9 to 29·6)*
15·9% 
(13·9 to 18·0)*
−5·4% 
(−6·8 to −4·1)*
−1·9% 
(−3·0 to −0·9)*
Acute myocarditis 740·8 
(656·3 to 830·8)
3071·0 
(2745·0 to 3451·2)
35·7 
(22·5 to 52·6)
33·3% 
(30·5 to 36·2)*
19·1% 
(16·7 to 21·6)*
−2·4% 
(−4·0 to −0·6)*
−1·3% 
(−2·9 to 0·2)
Heart failure due to 
myocarditis
1063·7 
(914·1 to 1215·2)
·· 95·7 
(63·9 to 133·5)
24·4% 
(21·0 to 28·2)*
14·8% 
(12·3 to 17·3)*
−6·5% 
(−8·1 to −4·9)*
−2·1% 
(−3·4 to −0·8)*
Alcoholic cardiomyopathy 1621·8 
(1370·5 to 1902·4)
·· 139·1 
(95·1 to 196·1)
20·7% 
(16·8 to 25·1)*
15·5% 
(12·9 to 18·1)*
−17·9% 
(−20·5 to −15·2)*
−9·5% 
(−11·2 to −7·7)*
Other cardiomyopathy 4212·7 
(3634·6 to 4869·9)
·· 353·3 
(237·9 to 493·9)
30·8% 
(27·2 to 34·9)*
25·7% 
(23·4 to 27·9)*
−12·8% 
(−15·6 to −9·9)*
−2·5% 
(−3·9 to −1·0)*
Atrial fibrillation and flutter 37 574·2 
(32 548·8 to 42 588·4)
3046·0 
(2605·8 to 3507·2)
2921·5 
(1992·6 to 4034·2)
49·0% 
(46·7 to 51·7)*
31·4% 
(30·3 to 32·5)*
−3·7% 
(−5·1 to −1·9)*
−1·2% 
(−1·9 to −0·6)*
Asymptomatic atrial 
fibrillation and flutter
22 545·7 
(19 530·0 to 25 680·2)
3046·0 
(2605·8 to 3507·2)
·· ·· ·· ·· ··
Symptomatic atrial 
fibrillation and flutter
15 028·5 
(13 016·1 to 17 142·8)
·· 2921·5 
(1992·6 to 4034·2)
49·0% 
(46·7 to 51·7)*
31·4% 
(30·3 to 32·5)*
−3·7% 
(−5·1 to −1·9)*
−1·2% 
(−1·9 to −0·6)*
Peripheral vascular disease 118 123·6 
(102 706·9 to 134 350·4)
10 811·7 
(9282·1 to 12 503·4)
515·6 
(237·6 to 938·4)
40·0% 
(37·6 to 42·8)*
27·8% 
(26·6 to 29·3)*
−8·5% 
(−9·6 to −7·0)*
−4·7% 
(−5·5 to −3·6)*
Asymptomatic peripheral 
arterial disease
78 631·6 
(66 970·1 to 91 233·4)
10 811·7 
(9282·1 to 12 503·4)
·· ·· ·· ·· ··
Symptomatic claudication 
due to peripheral arterial 
disease
39 492·0 
(31 074·7 to 50 227·2)
·· 515·6 
(237·6 to 938·4)
40·0% 
(37·6 to 42·8)*
27·8% 
(26·6 to 29·3)*
−8·5% 
(−9·6 to −7·0)*
−4·7% 
(−5·5 to −3·6)*
Endocarditis 654·1 
(567·5 to 743·8)
1222·5 
(1097·6 to 1334·0)
53·8 
(36·6 to 75·3)
31·1% 
(27·3 to 35·6)*
24·6% 
(22·1 to 27·3)*
−10·7% 
(−14·3 to −7·2)*
−2·5% 
(−4·4 to −0·8)*
Acute endocarditis 87·9 
(78·3 to 96·3)
1222·5 
(1097·6 to 1334·0)
4·9 
(3·2 to 7·3)
34·3% 
(31·7 to 36·9)*
26·2% 
(23·2 to 29·2)*
2·1% 
(1·4 to 2·9)*
4·3% 
(2·3 to 6·4)*
Heart failure due to 
endocarditis
566·2 
(480·9 to 655·8)
·· 48·9 
(33·3 to 68·7)
30·8% 
(26·5 to 35·7)*
24·5% 
(21·8 to 27·4)*
−11·7% 
(−15·5 to −8·1)*
−3·2% 
(−5·1 to −1·3)*
Other cardiovascular and 
circulatory diseases
75 599·8 
(64 068·9 to 88 170·3)
·· 3925·4 
(2650·1 to 5544·1)
32·5% 
(30·0 to 35·5)*
24·4% 
(22·5 to 26·2)*
−9·1% 
(−10·9 to −6·9)*
−0·5% 
(−1·4 to 0·4)
Heart failure due to other 
cardiovascular diseases
1562·0 
(1279·4 to 1882·1)
·· 129·6 
(86·6 to 185·3)
32·6% 
(28·4 to 37·1)*
30·0% 
(27·5 to 32·6)*
−15·0% 
(−18·0 to −12·0)*
−2·0% 
(−3·8 to −0·2)*
Other cardiovascular and 
circulatory disease episodes
74 037·8 
(62 741·1 to 86 283·3)
·· 3795·9 
(2564·1 to 5373·7)
32·4% 
(30·0 to 35·5)*
24·2% 
(22·3 to 26·0)*
−8·8% 
(−10·7 to −6·7)*
−0·4% 
(−1·3 to 0·5)
Chronic respiratory diseases 544 899·2 
(506 937·5 to 584 858·4)
62 161·4 
(55 134·8 to 69 320·7)
44 311·8 
(36 751·6 to 
51 407·1)
21·9% 
(19·7 to 24·3)*
22·8% 
(19·0 to 26·5)*
−12·5% 
(−13·7 to −11·3)*
−0·4% 
(−3·3 to 2·5)
Chronic obstructive 
pulmonary disease
299 398·2 
(269 025·2 to 330 073·8)
18 475·7 
(16 736·0 to 20 255·6)
30 611·5 
(26 034·9 to 
34 813·0)
24·9% 
(22·7 to 27·2)*
23·8% 
(18·6 to 28·6)*
−14·1% 
(−15·5 to −12·6)*
−2·8% 
(−6·9 to 0·9)
Chronic obstructive 
pulmonary disease with 
heart failure
14 890·7 
(12 183·6 to 17 715·3)
·· 5673·6 
(4163·8 to 7049·6)
66·5% 
(61·8 to 71·3)*
36·1% 
(32·1 to 39·1)*
5·4% 
(2·6 to 8·1)*
1·3% 
(−1·1 to 3·4)
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Chronic obstructive 
pulmonary disease without 
heart failure
284 507·4 
(254 368·4 to 315 515·1)
18 475·7 
(16 736·0 to 20 255·6)
24 937·9 
(21 040·1 to 
28 738·5)
18·9% 
(16·3 to 21·5)*
21·3% 
(15·4 to 26·8)*
−17·6% 
(−19·3 to −15·8)*
−3·7% 
(−8·4 to 0·6)
Pneumoconiosis 527·5 
(470·0 to 593·2)
60·1 
(53·1 to 67·0)
80·5 
(54·5 to 111·5)
41·3% 
(36·5 to 46·3)*
27·0% 
(22·8 to 31·2)*
−3·8% 
(−6·9 to −0·7)*
−2·0% 
(−5·2 to 1·1)
Silicosis 162·4 
(127·5 to 202·6)
23·7 
(19·1 to 29·0)
24·9 
(16·0 to 36·0)
45·4% 
(36·4 to 54·7)*
29·1% 
(21·3 to 37·1)*
−0·0% 
(−5·9 to 6·1)
0·2% 
(−5·8 to 6·4)
Heart failure due to 
silicosis
11·0 
(9·1 to 13·1)
·· 5·0 
(3·4 to 6·9)
64·3% 
(58·4 to 70·9)*
31·0% 
(26·8 to 35·3)*
8·7% 
(5·1 to 13·1)*
−1·6% 
(−4·8 to 1·9)
Silicosis without heart 
failure
151·4 
(117·1 to 190·0)
23·7 
(19·1 to 29·0)
19·8 
(12·2 to 29·4)
41·3% 
(30·6 to 52·9)*
28·6% 
(19·0 to 38·5)*
−2·1% 
(−9·3 to 5·9)
0·6% 
(−6·9 to 8·3)
Asbestosis 92·1 
(73·1 to 118·3)
9·4 
(7·7 to 11·6)
14·4 
(9·2 to 21·6)
42·6% 
(32·3 to 53·9)*
35·0% 
(29·6 to 41·3)*
−2·1% 
(−9·1 to 5·2)
4·4% 
(0·6 to 8·6)*
Asbestosis without heart 
failure
86·6 
(67·7 to 112·7)
9·4 
(7·7 to 11·6)
11·9 
(7·4 to 18·2)
38·3% 
(27·2 to 50·6)*
36·6% 
(30·1 to 44·7)*
−3·9% 
(−11·9 to 4·7)
7·1% 
(2·4 to 12·5)*
Heart failure due to 
asbestosis
5·6 
(4·7 to 6·5)
·· 2·5 
(1·7 to 3·5)
65·2% 
(54·7 to 77·6)*
27·6% 
(23·8 to 31·8)*
5·5% 
(−1·3 to 13·3)
−6·0% 
(−8·9 to −3·0)*
Coal worker 
pneumoconiosis
147·9 
(117·5 to 190·1)
15·1 
(12·0 to 19·8)
21·9 
(14·2 to 31·8)
39·1% 
(28·8 to 50·1)*
23·1% 
(13·8 to 32·3)*
−6·0% 
(−12·4 to 1·1)
−5·6% 
(−12·7 to 1·2)
Coal worker 
pneumoconiosis without 
heart failure
140·9 
(110·7 to 182·6)
15·1 
(12·0 to 19·8)
18·7 
(12·0 to 27·8)
36·5% 
(24·8 to 48·9)*
22·4% 
(11·6 to 33·0)*
−7·3% 
(−14·7 to 0·9)
−6·0% 
(−14·1 to 1·7)
Heart failure due to coal 
worker pneumoconiosis
7·0 
(5·9 to 8·2)
·· 3·2 
(2·2 to 4·3)
57·8% 
(51·8 to 64·5)*
27·5% 
(23·0 to 32·1)*
2·7% 
(−1·6 to 7·1)
−3·1% 
(−6·6 to 0·4)
Other pneumoconiosis 125·1 
(105·0 to 149·3)
11·9 
(9·9 to 14·3)
19·3 
(12·6 to 28·5)
38·2% 
(31·9 to 45·3)*
23·3% 
(18·5 to 27·9)*
−6·9% 
(−10·9 to −2·7)*
−5·0% 
(−8·4 to −1·6)*
Heart failure due to other 
pneumoconiosis
4·1 
(3·4 to 4·7)
·· 1·9 
(1·3 to 2·6)
80·7% 
(75·2 to 86·3)*
27·8% 
(23·5 to 31·9)*
15·2% 
(12·3 to 18·2)*
−4·5% 
(−7·5 to −1·9)*
Other pneumoconiosis 
without heart failure
121·0 
(100·9 to 145·2)
11·9 
(9·9 to 14·3)
17·5 
(11·2 to 26·0)
34·9% 
(28·3 to 42·1)*
22·8% 
(17·7 to 27·8)*
−8·8% 
(−12·9 to −4·5)*
−5·0% 
(−8·8 to −1·2)*
Asthma 272 677·5 
(242 295·9 to 304 699·6)
43 123·4 
(36 191·5 to 50 226·4)
10 622·9 
(7057·0 to 15 056·4)
8·0% 
(5·2 to 10·9)*
19·3% 
(15·3 to 23·1)*
−13·5% 
(−14·9 to −11·9)*
4·9% 
(1·0 to 8·4)*
Asymptomatic asthma 99 070·1 
(84 654·0 to 114 607·7)
15 631·4 
(12 827·3 to 18 539·7)
·· ·· ·· ·· ··
Symptomatic asthma 173 607·4 
(151 655·5 to 198 619·2)
27 492·0 
(22 746·9 to 32 507·6)
10 622·9 
(7057·0 to 15 056·4)
8·0% 
(5·2 to 10·9)*
19·3% 
(15·3 to 23·1)*
−13·5% 
(−14·9 to −11·9)*
4·9% 
(1·0 to 8·4)*
Interstitial lung disease and 
pulmonary sarcoidosis
6234·2 
(5661·0 to 6848·2)
502·2 
(458·8 to 550·0)
648·2 
(440·3 to 923·2)
44·3% 
(41·7 to 47·3)*
29·1% 
(26·5 to 31·8)*
−2·3% 
(−3·9 to −0·5)*
0·1% 
(−1·8 to 2·0)
Heart failure due to 
interstitial lung disease and 
pulmonary sarcoidosis
416·8 
(322·3 to 505·6)
·· 169·8 
(114·4 to 236·1)
60·8% 
(56·2 to 65·6)*
31·4% 
(28·6 to 34·2)*
5·5% 
(2·8 to 8·4)*
−1·2% 
(−3·3 to 0·9)
Interstitial lung disease and 
pulmonary sarcoidosis 
without heart failure
5817·3 
(5242·6 to 6431·9)
502·2 
(458·8 to 550·0)
478·5 
(320·7 to 690·8)
39·3% 
(36·3 to 42·8)*
28·2% 
(25·3 to 31·5)*
−4·9% 
(−6·9 to −2·7)*
0·5% 
(−1·7 to 2·8)
Other chronic respiratory 
diseases
·· ·· 2348·7 
(1930·8 to 2739·6)
62·5% 
(58·1 to 67·0)*
23·8% 
(19·2 to 28·5)*
21·4% 
(17·8 to 25·1)*
9·2% 
(5·0 to 13·3)*
Digestive diseases 2 049 831·2 
(1 983 314·3 to 
2 122 941·6)
465 978·6 
(429 600·4 to 
500 015·1)
19 939·7 
(13 858·2 to 
27 973·1)
31·1% 
(29·3 to 32·7)*
20·5% 
(19·5 to 21·6)*
−3·4% 
(−4·1 to −2·7)*
1·3% 
(0·6 to 2·0)*
Cirrhosis and other chronic 
liver diseases
1 500 585·1 
(1 448 741·6 to 
1 556 007·5)
5154·9 
(4935·4 to 5366·5)
1745·6 
(1221·5 to 2387·3)
50·7% 
(49·4 to 52·1)*
34·8% 
(33·0 to 36·3)*
8·4% 
(7·6 to 9·3)*
10·4% 
(9·0 to 11·6)*
Cirrhosis and other chronic 
liver diseases due to 
hepatitis B
431 116·3 
(395 729·0 to 468 718·9)
1531·5 
(1419·0 to 1643·9)
488·4 
(337·9 to 665·7)
53·7% 
(50·9 to 56·5)*
33·2% 
(30·7 to 35·6)*
8·7% 
(6·9 to 10·5)*
9·0% 
(7·1 to 10·9)*
(Table 1 continues on next page)
Global Health Metrics
www.thelancet.com   Vol 392   November 10, 2018 1815
Prevalence (thousands) 
2017 counts
Incidence (thousands) 
2017 counts
YLDs (thousands)
2017 counts Percentage 
change in counts, 
1990–2007
Percentage 
change in counts, 
2007–17
Percentage change 
in age-standardised 
rates, 1990–2007
Percentage change 
in age-standardised 
rates, 2007–17
(Continued from previous page)
Cirrhosis and other 
chronic liver diseases due 
to hepatitis B, 
decompensated
2974·2 
(2810·2 to 3124·4)
539·5 
(509·2 to 570·8)
488·4 
(337·9 to 665·7)
53·7% 
(50·9 to 56·5)*
33·2% 
(30·7 to 35·6)*
8·7% 
(6·9 to 10·5)*
9·0% 
(7·1 to 10·9)*
Chronic hepatitis B 
without cirrhosis
391 475·2 
(356 323·1 to 429 032·9)
·· ·· ·· ·· ·· ··
Cirrhosis and other 
chronic liver diseases due 
to hepatitis B, 
compensated
36 666·9 
(34 057·4 to 39 502·9)
992·1 
(890·6 to 1095·8)
·· ·· ·· ·· ··
Cirrhosis and other chronic 
liver diseases due to 
hepatitis C
134 493·9 
(118 558·2 to 153 823·8)
1178·2 
(1086·0 to 1272·2)
431·3 
(300·3 to 596·4)
56·1% 
(53·5 to 58·4)*
36·5% 
(33·9 to 38·9)*
8·4% 
(6·7 to 9·9)*
10·2% 
(8·2 to 11·9)*
Cirrhosis and other 
chronic liver diseases due 
to hepatitis C, 
decompensated
2641·5 
(2487·0 to 2806·1)
467·3 
(438·1 to 496·2)
431·3 
(300·3 to 596·4)
56·1% 
(53·5 to 58·4)*
36·5% 
(33·9 to 38·9)*
8·4% 
(6·7 to 9·9)*
10·2% 
(8·2 to 11·9)*
Chronic hepatitis C 
without cirrhosis
104 133·4 
(88 178·6 to 123 899·7)
·· ·· ·· ·· ·· ··
Cirrhosis and other 
chronic liver diseases due 
to hepatitis C, 
compensated
27 719·0 
(25 515·4 to 29 987·7)
710·9 
(628·8 to 800·8)
·· ·· ·· ·· ··
Cirrhosis and other chronic 
liver diseases due to alcohol 
use
26 041·9 
(24 252·8 to 28 011·2)
903·7 
(839·9 to 973·5)
400·1 
(280·3 to 551·5)
58·1% 
(55·4 to 61·0)*
37·7% 
(35·1 to 40·5)*
8·1% 
(6·3 to 9·9)*
9·8% 
(7·8 to 11·9)*
Cirrhosis and other 
chronic liver diseases due 
to alcohol, 
decompensated
2457·4 
(2313·9 to 2610·3)
433·1 
(407·6 to 458·5)
400·1 
(280·3 to 551·5)
58·1% 
(55·4 to 61·0)*
37·7% 
(35·1 to 40·5)*
8·1% 
(6·3 to 9·9)*
9·8% 
(7·8 to 11·9)*
Cirrhosis and other 
chronic liver diseases due 
to alcohol, compensated
23 584·5 
(21 876·0 to 25 478·8)
470·6 
(417·4 to 525·3)
·· ·· ·· ·· ··
Cirrhosis due to NASH 892 322·8 
(858 624·9 to 927 954·4)
367·8 
(334·5 to 403·7)
148·6 
(102·8 to 205·0)
83·2% 
(78·8 to 87·5)*
54·6% 
(51·0 to 58·3)*
25·6% 
(22·8 to 28·5)*
23·5% 
(20·7 to 26·4)*
Non-alcoholic fatty liver 
disease/NASH
882 058·3 
(847 914·0 to 917 435·7)
·· ·· ·· ·· ·· ··
Cirrhosis and other chronic 
liver diseases due to NASH
10 264·5 
(9358·1 to 11 216·7)
367·8 
(334·5 to 403·7)
148·6 
(102·8 to 205·0)
83·2% 
(78·8 to 87·5)*
54·6% 
(51·0 to 58·3)*
25·6% 
(22·8 to 28·5)*
23·5% 
(20·7 to 26·4)*
Cirrhosis and other chronic 
liver diseases due to other 
causes
16 616·0 
(15 165·6 to 17 954·6)
1173·7 
(1084·6 to 1260·7)
277·1 
(192·1 to 386·4)
24·0% 
(20·6 to 27·3)*
22·7% 
(20·0 to 25·7)*
2·6% 
(−0·0 to 5·0)
8·1% 
(5·8 to 10·6)*
Cirrhosis and other 
chronic liver diseases due 
to other cause, 
decompensated
1653·0 
(1550·5 to 1755·9)
248·4 
(231·4 to 265·9)
277·1 
(192·1 to 386·4)
24·0% 
(20·6 to 27·3)*
22·7% 
(20·0 to 25·7)*
2·6% 
(−0·0 to 5·0)
8·1% 
(5·8 to 10·6)*
Cirrhosis and other 
chronic liver diseases due 
to other cause, 
compensated
14 963·1 
(13 571·8 to 16 245·0)
925·4 
(840·5 to 1008·8)
·· ·· ·· ·· ··
Upper digestive system 
diseases
807 369·3 
(728 919·0 to 888 668·9)
384 665·9 
(348 550·3 to 419 766·4)
13 042·1 
(8272·3 to 19 986·6)
32·0% 
(29·9 to 33·8)*
19·3% 
(18·1 to 20·6)*
−3·6% 
(−4·5 to −2·7)*
0·6% 
(−0·2 to 1·4)
Peptic ulcer disease 17 161·2 
(15 032·4 to 19 357·3)
6719·1 
(6078·7 to 7434·1)
832·8 
(555·4 to 1184·1)
22·2% 
(20·1 to 24·6)*
18·9% 
(16·5 to 21·1)*
−14·2% 
(−15·6 to −12·6)*
−1·6% 
(−3·5 to −0·1)*
Acute peptic ulcer disease 7·8 
(6·8 to 8·9)
·· 2·5 
(1·7 to 3·6)
32·0% 
(25·8 to 39·1)*
12·6% 
(10·9 to 14·4)*
−10·3% 
(−14·4 to −5·4)*
−12·2% 
(−13·1 to −11·3)*
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Chronic peptic ulcer 
disease
17 153·4 
(15 023·5 to 19 349·4)
6719·1 
(6078·7 to 7434·1)
830·2 
(553·1 to 1180·9)
22·2% 
(20·1 to 24·5)*
18·9% 
(16·5 to 21·2)*
−14·2% 
(−15·6 to −12·6)*
−1·6% 
(−3·5 to −0·0)*
Gastritis and duodenitis 140 449·0 
(120 336·3 to 161 832·9)
96 720·4 
(85 853·2 to 108 445·4)
6196·0 
(3976·7 to 8960·7)
27·7% 
(25·0 to 30·3)*
18·2% 
(16·1 to 20·4)*
−4·5% 
(−5·8 to −3·3)*
0·3% 
(−1·2 to 1·7)
Acute gastritis and 
duodenitis
40·1 
(34·5 to 46·3)
·· 13·1 
(8·6 to 18·7)
27·8% 
(25·2 to 30·5)*
15·4% 
(13·9 to 16·9)*
−10·2% 
(−11·4 to −8·9)*
−6·1% 
(−7·0 to −5·3)*
Chronic gastritis and 
duodenitis
140 408·8 
(120 292·9 to 161 787·1)
96 720·4 
(85 853·2 to 108 445·4)
6182·8 
(3967·9 to 8944·1)
27·7% 
(25·0 to 30·3)*
18·2% 
(16·1 to 20·4)*
−4·5% 
(−5·8 to −3·3)*
0·3% 
(−1·2 to 1·7)
Gastro-oesophageal reflux 
disease
709 264·3 
(625 708·7 to 794 604·2)
281 226·3 
(246 633·4 to 315 761·3)
6013·4 
(3215·9 to 10 192·9)
38·5% 
(36·3 to 40·4)*
20·7% 
(19·1 to 22·3)*
−0·7% 
(−1·5 to −0·0)*
1·3% 
(0·6 to 2·0)*
Appendicitis 722·7 
(673·2 to 775·6)
19 016·1 
(17 716·4 to 20 344·0)
223·6 
(149·1 to 306·5)
27·7% 
(23·9 to 31·9)*
10·3% 
(6·6 to 14·0)*
2·3% 
(−0·7 to 5·5)
0·2% 
(−3·1 to 3·7)
Paralytic ileus and intestinal 
obstruction
140·2 
(128·1 to 152·3)
3855·4 
(3520·1 to 4187·5)
44·2 
(30·0 to 60·4)
36·0% 
(32·4 to 39·3)*
25·5% 
(22·8 to 28·4)*
2·9% 
(1·2 to 4·5)*
4·2% 
(2·1 to 6·4)*
Inguinal, femoral, and 
abdominal hernia
26 490·8 
(24 196·8 to 28 760·4)
41 182·8 
(36 372·8 to 46 265·0)
2567·0 
(1713·5 to 3550·5)
21·2% 
(17·9 to 24·8)*
14·5% 
(12·3 to 17·0)*
−7·1% 
(−8·9 to −5·3)*
−2·9% 
(−4·4 to −1·2)*
Inflammatory bowel disease 6848·9 
(6421·4 to 7304·4)
4048·8 
(3776·1 to 4377·4)
1019·4 
(705·4 to 1381·8)
48·5% 
(44·4 to 52·7)*
21·7% 
(18·0 to 25·1)*
4·7% 
(1·9 to 7·6)*
−0·2% 
(−3·1 to 2·3)
Ulcerative colitis 4701·0 
(4318·4 to 5113·6)
2690·9 
(2440·5 to 2994·3)
684·0 
(468·6 to 935·0)
54·8% 
(50·4 to 59·5)*
29·5% 
(24·9 to 33·9)*
7·7% 
(4·8 to 10·9)*
4·6% 
(1·2 to 7·8)*
Crohn’s disease 2147·9 
(2007·7 to 2301·8)
1357·8 
(1240·2 to 1484·4)
335·4 
(227·1 to 460·4)
38·8% 
(34·0 to 43·8)*
8·6% 
(5·0 to 11·8)*
−0·1% 
(−3·5 to 3·4)
−8·7% 
(−11·5 to −6·2)*
Vascular intestinal disorders 89·8 
(80·0 to 100·8)
619·8 
(555·7 to 686·7)
27·1 
(18·5 to 36·7)
56·5% 
(50·4 to 63·2)*
25·2% 
(20·2 to 30·8)*
12·4% 
(8·9 to 16·2)*
−1·3% 
(−5·1 to 2·8)
Gallbladder and biliary 
diseases
30 575·9 
(27 503·2 to 34 125·0)
5790·7 
(5195·0 to 6386·5)
26·4 
(18·0 to 37·5)
29·3% 
(26·7 to 32·1)*
27·5% 
(24·1 to 31·3)*
−9·6% 
(−11·0 to −8·1)*
3·9% 
(1·7 to 6·3)*
Pancreatitis 6115·8 
(5533·9 to 6704·1)
1644·2 
(1525·6 to 1769·5)
364·4 
(186·3 to 612·8)
52·0% 
(48·7 to 54·8)*
26·6% 
(23·3 to 29·7)*
6·5% 
(4·1 to 8·3)*
2·5% 
(0·0 to 4·9)*
Acute pancreatitis 118·6 
(107·5 to 130·0)
1300·9 
(1181·4 to 1426·0)
47·7 
(34·2 to 63·9)
33·9% 
(30·5 to 37·3)*
17·5% 
(15·7 to 19·4)*
−6·6% 
(−8·6 to −4·2)*
−4·4% 
(−5·6 to −3·2)*
Chronic pancreatitis 5997·3 
(5412·4 to 6583·8)
343·3 
(311·5 to 375·0)
316·7 
(145·2 to 556·1)
55·5% 
(52·7 to 58·8)*
28·1% 
(24·5 to 31·8)*
9·0% 
(7·2 to 11·1)*
3·7% 
(0·9 to 6·5)*
Other digestive diseases ·· ·· 879·9 
(605·6 to 1191·4)
0·9% 
(−2·8 to 5·0)
30·6% 
(28·9 to 32·1)*
−19·4% 
(−21·5 to −17·3)*
9·5% 
(8·2 to 10·6)*
Neurological disorders 3 121 435·3 
(2 951 124·5 to 
3 316 268·0)
1 006 294·5 
(907 590·7 to 
1 098 468·9)
73 161·8 
(50 721·9 to 
100 409·9)
35·1% 
(31·9 to 38·1)*
17·8% 
(15·8 to 20·2)*
0·5% 
(−1·6 to 2·4)
1·4% 
(−0·3 to 3·4)
Alzheimer’s disease and other 
dementias
44 988·8 
(39 716·2 to 50 377·8)
7300·6 
(6515·7 to 8133·4)
6570·4 
(4678·1 to 8588·5)
62·7% 
(60·6 to 64·9)*
36·9% 
(35·2 to 38·8)*
−2·3% 
(−3·3 to −1·2)*
−1·7% 
(−2·3 to −1·1)*
Parkinson’s disease 8525·4 
(7037·3 to 10 185·6)
1025·9 
(854·1 to 1229·9)
1219·0 
(823·7 to 1662·2)
69·2% 
(66·5 to 72·6)*
34·3% 
(32·5 to 36·2)*
8·9% 
(7·1 to 11·0)*
1·0% 
(−0·1 to 2·1)
Epilepsy 27 288·3 
(21 576·0 to 33 443·8)
2470·8 
(1905·5 to 3062·9)
8561·9 
(5380·6 to 12 551·5)
24·1% 
(8·0 to 42·9)*
15·9% 
(3·5 to 31·2)*
0·1% 
(−12·3 to 14·9)
3·4% 
(−7·8 to 16·8)
Multiple sclerosis 1761·1 
(1598·2 to 1947·9)
54·9 
(50·1 to 60·8)
456·6 
(327·7 to 595·0)
41·6% 
(38·2 to 45·2)*
18·3% 
(16·1 to 20·5)*
−0·9% 
(−3·2 to 1·4)
−2·4% 
(−4·2 to −0·4)*
Motor neuron disease 237·1 
(211·2 to 264·1)
67·3 
(60·7 to 74·3)
50·4 
(35·7 to 67·5)
39·6% 
(36·3 to 43·2)*
25·9% 
(23·1 to 28·9)*
4·6% 
(3·5 to 5·9)*
4·5% 
(3·0 to 6·1)*
Headache disorders 3 072 812·1 
(2 904 886·2 to 
3 266 065·0)
995 374·9 
(896 864·3 to 
1 087 335·4)
54 341·8 
(35 570·5 to 
76 780·4)
34·0% 
(33·0 to 35·1)*
15·4% 
(14·6 to 16·2)*
0·4% 
(−0·2 to 1·0)
1·0% 
(0·5 to 1·5)*
Migraine 1 331 364·6 
(1 237 219·6 to 
1 433 357·2)
112 933·5 
(102 829·9 to 122 899·8)
47 245·4 
(29 986·7 to 
68 669·3)
34·2% 
(33·1 to 35·4)*
15·3% 
(14·5 to 16·2)*
0·6% 
(−0·0 to 1·2)
1·1% 
(0·6 to 1·7)*
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Medication overuse 
headache due to migraine
83 755·8 
(70 723·8 to 97 287·8)
·· 9166·1 
(5759·6 to 
13 329·2)
35·5% 
(33·6 to 37·3)*
17·5% 
(16·2 to 18·7)*
−1·4% 
(−2·5 to −0·5)*
0·1% 
(−0·3 to 0·6)
Migraine 1 247 608·8 
(1 154 817·3 to 
1 347 980·9)
112 933·5 
(102 829·9 to 122 899·8)
38 079·3 
(23 576·3 to 
57 421·4)
33·9% 
(32·6 to 35·3)*
14·8% 
(13·8 to 15·8)*
1·1% 
(0·4 to 1·9)*
1·3% 
(0·7 to 2·0)*
Tension-type headache 2 331 334·7 
(2 110 373·3 to 
2 575 461·4)
882 441·4 
(783 241·2 to 975 064·3)
7096·4 
(4044·6 to 
11 213·5)
32·7% 
(31·0 to 34·6)*
15·6% 
(14·5 to 16·9)*
−0·9% 
(−1·7 to −0·3)*
0·3% 
(−0·1 to 0·6)
Medication overuse 
headache due to 
tension-type headache
31 134·3 
(21 220·1 to 41 990·3)
·· 3382·8 
(1753·7 to 5875·5)
35·5% 
(33·5 to 37·5)*
17·5% 
(16·0 to 18·8)*
−1·4% 
(−2·5 to −0·4)*
0·1% 
(−0·6 to 0·8)
Tension-type headache 2 300 200·4 
(2 079 425·9 to 
2 547 509·0)
882 441·4 
(783 241·2 to 975 064·3)
3713·6 
(1525·8 to 6887·1)
30·3% 
(28·5 to 32·4)*
14·0% 
(12·9 to 15·3)*
−0·5% 
(−1·4 to 0·4)
0·4% 
(0·0 to 0·7)*
Other neurological disorders 38·9 
(25·6 to 53·2)
·· 1961·8 
(1276·3 to 2823·8)
35·7% 
(19·8 to 54·5)*
31·9% 
(18·8 to 47·1)*
11·8% 
(−0·5 to 26·1)
19·5% 
(7·2 to 33·4)*
Other neurological 
disorders
·· ·· 1950·3 
(1267·2 to 2813·5)
35·8% 
(19·7 to 54·7)*
32·0% 
(18·8 to 47·3)*
11·9% 
(−0·5 to 26·4)
19·6% 
(7·2 to 33·6)*
Guillain-Barré syndrome 
due to other neurological 
disorders
38·9 
(25·6 to 53·2)
·· 11·5 
(6·4 to 18·1)
29·7% 
(25·8 to 34·1)*
18·2% 
(15·8 to 20·8)*
2·7% 
(1·0 to 4·3)*
3·1% 
(2·0 to 4·3)*
Mental disorders 970 812·4 
(923 455·4 to 
1 020 930·6)
336 996·3 
(315 596·6 to 
362 049·6)
122 746·3 
(91 620·8 to 
157 883·6)
31·6% 
(30·5 to 32·7)*
13·5% 
(12·9 to 14·1)*
−0·6% 
(−1·2 to −0·0)*
−1·1% 
(−1·5 to −0·7)*
Schizophrenia 19 776·9 
(17 578·3 to 22 210·7)
1130·5 
(1004·6 to 1281·9)
12 657·9 
(9481·9 to 15 563·7)
38·6% 
(37·1 to 40·2)*
17·2% 
(16·1 to 18·3)*
−0·0% 
(−0·8 to 0·7)
−0·3% 
(−1·1 to 0·4)
Depressive disorders 264 455·6 
(246 380·1 to 286 312·0)
258 164·5 
(238 280·7 to 281 665·5)
43 099·9 
(30 536·4 to 
58 895·6)
33·4% 
(31·0 to 35·8)*
14·3% 
(13·1 to 15·6)*
−1·9% 
(−3·2 to −0·4)*
−2·6% 
(−3·5 to −1·8)*
Major depressive disorder 163 044·1 
(149 530·9 to 178 929·1)
241 893·3 
(222 032·7 to 265 574·7)
32 846·7 
(23 081·1 to 
44 291·2)
32·1% 
(29·2 to 35·0)*
12·6% 
(11·3 to 14·0)*
−2·4% 
(−4·0 to −0·6)*
−3·6% 
(−4·6 to −2·7)*
Dysthymia 106 904·4 
(93 445·9 to 122 812·3)
16 271·1 
(14 236·4 to 18 420·1)
10 253·2 
(6878·0 to 14 982·1)
38·3% 
(35·5 to 41·0)*
20·4% 
(18·2 to 22·6)*
−0·3% 
(−1·8 to 1·3)
0·8% 
(−0·8 to 2·3)
Bipolar disorder 45 549·4 
(39 864·5 to 52 852·8)
4525·2 
(3944·7 to 5237·5)
9293·8 
(5868·2 to 13 748·5)
34·0% 
(32·6 to 35·4)*
15·2% 
(14·0 to 16·6)*
0·4% 
(−0·3 to 1·1)
1·2% 
(0·6 to 1·8)*
Anxiety disorders 284 360·1 
(265 607·5 to 304 531·7)
42 340·0 
(39 597·5 to 45 199·5)
27 121·4 
(19 248·3 to 
36 106·3)
32·3% 
(30·6 to 34·0)*
12·8% 
(11·7 to 14·0)*
0·4% 
(−0·5 to 1·3)
−1·2% 
(−2·0 to −0·4)*
Eating disorders 15 801·7 
(12 596·2 to 19 488·6)
9589·7 
(6950·1 to 13 126·9)
3351·9 
(2149·3 to 4871·6)
37·7% 
(35·4 to 40·0)*
18·9% 
(17·3 to 20·5)*
7·9% 
(6·8 to 8·9)*
9·4% 
(8·2 to 10·5)*
Anorexia nervosa 3360·3 
(2533·8 to 4321·5)
1027·8 
(777·5 to 1329·1)
715·8 
(440·9 to 1066·2)
30·9% 
(28·0 to 33·9)*
13·5% 
(11·0 to 15·7)*
5·4% 
(3·3 to 7·2)*
6·2% 
(4·1 to 8·1)*
Bulimia nervosa 12 509·7 
(9480·4 to 15 976·5)
8561·9 
(5957·9 to 12 142·7)
2636·2 
(1660·3 to 3937·1)
39·7% 
(36·9 to 42·7)*
20·5% 
(18·6 to 22·2)*
8·6% 
(7·5 to 9·8)*
10·3% 
(9·0 to 11·6)*
Autism spectrum disorders 31 179·7 
(28 000·9 to 34 413·8)
670·7 
(602·2 to 739·1)
4731·3 
(3238·8 to 6518·6)
22·8% 
(22·1 to 23·5)*
11·4% 
(10·8 to 12·1)*
−0·7% 
(−1·2 to −0·2)*
−0·3% 
(−0·8 to 0·3)
Attention-deficit/
hyperactivity disorder
73 317·5 
(62 267·0 to 85 889·6)
3302·7 
(2683·9 to 4031·4)
888·8 
(543·2 to 1411·8)
20·1% 
(17·5 to 22·6)*
6·9% 
(5·2 to 8·5)*
−0·2% 
(−2·1 to 1·7)
−0·6% 
(−2·1 to 0·8)
Conduct disorder 53 228·4 
(41 976·6 to 65 750·3)
17 273·1 
(13 809·1 to 20 989·8)
6445·2 
(3869·6 to 
10 299·8)
16·1% 
(14·4 to 17·8)*
4·8% 
(3·1 to 6·5)*
1·5% 
(0·1 to 2·9)*
2·4% 
(0·9 to 3·8)*
Idiopathic developmental 
intellectual disability
100 572·2 
(58 404·5 to 143 878·6)
·· 4046·4 
(1940·2 to 6859·5)
13·0% 
(9·1 to 15·9)*
0·0% 
(−2·8 to 1·5)
−5·8% 
(−9·0 to −3·1)*
−8·7% 
(−11·1 to −7·5)*
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Other mental disorders 149 478·6 
(130 882·3 to 170 462·4)
·· 11 109·6 
(7355·5 to 15 324·6)
37·7% 
(36·9 to 38·6)*
17·6% 
(17·0 to 18·3)*
0·0% 
(−0·5 to 0·4)
0·0% 
(−0·4 to 0·5)
Substance use disorders 175 588·8 
(161 747·6 to 189 304·3)
60 099·6 
(53 685·6 to 67 048·7)
31 052·9 
(22 217·1 to 
40 499·7)
34·3% 
(32·2 to 36·2)*
16·7% 
(14·4 to 19·2)*
2·2% 
(1·1 to 3·4)*
2·9% 
(0·8 to 5·1)*
Alcohol use disorders 107 420·2 
(95 908·0 to 119 660·2)
52 406·2 
(45 976·6 to 59 250·1)
10 712·5 
(7368·0 to 14 760·1)
35·9% 
(33·8 to 38·3)*
10·1% 
(8·5 to 11·7)*
0·9% 
(−0·1 to 1·9)
−4·3% 
(−5·4 to −3·1)*
Alcohol dependence 107 118·2 
(95 586·5 to 119 383·0)
52 397·0 
(45 967·6 to 59 241·9)
10 701·5 
(7361·4 to 14 747·1)
36·0% 
(33·8 to 38·4)*
10·1% 
(8·5 to 11·7)*
0·9% 
(−0·1 to 2·0)
−4·3% 
(−5·4 to −3·1)*
Fetal alcohol syndrome 302·0 
(240·9 to 370·5)
9·1 
(7·5 to 11·1)
11·1 
(6·6 to 17·0)
2·5% 
(−3·2 to 7·2)
−4·7% 
(−10·1 to −0·2)*
−17·6% 
(−22·1 to −13·9)*
−14·7% 
(−19·4 to −10·6)*
Drug use disorders 71 244·4 
(63 963·8 to 79 771·6)
7693·4 
(6880·2 to 8628·5)
20 340·3 
(14 276·7 to 
26 665·5)
33·3% 
(30·3 to 36·3)*
20·4% 
(17·4 to 23·6)*
3·1% 
(1·3 to 4·8)*
7·1% 
(4·3 to 9·9)*
Opioid use disorders 40 484·6 
(34 271·4 to 47 941·6)
4085·2 
(3463·6 to 4794·2)
16 844·7 
(11 549·8 to 
22 534·5)
38·4% 
(35·4 to 41·9)*
23·7% 
(20·2 to 27·2)*
6·2% 
(4·5 to 8·2)*
9·3% 
(6·0 to 12·5)*
Cocaine use disorders 5017·2 
(4521·0 to 5610·4)
260·3 
(227·9 to 301·6)
680·0 
(446·1 to 974·8)
24·7% 
(21·2 to 28·6)*
12·6% 
(11·0 to 14·4)*
−4·7% 
(−6·9 to −2·1)*
0·3% 
(−1·2 to 2·0)
Amphetamine use disorders 7382·6 
(5376·5 to 9821·8)
887·2 
(666·2 to 1170·2)
977·5 
(560·1 to 1537·4)
5·8% 
(1·9 to 10·9)*
2·7% 
(−0·4 to 5·7)
−13·8% 
(−16·6 to −10·4)*
−4·0% 
(−6·8 to −1·5)*
Cannabis use disorders 17 857·3 
(14 597·9 to 21 953·6)
2460·7 
(2061·0 to 3022·0)
517·7 
(329·1 to 765·6)
23·8% 
(19·7 to 28·5)*
4·4% 
(2·2 to 6·6)*
−2·2% 
(−4·7 to 0·6)
−3·7% 
(−5·7 to −1·7)*
Other drug use disorders 2237·7 
(1984·3 to 2509·6)
·· 1320·5 
(888·2 to 1854·3)
16·8% 
(12·0 to 22·4)*
8·2% 
(5·2 to 11·2)*
−8·3% 
(−11·3 to −4·9)*
−1·9% 
(−4·3 to 0·6)
Diabetes and kidney 
diseases
1 011 116·6 
(962 767·9 to 
1 065 061·5)
43 444·6 
(40 700·3 to 46 375·6)
45 884·4 
(32 018·9 to 
62 235·3)
68·4% 
(66·5 to 70·4)*
29·1% 
(24·8 to 34·0)*
15·4% 
(14·2 to 16·7)*
3·2% 
(−0·4 to 6·9)
Diabetes mellitus 475 995·8 
(436 590·5 to 522 782·8)
22 935·6 
(21 082·9 to 25 040·9)
38 575·4 
(26 083·6 to 
53 398·2)
75·9% 
(73·5 to 78·3)*
30·1% 
(25·0 to 35·8)*
20·3% 
(18·8 to 21·9)*
3·9% 
(−0·1 to 8·3)
Type 1 diabetes mellitus 13 019·0 
(11 698·8 to 14 614·6)
400·3 
(362·3 to 441·7)
964·3 
(659·9 to 1356·0)
40·6% 
(38·2 to 43·1)*
15·1% 
(13·8 to 16·7)*
3·5% 
(2·0 to 4·9)*
−1·2% 
(−2·3 to −0·1)*
Uncomplicated type 1 
diabetes mellitus
8762·6 
(7743·9 to 9877·9)
400·3 
(362·3 to 441·7)
412·4 
(256·1 to 601·4)
34·7% 
(32·1 to 37·3)*
11·9% 
(10·1 to 13·6)*
3·5% 
(1·8 to 5·1)*
−1·2% 
(−2·7 to 0·1)
Vision loss due to type 1 
diabetes mellitus 
retinopathy
82·5 
(65·3 to 102·7)
·· 6·9 
(4·5 to 10·1)
61·4% 
(56·5 to 66·9)*
4·0% 
(−0·9 to 9·0)
10·4% 
(7·4 to 14·1)*
−15·1% 
(−19·2 to −11·1)*
Diabetic neuropathy due 
to type 1 diabetes mellitus
4173·9 
(3612·2 to 4837·5)
·· 545·0 
(365·7 to 762·7)
45·4% 
(42·2 to 48·6)*
17·9% 
(15·2 to 20·7)*
3·3% 
(1·4 to 5·3)*
−1·0% 
(−3·3 to 1·2)
Type 2 diabetes mellitus 462 976·9 
(423 591·9 to 509 485·3)
22 535·3 
(20 693·8 to 24 626·7)
37 611·1 
(25 451·4 to 
52 049·5)
77·2% 
(74·7 to 79·8)*
30·5% 
(25·3 to 36·4)*
20·9% 
(19·3 to 22·5)*
4·0% 
(−0·1 to 8·6)
Uncomplicated type 2 
diabetes mellitus
263 762·9 
(232 967·8 to 297 029·0)
22 535·3 
(20 693·8 to 24 626·7)
12 152·7 
(7658·0 to 17 914·1)
74·0% 
(70·9 to 77·3)*
28·5% 
(22·8 to 34·5)*
20·6% 
(18·5 to 22·8)*
4·0% 
(−0·7 to 8·9)
Vision loss due to type 2 
diabetes mellitus 
retinopathy
4509·0 
(3835·7 to 5282·0)
·· 362·5 
(252·6 to 500·2)
97·1% 
(90·5 to 104·5)*
21·1% 
(18·2 to 23·6)*
31·3% 
(27·0 to 36·3)*
−5·7% 
(−7·7 to −3·8)*
Diabetic neuropathy due 
to type 2 diabetes mellitus
194 704·9 
(169 971·1 to 224 314·8)
·· 25 095·9 
(16 801·1 to 
34 866·6)
78·5% 
(75·0 to 82·2)*
31·6% 
(25·7 to 38·1)*
20·9% 
(18·6 to 23·3)*
4·2% 
(−0·4 to 9·2)
Chronic kidney disease 697 509·5 
(649 209·4 to 752 050·7)
19 735·6 
(17 726·6 to 21 982·7)
7306·3 
(5434·9 to 9214·6)
38·8% 
(35·2 to 42·7)*
24·4% 
(19·7 to 29·5)*
−4·1% 
(−6·9 to −1·3)*
−0·2% 
(−3·8 to 3·8)
Chronic kidney disease due 
to type 1 diabetes mellitus
3246·5 
(2916·0 to 3615·5)
118·3 
(100·5 to 141·5)
264·7 
(187·5 to 353·0)
58·2% 
(52·8 to 63·9)*
21·7% 
(17·4 to 26·3)*
10·3% 
(6·8 to 14·0)*
0·3% 
(−3·0 to 3·7)
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Albuminuria with 
preserved GFR due to 
type 1 diabetes mellitus
1406·8 
(1223·8 to 1605·5)
·· ·· ·· ·· ·· ··
End-stage chronic kidney 
disease due to type 1 
diabetes mellitus
412·3 
(326·6 to 512·2)
·· 168·0 
(110·5 to 233·7)
67·5% 
(60·5 to 75·9)*
22·1% 
(16·5 to 27·4)*
13·8% 
(8·8 to 19·2)*
−0·2% 
(−4·4 to 3·9)
Stage III chronic kidney 
disease due to type 1 
diabetes mellitus
1186·3 
(1002·9 to 1413·2)
118·3 
(100·5 to 141·5)
22·8 
(15·1 to 33·1)
12·2% 
(5·2 to 23·4)*
14·8% 
(5·8 to 24·0)*
−13·6% 
(−18·6 to −5·9)*
0·4% 
(−7·6 to 8·5)
Stage IV chronic kidney 
disease due to type 1 
diabetes mellitus
149·4 
(118·7 to 187·7)
·· 20·5 
(12·8 to 29·7)
54·8% 
(47·9 to 62·3)*
25·6% 
(16·0 to 34·9)*
7·4% 
(2·8 to 12·3)*
1·6% 
(−6·2 to 9·2)
Stage V chronic kidney 
disease due to type 1 
diabetes mellitus
91·7 
(74·9 to 111·7)
·· 53·5 
(36·6 to 73·1)
61·3% 
(54·0 to 69·3)*
22·1% 
(15·2 to 29·4)*
14·7% 
(10·1 to 19·9)*
1·5% 
(−4·2 to 7·5)
Chronic kidney disease due 
to type 2 diabetes mellitus
125 811·6 
(116 308·7 to 135 941·1)
2352·5 
(2063·9 to 2680·9)
1450·3 
(1080·6 to 1875·1)
49·9% 
(41·4 to 55·6)*
29·6% 
(23·0 to 35·6)*
0·7% 
(−3·5 to 4·3)
−0·5% 
(−5·2 to 4·0)
Albuminuria with 
preserved GFR due to 
type 2 diabetes mellitus
85 416·5 
(76 825·4 to 94 433·7)
·· ·· ·· ·· ·· ··
End-stage chronic kidney 
disease due to type 2 
diabetes mellitus
1046·2 
(889·3 to 1236·3)
·· 432·3 
(296·9 to 564·4)
94·0% 
(85·7 to 104·3)*
32·2% 
(27·7 to 36·7)*
31·7% 
(26·2 to 38·3)*
0·8% 
(−2·5 to 4·0)
Stage III chronic kidney 
disease due to type 2 
diabetes mellitus
35 357·3 
(31 403·1 to 39 849·1)
2352·5 
(2063·9 to 2680·9)
156·1 
(102·1 to 234·4)
10·9% 
(5·6 to 17·2)*
19·0% 
(10·9 to 27·0)*
−26·2% 
(−29·6 to −22·1)*
−8·1% 
(−14·2 to −1·9)*
Stage IV chronic kidney 
disease due to type 2 
diabetes mellitus
2906·1 
(2314·3 to 3621·8)
·· 308·5 
(198·6 to 443·0)
37·1% 
(31·0 to 41·1)*
30·5% 
(21·2 to 40·3)*
−9·4% 
(−11·7 to −7·4)*
−0·8% 
(−7·6 to 6·7)
Stage V chronic kidney 
disease due to type 2 
diabetes mellitus
1085·5 
(915·0 to 1281·7)
·· 553·5 
(383·2 to 745·7)
47·7% 
(30·4 to 55·4)*
30·4% 
(19·5 to 39·2)*
0·2% 
(−7·0 to 4·8)
1·2% 
(−6·6 to 7·8)
Chronic kidney disease due 
to hypertension
23 605·4 
(21 734·7 to 25 994·1)
911·2 
(810·0 to 1033·5)
1390·7 
(1036·0 to 1772·1)
47·7% 
(44·0 to 52·1)*
28·0% 
(23·0 to 33·1)*
0·8% 
(−1·7 to 3·7)
1·4% 
(−2·4 to 5·4)
Albuminuria with 
preserved GFR due to 
hypertension
4310·3 
(3891·2 to 4793·2)
·· ·· ·· ·· ·· ··
End-stage chronic kidney 
disease due to 
hypertension
825·3 
(700·2 to 968·4)
·· 341·2 
(232·8 to 450·8)
78·0% 
(70·5 to 86·4)*
33·5% 
(28·9 to 37·6)*
20·2% 
(15·4 to 25·5)*
2·6% 
(−0·7 to 5·4)
Stage III chronic kidney 
disease due to 
hypertension
14 545·5 
(13 086·5 to 16 401·2)
911·2 
(810·0 to 1033·5)
123·0 
(81·8 to 181·1)
16·0% 
(10·7 to 22·4)*
16·6% 
(9·1 to 23·6)*
−22·9% 
(−26·2 to −18·7)*
−9·3% 
(−14·9 to −3·8)*
Stage IV chronic kidney 
disease due to 
hypertension
2743·0 
(2268·8 to 3328·2)
·· 299·7 
(200·7 to 418·4)
39·4% 
(36·2 to 42·9)*
29·0% 
(20·5 to 37·3)*
−7·1% 
(−8·7 to −5·1)*
0·4% 
(−5·9 to 6·7)
Stage V chronic kidney 
disease due to 
hypertension
1181·3 
(1017·6 to 1370·2)
·· 626·7 
(432·1 to 829·9)
47·3% 
(43·9 to 52·4)*
27·2% 
(20·9 to 33·9)*
3·3% 
(1·3 to 6·5)*
3·6% 
(−1·2 to 9·0)
Chronic kidney disease due 
to glomerulonephritis
28 809·4 
(26 470·2 to 31 575·8)
1509·5 
(1345·4 to 1699·8)
1047·9 
(753·5 to 1372·2)
38·1% 
(34·5 to 43·1)*
20·4% 
(15·5 to 25·6)*
0·8% 
(−1·4 to 3·8)
2·2% 
(−1·8 to 6·8)
Albuminuria with 
preserved GFR due to 
glomerulonephritis
5008·3 
(4410·3 to 5616·9)
·· ·· ·· ·· ·· ··
End-stage chronic kidney 
disease due to 
glomerulonephritis
691·9 
(594·2 to 812·8)
·· 270·4 
(188·0 to 360·3)
57·3% 
(52·0 to 63·4)*
22·7% 
(18·4 to 27·2)*
10·2% 
(6·6 to 14·3)*
−0·4% 
(−3·6 to 2·8)
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Stage III chronic kidney 
disease due to 
glomerulonephritis
20 751·9 
(18 673·1 to 23 071·0)
1509·5 
(1345·4 to 1699·8)
85·8 
(55·6 to 125·3)
7·4% 
(1·1 to 17·8)*
8·3% 
(0·1 to 16·9)*
−17·2% 
(−21·6 to −10·0)*
−4·7% 
(−12·1 to 2·5)
Stage IV chronic kidney 
disease due to 
glomerulonephritis
1435·8 
(1169·9 to 1762·1)
·· 172·4 
(110·5 to 246·3)
30·8% 
(27·3 to 35·6)*
21·3% 
(13·0 to 29·7)*
−6·1% 
(−8·3 to −3·2)*
2·2% 
(−5·4 to 9·3)
Stage V chronic kidney 
disease due to 
glomerulonephritis
921·6 
(765·1 to 1104·5)
·· 519·3 
(351·4 to 713·8)
39·4% 
(35·4 to 44·9)*
21·2% 
(14·8 to 28·3)*
2·8% 
(0·7 to 6·2)*
4·9% 
(−0·7 to 10·7)
Chronic kidney disease due 
to other and unspecified 
causes
516 036·7 
(480 273·8 to 555 659·4)
14 844·1 
(13 340·7 to 16 532·6)
3152·6 
(2327·5 to 4005·4)
30·2% 
(27·0 to 34·6)*
22·2% 
(17·2 to 27·6)*
−10·3% 
(−13·0 to −7·3)*
−1·5% 
(−5·5 to 2·8)
Albuminuria with 
preserved GFR due to 
other and unspecified 
causes
285 109·9 
(256 788·7 to 314 368·4)
·· ·· ·· ·· ·· ··
End-stage chronic kidney 
disease due to other and 
unspecified causes
955·4 
(822·5 to 1111·7)
·· 380·7 
(257·9 to 504·2)
59·9% 
(54·4 to 66·0)*
23·9% 
(19·3 to 28·3)*
13·4% 
(9·5 to 17·3)*
0·2% 
(−3·1 to 3·2)
Stage III chronic kidney 
disease due to other and 
unspecified causes
222 956·2 
(200 778·0 to 247 902·5)
14 844·1 
(13 340·7 to 16 532·6)
1105·1 
(727·3 to 1640·7)
11·4% 
(7·2 to 15·7)*
15·6% 
(9·4 to 22·0)*
−24·8% 
(−27·6 to −22·1)*
−8·4% 
(−13·4 to −3·2)*
Stage IV chronic kidney 
disease due to other and 
unspecified causes
4825·1 
(4024·2 to 5754·4)
·· 520·5 
(346·0 to 725·0)
37·3% 
(34·0 to 40·9)*
27·9% 
(20·0 to 36·0)*
−7·8% 
(−9·3 to −5·9)*
0·3% 
(−5·5 to 6·5)
Stage V chronic kidney 
disease due to other and 
unspecified causes
2190·0 
(1894·3 to 2551·5)
·· 1146·3 
(788·6 to 1517·9)
43·4% 
(39·4 to 49·2)*
25·9% 
(19·9 to 32·2)*
2·9% 
(0·8 to 6·3)*
4·5% 
(−0·4 to 9·7)
Acute glomerulonephritis 52·4 
(45·5 to 60·7)
773·4 
(672·8 to 877·3)
2·6 
(1·6 to 4·0)
−1·3% 
(−13·9 to 2·3)
1·0% 
(−2·1 to 3·5)
−24·3% 
(−34·2 to −21·4)*
−12·6% 
(−15·3 to −10·1)*
Skin and subcutaneous 
diseases
1 974 238·4 
(1 916 671·8 to 
2 034 645·7)
4 185 971·3 
(3 971 760·5 to 
4 391 218·2)
41 621·9 
(27 371·7 to 
61 859·5)
24·0% 
(22·9 to 25·3)*
13·0% 
(12·5 to 13·6)*
0·9% 
(0·4 to 1·4)*
0·6% 
(0·1 to 1·1)*
Dermatitis 291 689·4 
(276 520·7 to 308 059·0)
274 034·1 
(246 120·0 to 302 497·5)
11 128·1 
(6484·1 to 17 733·4)
19·3% 
(18·2 to 20·7)*
12·1% 
(11·3 to 12·8)*
−0·1% 
(−0·7 to 0·5)
1·1% 
(0·4 to 1·8)*
Atopic dermatitis 205 517·2 
(193 701·2 to 218 582·4)
27 134·4 
(25 282·9 to 29 055·0)
9003·4 
(4887·0 to 
14 981·0)
17·0% 
(16·1 to 17·9)*
11·6% 
(10·8 to 12·5)*
0·4% 
(−0·4 to 1·1)
1·7% 
(0·9 to 2·6)*
Contact dermatitis 79 666·7 
(70 425·7 to 89 554·9)
221 252·8 
(193 775·3 to 249 726·6)
1989·2 
(1304·4 to 2950·5)
31·0% 
(28·8 to 33·2)*
14·4% 
(12·6 to 16·2)*
−1·6% 
(−2·3 to −1·0)*
−1·1% 
(−1·7 to −0·5)*
Seborrhoeic dermatitis 10 035·9 
(9450·2 to 10 668·4)
25 646·9 
(23 981·6 to 27 315·9)
135·6 
(78·1 to 215·0)
20·8% 
(18·5 to 23·3)*
8·4% 
(6·6 to 10·3)*
−7·7% 
(−9·0 to −6·4)*
−7·1% 
(−8·3 to −5·8)*
Psoriasis 64 609·6 
(62 454·3 to 66 767·5)
7846·6 
(7564·9 to 8162·8)
5569·5 
(3956·1 to 7354·3)
43·1% 
(42·0 to 44·2)*
21·1% 
(20·3 to 21·9)*
5·1% 
(4·3 to 5·8)*
2·3% 
(1·6 to 2·9)*
Bacterial skin diseases 11 397·9 
(11 061·4 to 11 741·7)
266 779·7 
(260 229·3 to 273 665·3)
177·9 
(112·3 to 274·1)
29·2% 
(27·2 to 31·0)*
15·5% 
(14·0 to 17·1)*
2·0% 
(−0·5 to 4·4)
0·8% 
(−1·1 to 2·9)
Cellulitis 2071·5 
(1952·2 to 2186·2)
42 958·6 
(40 535·7 to 45 172·9)
118·2 
(78·7 to 167·8)
26·7% 
(24·9 to 28·6)*
12·9% 
(11·7 to 14·2)*
−2·6% 
(−3·8 to −1·3)*
−2·9% 
(−3·8 to −2·0)*
Pyoderma 10 557·2 
(10 245·5 to 10 853·2)
223 821·2 
(217 649·0 to 230 259·5)
59·6 
(23·9 to 123·5)
35·0% 
(33·7 to 36·4)*
20·9% 
(19·8 to 22·2)*
13·0% 
(11·9 to 14·2)*
8·8% 
(7·8 to 9·9)*
Impetigo 4620·7 
(4358·2 to 4870·5)
84 007·5 
(79 485·3 to 88 529·9)
26·4 
(10·4 to 55·8)
35·7% 
(33·6 to 37·8)*
20·7% 
(18·7 to 22·7)*
24·1% 
(22·2 to 26·0)*
13·4% 
(11·5 to 15·2)*
Abscess and other 
bacterial skin diseases
5936·4 
(5770·4 to 6098·7)
139 813·6 
(135 314·1 to 143 965·8)
33·2 
(13·4 to 69·5)
34·5% 
(32·8 to 36·3)*
21·1% 
(19·7 to 22·6)*
5·5% 
(4·2 to 6·8)*
5·1% 
(3·8 to 6·4)*
Scabies 175 406·7 
(154 517·9 to 198 404·1)
527 476·5 
(462 050·9 to 598 087·9)
4528·7 
(2506·4 to 7414·6)
16·1% 
(13·8 to 18·5)*
6·6% 
(5·3 to 8·0)*
−4·3% 
(−5·0 to −3·6)*
−3·1% 
(−3·6 to −2·6)*
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Fungal skin diseases 743 458·4 
(681 568·4 to 808 149·7)
2 126 927·9 
(1 917 361·6 to 
2 317 274·7)
4154·5 
(1651·4 to 8633·2)
21·5% 
(19·0 to 24·0)*
10·9% 
(9·2 to 12·5)*
−3·1% 
(−3·8 to −2·4)*
−4·4% 
(−5·4 to −3·4)*
Tinea capitis 160 239·3 
(133 390·6 to 194 439·3)
303 016·6 
(245 340·4 to 369 760·2)
916·5 
(357·3 to 1965·4)
−5·8% 
(−7·3 to −4·3)*
−13·0% 
(−14·5 to −11·3)*
−13·8% 
(−15·0 to −12·7)*
−19·0% 
(−20·4 to −17·3)*
Other fungal skin diseases 583 219·1 
(526 500·8 to 645 363·9)
1 823 911·3 
(1 638 297·9 to 
2 009 788·9)
3238·0 
(1305·4 to 6694·4)
37·1% 
(35·2 to 39·3)*
20·2% 
(19·0 to 21·6)*
1·8% 
(1·5 to 2·1)*
1·3% 
(1·1 to 1·5)*
Viral skin diseases 130 639·2 
(125 604·0 to 136 047·9)
116 329·8 
(111 012·4 to 121 710·1)
4033·0 
(2595·4 to 5995·6)
10·4% 
(9·8 to 11·1)*
6·4% 
(6·0 to 6·9)*
−2·8% 
(−3·2 to −2·3)*
−1·8% 
(−2·2 to −1·4)*
Viral warts 54 309·6 
(52 104·2 to 56 403·2)
30 140·5 
(29 078·5 to 31 211·0)
1662·2 
(1066·0 to 2439·8)
13·7% 
(12·8 to 14·6)*
5·6% 
(4·8 to 6·3)*
−6·8% 
(−7·3 to −6·3)*
−4·8% 
(−5·4 to −4·3)*
Molluscum contagiosum 76 329·6 
(71 596·6 to 81 134·1)
86 189·3 
(80 984·6 to 91 427·2)
2370·7 
(1511·7 to 3525·9)
8·2% 
(7·5 to 8·9)*
7·1% 
(6·5 to 7·6)*
0·2% 
(−0·3 to 0·8)
0·3% 
(−0·3 to 0·8)
Acne vulgaris 119 082·3 
(107 127·9 to 133 651·4)
60 118·8 
(53 260·2 to 68 180·7)
2547·6 
(1518·8 to 4056·6)
46·1% 
(44·6 to 47·6)*
16·2% 
(15·2 to 17·2)*
19·8% 
(18·6 to 20·9)*
11·4% 
(10·3 to 12·5)*
Alopecia areata 15 981·0 
(15 477·3 to 16 515·9)
28 185·2 
(27 302·2 to 29 126·3)
523·1 
(334·9 to 774·8)
28·8% 
(27·6 to 30·1)*
12·7% 
(11·8 to 13·8)*
−2·3% 
(−3·1 to −1·4)*
−1·5% 
(−2·3 to −0·6)*
Pruritus 71 224·3 
(63 948·2 to 80 034·2)
55 643·1 
(49 208·3 to 62 689·4)
755·6 
(356·1 to 1433·2)
36·4% 
(34·1 to 38·8)*
18·9% 
(17·5 to 20·4)*
2·9% 
(2·5 to 3·4)*
1·6% 
(1·2 to 2·0)*
Urticaria 83 610·0 
(73 335·4 to 95 162·9)
147 198·5 
(129 941·2 to 166 345·6)
5014·8 
(3321·0 to 7046·4)
19·3% 
(17·4 to 21·5)*
10·8% 
(9·8 to 11·9)*
0·7% 
(0·2 to 1·2)*
0·3% 
(−0·2 to 0·8)
Decubitus ulcer 1143·7 
(1022·6 to 1288·5)
4199·3 
(3752·4 to 4741·3)
181·2 
(125·8 to 244·3)
45·2% 
(42·7 to 47·7)*
28·9% 
(26·3 to 31·9)*
−3·3% 
(−4·9 to −1·8)*
−0·4% 
(−2·2 to 1·5)
Other skin and subcutaneous 
diseases
550 810·3 
(538 490·7 to 563 961·3)
571 231·9 
(558 726·3 to 584 649·5)
3008·1 
(1446·7 to 5557·4)
45·1% 
(44·6 to 45·6)*
25·6% 
(25·2 to 26·0)*
6·6% 
(6·4 to 6·8)*
4·3% 
(4·1 to 4·5)*
Sense organ diseases 2 035 737·0 
(1 994 115·8 to 
2 079 908·6)
·· 66 576·1 
(44 700·8 to 
95 675·1)
42·0% 
(41·1 to 42·8)*
24·1% 
(23·4 to 24·8)*
−1·0% 
(−1·6 to −0·5)*
−0·9% 
(−1·5 to −0·3)*
Blindness and vision 
impairment
1 193 642·8 
(1 154 777·0 to 1 237 118·0)
·· 29 895·2 
(20 277·7 to 
44 036·0)
39·3% 
(37·8 to 40·5)*
23·1% 
(22·0 to 24·0)*
−2·7% 
(−3·5 to −1·9)*
−1·8% 
(−2·7 to −0·9)*
Glaucoma 5993·5 
(5157·5 to 6984·8)
·· 686·1 
(462·9 to 948·8)
41·5% 
(39·1 to 44·2)*
27·9% 
(26·4 to 29·4)*
−6·0% 
(−7·4 to −4·2)*
−4·7% 
(−5·8 to −3·6)*
Cataract 107 987·7 
(95 775·3 to 122 319·3)
·· 8005·8 
(5579·2 to 10 820·9)
49·4% 
(46·9 to 52·0)*
29·6% 
(27·4 to 31·7)*
−2·8% 
(−4·2 to −1·2)*
−2·0% 
(−3·6 to −0·5)*
Age-related macular 
degeneration
6758·8 
(5612·6 to 8183·0)
·· 530·7 
(363·6 to 728·6)
59·3% 
(54·5 to 63·9)*
30·7% 
(28·6 to 32·9)*
2·8% 
(−0·7 to 6·1)
−3·7% 
(−5·3 to −2·1)*
Refraction disorders 185 392·8 
(165 673·9 to 208 575·2)
·· 7984·3 
(5353·0 to 11 487·0)
24·6% 
(21·7 to 27·7)*
15·3% 
(13·6 to 17·0)*
−6·1% 
(−7·8 to −4·3)*
−3·1% 
(−4·2 to −1·9)*
Near vision loss 969 669·5 
(932 613·8 to 1 009 067·7)
·· 9802·9 
(4669·6 to 17 922·5)
46·4% 
(45·6 to 47·1)*
24·6% 
(24·0 to 25·2)*
1·2% 
(0·8 to 1·7)*
0·5% 
(0·1 to 0·9)*
Other vision loss 34 607·5 
(30 956·5 to 38 397·4)
·· 2885·3 
(2013·7 to 3884·0)
36·7% 
(34·6 to 38·8)*
21·0% 
(19·4 to 22·6)*
−4·6% 
(−5·8 to −3·3)*
−3·7% 
(−4·8 to −2·6)*
Age-related and other 
hearing loss
1 317 431·7 
(1 276 962·6 to 
1 356 229·1)
·· 34 229·6 
(23 176·8 to 
48 684·1)
44·4% 
(43·0 to 45·7)*
24·9% 
(23·9 to 26·0)*
0·4% 
(−0·4 to 1·1)
−0·2% 
(−1·0 to 0·5)
Other sense organ diseases 103 750·5 
(100 613·2 to 107 050·4)
·· 2451·3 
(1519·6 to 3573·5)
42·1% 
(41·1 to 43·1)*
25·0% 
(24·2 to 25·8)*
1·8% 
(1·3 to 2·3)*
0·9% 
(0·4 to 1·4)*
Chronic other sense organ 
diseases
87 788·5 
(84 748·6 to 91 039·5)
·· 2232·4 
(1381·5 to 3246·2)
44·3% 
(43·4 to 45·3)*
26·1% 
(25·4 to 26·9)*
1·8% 
(1·3 to 2·3)*
0·9% 
(0·4 to 1·4)*
Acute other sense organ 
diseases
15 962·1 
(15 501·3 to 16 458·6)
·· 218·9 
(133·2 to 332·7)
24·3% 
(22·6 to 25·9)*
14·6% 
(13·2 to 16·2)*
1·7% 
(0·5 to 2·9)*
1·0% 
(−0·3 to 2·4)
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Musculoskeletal disorders 1 312 131·3 
(1 248 058·7 to 
1 383 422·6)
334 744·9 
(309 934·0 to 
363 175·8)
135 881·3 
(99 022·6 to 
179 645·0)
38·4% 
(36·4 to 40·2)*
19·9% 
(18·8 to 21·2)*
−2·3% 
(−3·3 to −1·2)*
−1·1% 
(−1·7 to −0·5)*
Rheumatoid arthritis 19 965·1 
(17 990·5 to 21 955·7)
1204·6 
(1071·1 to 1331·7)
2626·0 
(1783·4 to 3529·9)
45·8% 
(44·1 to 47·5)*
33·5% 
(30·6 to 36·4)*
0·9% 
(−0·1 to 1·9)
6·7% 
(4·7 to 8·8)*
Osteoarthritis 303 096·5 
(273 279·8 to 338 632·0)
14 933·5 
(13 386·3 to 16 739·6)
9604·0 
(4808·6 to 
19 139·0)
63·1% 
(61·5 to 64·9)*
31·4% 
(30·7 to 32·1)*
8·5% 
(7·5 to 9·6)*
1·0% 
(0·5 to 1·6)*
Osteoarthritis of the hip 40 010·0 
(37 473·8 to 42 725·7)
2045·1 
(1913·7 to 2195·9)
1265·4 
(648·2 to 2609·3)
59·1% 
(57·9 to 60·4)*
35·3% 
(34·5 to 36·2)*
5·7% 
(4·9 to 6·4)*
3·8% 
(3·2 to 4·4)*
Osteoarthritis of the knee 263 086·5 
(232 661·9 to 298 640·0)
12 888·4 
(11 375·0 to 14 656·0)
8338·6 
(4152·3 to 16 431·9)
63·7% 
(61·8 to 65·8)*
30·8% 
(30·1 to 31·6)*
9·0% 
(7·7 to 10·3)*
0·6% 
(0·1 to 1·2)*
Low back pain 576 980·9 
(518 940·4 to 637 177·9)
245 858·9 
(221 816·5 to 272 419·6)
64 946·7 
(46 512·3 to 
87 417·1)
30·0% 
(27·9 to 31·9)*
17·5% 
(16·2 to 19·0)*
−7·2% 
(−8·4 to −6·0)*
−2·1% 
(−2·6 to −1·6)*
Low back pain with leg pain 187 103·9 
(167 946·8 to 209 695·8)
78 640·7 
(69 782·0 to 87 714·4)
26 843·2 
(19 173·1 to 
36 078·7)
31·2% 
(29·0 to 33·4)*
19·0% 
(17·6 to 20·6)*
−7·8% 
(−8·9 to −6·5)*
−2·2% 
(−2·7 to −1·6)*
Low back pain without leg 
pain
389 877·0 
(350 624·1 to 429 901·0)
167 218·2 
(150 726·4 to 185 159·5)
38 103·5 
(27 216·0 to 
51 524·8)
29·1% 
(27·1 to 31·1)*
16·5% 
(15·1 to 18·0)*
−6·9% 
(−8·1 to −5·7)*
−2·0% 
(−2·5 to −1·6)*
Neck pain 288 718·6 
(254 715·3 to 323 483·0)
65 310·3 
(57 678·2 to 73 917·2)
28 631·1 
(19 951·8 to 
40 202·3)
44·4% 
(41·9 to 47·0)*
21·4% 
(19·5 to 23·6)*
−0·0% 
(−1·2 to 1·2)
−0·7% 
(−1·6 to 0·5)
Gout 41 217·7 
(36 699·8 to 46 101·3)
7437·7 
(6573·8 to 8457·4)
1285·0 
(867·4 to 1768·9)
54·7% 
(52·5 to 56·9)*
30·9% 
(29·2 to 32·6)*
4·4% 
(3·1 to 5·8)*
2·7% 
(1·6 to 3·7)*
Other musculoskeletal 
disorders
336 467·8 
(285 415·0 to 383 783·9)
·· 28 788·6 
(19 498·0 to 
39 995·7)
46·1% 
(43·6 to 48·6)*
19·0% 
(15·5 to 22·4)*
4·3% 
(3·3 to 5·4)*
−0·8% 
(−3·3 to 1·4)
Other non-communicable 
diseases
4 916 184·8 
(4 793 498·0 to 
5 046 526·7)
4 209 631·0 
(3 838 652·6 to 
4 611 876·0)
53 645·9 
(36 899·7 to 
74 479·3)
25·7% 
(24·2 to 27·5)*
12·9% 
(11·8 to 14·2)*
−5·3% 
(−6·0 to −4·6)*
−3·2% 
(−3·9 to −2·4)*
Congenital anomalies 100 366·3 
(95 153·7 to 106 524·9)
5445·3 
(5088·8 to 5844·4)
12 056·9 
(8552·1 to 
16 062·8)
23·1% 
(22·0 to 24·2)*
12·7% 
(11·7 to 13·7)*
−0·1% 
(−0·9 to 0·8)
0·8% 
(−0·2 to 1·6)
Neural tube defects 2874·4 
(2566·3 to 3205·2)
163·9 
(145·4 to 185·1)
854·7 
(600·1 to 1133·9)
25·1% 
(22·7 to 27·5)*
17·0% 
(13·8 to 20·3)*
2·1% 
(0·2 to 4·1)*
5·1% 
(2·2 to 8·0)*
Severe motor and 
cognitive impairment 
due to anencephaly
0·1 
(0·1 to 0·1)
12·8 
(10·2 to 16·3)
0·0 
(0·0 to 0·1)
−5·3% 
(−7·2 to −3·3)*
−6·5% 
(−8·6 to −4·5)*
−4·5% 
(−6·4 to −2·4)*
−8·9% 
(−11·0 to −7·0)*
Encephalocoele due to 
neural tube defects
300·6 
(246·9 to 354·9)
28·8 
(22·3 to 37·4)
51·8 
(34·6 to 72·3)
17·0% 
(14·3 to 20·0)*
12·8% 
(9·8 to 15·6)*
−6·3% 
(−8·1 to −4·4)*
−0·7% 
(−3·4 to 1·9)
Spina bifida due to neural 
tube defects
2573·8 
(2296·6 to 2874·9)
122·3 
(106·0 to 141·4)
802·9 
(557·1 to 1069·3)
25·7% 
(23·1 to 28·3)*
17·3% 
(14·1 to 20·6)*
2·8% 
(0·7 to 4·8)*
5·5% 
(2·6 to 8·5)*
Congenital heart anomalies 11 998·3 
(10 958·7 to 13 123·9)
2481·7 
(2203·2 to 2775·4)
589·5 
(287·2 to 973·4)
12·2% 
(9·7 to 13·9)*
7·6% 
(5·7 to 9·1)*
1·9% 
(0·4 to 3·2)*
0·2% 
(−1·5 to 1·5)
Critical malformations of 
great vessels, congenital 
valvular heart disease, and 
patent ductus arteriosus
2075·2 
(1788·4 to 2407·9)
519·5 
(406·2 to 650·6)
124·7 
(62·7 to 201·6)
10·0% 
(7·1 to 12·6)*
6·9% 
(4·3 to 9·1)*
0·9% 
(−1·5 to 2·9)
−0·1% 
(−2·3 to 2·1)
Other congenital heart 
anomalies
2540·8 
(2333·1 to 2769·7)
398·3 
(353·7 to 445·6)
142·9 
(62·3 to 243·7)
14·2% 
(11·1 to 16·6)*
8·9% 
(6·5 to 11·1)*
1·5% 
(−0·6 to 3·5)
0·4% 
(−1·8 to 2·4)
Severe congenital heart 
anomalies excluding single 
ventricle heart defects
2899·7 
(2567·0 to 3266·8)
565·8 
(453·1 to 699·6)
170·9 
(86·1 to 282·1)
20·6% 
(17·0 to 23·4)*
9·2% 
(6·5 to 11·6)*
6·5% 
(4·1 to 8·7)*
0·7% 
(−1·7 to 3·0)
(Table 1 continues on next page)
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Single ventricle and single 
ventricle pathway 
congenital heart 
anomalies
344·0 
(285·0 to 413·7)
263·5 
(186·1 to 356·8)
21·1 
(11·3 to 33·7)
13·0% 
(9·0 to 17·2)*
7·2% 
(3·2 to 11·1)*
5·5% 
(1·8 to 9·4)*
0·8% 
(−3·1 to 4·6)
Ventricular septal defect 
and atrial septal defect
4138·6 
(3401·3 to 4864·5)
734·5 
(588·6 to 908·7)
129·8 
(62·0 to 225·5)
2·9% 
(−0·0 to 5·7)
5·1% 
(2·5 to 7·5)*
−2·4% 
(−4·7 to −0·0)*
−0·7% 
(−3·3 to 1·6)
Orofacial clefts 10 816·4 
(9945·7 to 11 654·1)
195·5 
(152·0 to 249·3)
320·8 
(211·9 to 468·2)
8·7% 
(3·4 to 14·7)*
13·5% 
(7·5 to 20·0)*
−11·2% 
(−15·5 to −6·4)*
1·5% 
(−4·0 to 7·3)
Down syndrome 3535·7 
(3092·1 to 4015·5)
110·5 
(95·2 to 130·6)
326·4 
(222·7 to 452·6)
22·5% 
(21·3 to 23·8)*
11·8% 
(9·1 to 14·7)*
−1·5% 
(−2·6 to −0·5)*
−0·2% 
(−2·6 to 2·4)
Turner syndrome 572·3 
(502·0 to 652·8)
19·6 
(17·0 to 22·9)
10·1 
(5·0 to 16·5)
21·6% 
(19·5 to 24·1)*
9·1% 
(7·3 to 10·9)*
1·1% 
(−0·6 to 2·7)
0·9% 
(−0·7 to 2·5)
Klinefelter syndrome 866·8 
(747·4 to 994·2)
28·3 
(24·2 to 32·8)
5·2 
(2·4 to 9·7)
28·6% 
(24·5 to 33·0)*
7·4% 
(4·3 to 10·7)*
4·4% 
(1·4 to 7·6)*
−1·7% 
(−4·5 to 1·1)
Other chromosomal 
abnormalities
6379·1 
(5052·5 to 7827·4)
301·3 
(236·2 to 371·0)
593·1 
(389·9 to 833·1)
24·2% 
(22·1 to 26·3)*
19·6% 
(16·9 to 22·4)*
2·3% 
(0·7 to 4·1)*
7·1% 
(4·7 to 9·5)*
Congenital musculoskeletal 
and limb anomalies
31 506·6 
(28 137·2 to 36 022·4)
1537·0 
(1327·4 to 1777·0)
4622·5 
(3030·7 to 6345·8)
24·8% 
(23·9 to 25·8)*
13·4% 
(12·5 to 14·2)*
−0·6% 
(−1·4 to 0·1)
0·4% 
(−0·4 to 1·1)
Polydactyly and 
syndactyly
432·6 
(342·4 to 538·9)
218·7 
(158·9 to 295·2)
4·7 
(2·1 to 9·1)
0·3% 
(−3·9 to 5·2)
7·1% 
(3·1 to 10·9)*
−4·4% 
(−8·1 to −0·2)*
0·9% 
(−3·2 to 4·7)
Congenital limb 
deficiency
14 811·3 
(13 154·2 to 17 016·1)
389·3 
(343·2 to 449·2)
2217·3 
(1452·1 to 3057·6)
22·4% 
(21·2 to 23·6)*
11·8% 
(10·8 to 12·9)*
−0·1% 
(−1·1 to 0·8)
0·5% 
(−0·4 to 1·5)
Other congenital 
musculoskeletal anomalies
16 262·8 
(14 519·3 to 18 611·7)
929·0 
(801·7 to 1074·0)
2400·4 
(1574·9 to 3296·1)
27·3% 
(26·1 to 28·5)*
14·8% 
(13·8 to 15·8)*
−1·1% 
(−2·1 to −0·2)*
0·2% 
(−0·7 to 1·0)
Urogenital congenital 
anomalies
5725·5 
(4984·9 to 6504·8)
249·7 
(216·9 to 285·3)
141·0 
(82·3 to 233·3)
13·0% 
(11·5 to 14·6)*
4·2% 
(2·2 to 6·3)*
−4·7% 
(−5·8 to −3·6)*
−4·1% 
(−6·0 to −2·3)*
Digestive congenital 
anomalies
17 662·5 
(15 899·6 to 19 748·8)
357·9 
(323·3 to 398·8)
794·3 
(528·2 to 1134·1)
16·3% 
(15·0 to 17·5)*
8·7% 
(4·3 to 13·2)*
−8·5% 
(−9·5 to −7·5)*
−4·3% 
(−8·3 to −0·4)*
Congenital 
diaphragmatic hernia
315·6 
(276·8 to 357·7)
15·5 
(12·9 to 17·9)
6·2 
(3·6 to 10·1)
13·9% 
(12·9 to 14·9)*
6·5% 
(5·6 to 7·3)*
−1·3% 
(−2·0 to −0·5)*
−1·8% 
(−2·6 to −1·0)*
Congenital atresia or 
stenosis of the digestive 
tract
111·9 
(83·4 to 142·7)
137·3 
(96·5 to 174·1)
8·9 
(5·4 to 13·7)
−5·9% 
(−8·5 to −3·4)*
6·1% 
(3·2 to 9·1)*
−7·8% 
(−10·3 to −5·4)*
0·7% 
(−2·1 to 3·6)
Congenital malformations 
of the abdominal wall 
after treatment
1258·9 
(1109·6 to 1431·5)
84·7 
(71·3 to 99·3)
54·0 
(34·5 to 79·4)
15·2% 
(14·3 to 16·2)*
7·4% 
(6·6 to 8·2)*
0·1% 
(−0·6 to 0·8)
−0·8% 
(−1·6 to −0·1)*
Other congenital 
malformations of the 
digestive tract
15 976·1 
(14 219·3 to 18 092·5)
120·3 
(88·9 to 169·7)
725·2 
(480·5 to 1035·6)
16·7% 
(15·2 to 18·2)*
8·8% 
(4·0 to 13·7)*
−9·2% 
(−10·3 to −8·1)*
−4·7% 
(−9·0 to −0·4)*
Other congenital anomalies 25 911·9 
(22 431·7 to 30 006·9)
·· 3799·4 
(2595·5 to 5226·3)
25·9% 
(23·0 to 28·7)*
12·1% 
(9·6 to 14·5)*
2·9% 
(0·5 to 5·3)*
0·8% 
(−1·4 to 3·0)
Other congenital birth 
defects
·· ·· 446·4 
(309·1 to 601·8)
34·8% 
(32·6 to 37·3)*
19·3% 
(17·3 to 22·0)*
19·0% 
(17·6 to 20·5)*
9·8% 
(8·0 to 11·9)*
Hearing loss due to other 
congenital anomalies
25 911·9 
(22 431·7 to 30 006·9)
·· 3353·0 
(2227·2 to 4697·0)
24·8% 
(21·6 to 28·0)*
11·2% 
(8·4 to 13·9)*
1·1% 
(−1·4 to 3·6)
−0·4% 
(−2·8 to 2·1)
Urinary diseases and male 
infertility
110 267·4 
(99 363·2 to 120 483·9)
366 721·5 
(337 838·9 to 396 838·4)
3135·6 
(2053·6 to 4529·0)
33·7% 
(31·9 to 35·6)*
26·9% 
(25·5 to 28·4)*
−7·6% 
(−9·0 to −6·2)*
−0·8% 
(−1·7 to 0·1)
Urinary tract infections 5250·9 
(4741·8 to 5801·2)
274 626·5 
(247 558·6 to 303 427·3)
173·0 
(106·4 to 256·5)
29·8% 
(27·1 to 32·4)*
16·6% 
(14·0 to 19·3)*
0·3% 
(−1·2 to 1·9)
1·9% 
(0·1 to 3·7)*
Urolithiasis 3147·5 
(2808·1 to 3483·6)
83 173·6 
(74 603·1 to 91 918·7)
230·9 
(159·6 to 317·0)
31·2% 
(28·7 to 34·1)*
18·6% 
(16·2 to 20·9)*
−7·5% 
(−9·3 to −5·7)*
−2·0% 
(−3·5 to −0·3)*
Benign prostatic 
hyperplasia
74 541·9 
(65 358·9 to 84 081·8)
8921·5 
(7859·8 to 10 046·2)
2427·3 
(1562·8 to 3460·0)
36·7% 
(34·1 to 39·5)*
32·0% 
(30·7 to 33·3)*
−8·0% 
(−9·5 to −6·2)*
−0·2% 
(−1·1 to 0·8)
Male infertility 30 432·7 
(24 686·0 to 36 812·7)
·· 180·9 
(74·8 to 373·9)
33·1% 
(29·7 to 36·8)*
17·0% 
(13·7 to 20·1)*
1·3% 
(−0·5 to 3·3)
6·9% 
(4·1 to 9·7)*
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Other urinary diseases ·· ·· 123·5 
(84·7 to 170·6)
8·4% 
(6·5 to 10·3)*
−7·1% 
(−8·6 to −5·7)*
−18·0% 
(−19·3 to −16·7)*
−20·3% 
(−21·5 to −19·2)*
Gynaecological diseases 815 073·8 
(787 646·5 to 843 595·7)
195 631·4 
(189 141·1 to 202 275·1)
11 619·6 
(7966·6 to 16 279·1)
33·9% 
(31·3 to 36·5)*
10·2% 
(9·0 to 11·6)*
−1·9% 
(−3·4 to −0·5)*
−2·4% 
(−3·3 to −1·4)*
Uterine fibroids 159 444·4 
(139 576·9 to 182 588·5)
8445·5 
(7062·0 to 10 077·7)
1473·4 
(866·6 to 2386·3)
44·3% 
(39·5 to 48·4)*
8·1% 
(3·9 to 11·7)*
−2·5% 
(−5·7 to 0·4)
−8·0% 
(−11·5 to −5·1)*
Polycystic ovarian 
syndrome
52 159·9 
(41 652·7 to 66 540·8)
2129·0 
(1727·3 to 2716·3)
459·4 
(203·7 to 886·2)
33·2% 
(31·8 to 34·6)*
13·1% 
(12·1 to 14·1)*
0·6% 
(−0·3 to 1·4)
1·8% 
(1·0 to 2·7)*
Female infertility 61 238·4 
(43 321·2 to 82 668·2)
·· 342·6 
(129·5 to 723·4)
32·1% 
(26·8 to 37·5)*
27·5% 
(22·2 to 32·7)*
−0·0% 
(−2·6 to 2·7)
16·5% 
(12·0 to 20·8)*
Endometriosis 44 656·0 
(37 289·1 to 52 852·4)
6291·6 
(5083·7 to 7555·2)
4121·5 
(2752·3 to 5940·5)
31·2% 
(26·0 to 37·5)*
9·2% 
(7·9 to 10·5)*
−3·1% 
(−6·3 to 0·5)
−3·0% 
(−3·9 to −2·0)*
Genital prolapse 108 559·4 
(96 272·0 to 121 882·8)
12 319·0 
(10 947·3 to 13 860·3)
337·3 
(161·9 to 634·2)
26·0% 
(25·0 to 27·2)*
19·9% 
(18·5 to 21·3)*
−13·7% 
(−14·4 to −12·9)*
−3·6% 
(−4·4 to −2·8)*
Premenstrual syndrome 472 189·7 
(451 411·0 to 493 266·2)
127 157·4 
(121 707·4 to 132 919·3)
3930·0 
(2533·7 to 5900·3)
32·3% 
(30·9 to 33·7)*
8·8% 
(7·2 to 10·1)*
−0·6% 
(−1·4 to 0·3)
−2·2% 
(−3·6 to −1·0)*
Other gynaecological 
diseases
50 421·8 
(48 042·0 to 52 824·5)
39 288·9 
(37 076·3 to 41 538·6)
955·4 
(643·6 to 1384·7)
42·2% 
(36·5 to 47·7)*
14·5% 
(11·6 to 17·4)*
3·0% 
(−0·6 to 6·7)
1·3% 
(−1·5 to 3·9)
Other gynaecological 
diseases
45 859·4 
(43 492·6 to 48 226·9)
39 288·9 
(37 076·3 to 41 538·6)
855·8 
(576·7 to 1238·9)
41·5% 
(35·6 to 47·2)*
15·5% 
(12·2 to 18·6)*
2·5% 
(−1·2 to 6·4)
1·9% 
(−1·1 to 5·0)
Other gynaecological 
diseases with anaemia
4562·4 
(4423·1 to 4703·7)
·· 99·6 
(66·3 to 146·8)
47·3% 
(39·9 to 55·6)*
6·6% 
(1·1 to 11·8)*
6·4% 
(0·9 to 12·5)*
−4·2% 
(−8·9 to 0·6)
Haemoglobinopathies and 
haemolytic anaemias
1 922 603·3 
(1 878 676·9 to 
1 967 411·4)
42 237·7 
(40 961·6 to 43 660·7)
5313·7 
(3608·1 to 7683·0)
1·1% 
(−2·0 to 4·1)
−5·3% 
(−8·4 to −2·3)*
−17·8% 
(−20·2 to −15·5)*
−15·2% 
(−17·9 to −12·5)*
Thalassaemias 411·4 
(384·1 to 441·7)
106·3 
(99·7 to 113·5)
17·2 
(11·4 to 25·3)
−38·9% 
(−42·9 to −34·6)*
−20·0% 
(−25·4 to −15·4)*
−41·0% 
(−44·8 to −36·6)*
−24·4% 
(−29·6 to −20·0)*
Thalassaemias trait 298 566·6 
(287 549·2 to 309 863·6)
4868·2 
(4697·5 to 5051·2)
1908·8 
(1282·8 to 2781·8)
−8·2% 
(−12·8 to −3·6)*
−12·1% 
(−16·1 to −7·7)*
−25·7% 
(−29·1 to −22·1)*
−21·6% 
(−25·1 to −18·0)*
Sickle cell disorders 3131·7 
(2845·5 to 3434·9)
613·1 
(514·6 to 732·0)
252·7 
(173·0 to 354·4)
42·0% 
(34·4 to 50·4)*
15·1% 
(8·0 to 21·2)*
28·0% 
(21·0 to 35·3)*
8·4% 
(1·8 to 14·2)*
Sickle cell trait 460 730·8 
(416 642·3 to 511 272·8)
10 822·4 
(9887·9 to 11 861·3)
1203·4 
(812·3 to 1731·4)
20·5% 
(16·4 to 24·3)*
−1·3% 
(−5·1 to 2·9)
1·2% 
(−1·9 to 4·2)
−10·3% 
(−13·9 to −6·4)*
G6PD deficiency 359 180·8 
(344 591·4 to 374 393·5)
7844·9 
(7507·8 to 8199·3)
24·7 
(17·1 to 34·4)
13·8% 
(8·1 to 21·1)*
2·3% 
(−4·6 to 8·7)
−6·9% 
(−11·5 to −1·1)*
−8·8% 
(−15·2 to −3·1)*
G6PD trait 940 308·4 
(924 830·5 to 955 818·2)
17 982·7 
(17 673·9 to 18 299·5)
0·4 
(0·3 to 0·6)
28·3% 
(22·4 to 34·0)*
3·0% 
(−1·7 to 7·8)
1·3% 
(−3·2 to 5·7)
−8·1% 
(−12·2 to −3·9)*
Other 
haemoglobinopathies and 
haemolytic anaemias
79 442·9 
(77 864·8 to 81 099·0)
·· 1906·4 
(1289·0 to 2768·5)
−0·4% 
(−3·3 to 2·5)
−2·5% 
(−5·8 to 1·0)
−20·8% 
(−23·0 to −18·7)*
−13·8% 
(−16·8 to −10·6)*
Endocrine, metabolic, blood, 
and immune disorders
109 922·2 
(106 937·4 to 113 100·4)
·· 3215·7 
(2232·5 to 4501·4)
6·1% 
(4·1 to 8·2)*
3·2% 
(1·0 to 5·4)*
−16·0% 
(−17·4 to −14·5)*
−9·5% 
(−11·4 to −7·4)*
Anaemia due to endocrine, 
metabolic, blood, and 
immune disorders
81 387·3 
(80 146·9 to 82 729·4)
·· 2177·1 
(1481·4 to 3130·1)
0·0% 
(−2·5 to 2·6)
−4·9% 
(−8·1 to −1·5)*
−19·4% 
(−21·4 to −17·4)*
−14·3% 
(−17·2 to −11·3)*
Endocrine, metabolic, blood, 
and immune disorders
28 144·8 
(25 572·5 to 30 946·4)
·· 1005·7 
(684·2 to 1398·9)
27·2% 
(24·6 to 30·0)*
25·4% 
(22·2 to 28·7)*
−5·4% 
(−6·6 to −4·0)*
3·3% 
(1·0 to 5·5)*
Heart failure due to 
endocrine, metabolic, blood, 
and immune disorders
390·1 
(322·2 to 465·9)
·· 32·9 
(21·8 to 46·4)
34·0% 
(27·5 to 40·8)*
28·1% 
(24·7 to 31·5)*
−13·9% 
(−18·2 to −9·7)*
−4·6% 
(−6·9 to −2·1)*
Oral disorders 3 466 894·0 
(3 271 733·1 to 
3 676 485·6)
3 599 595·0 
(3 233 032·9 to 
3 992 824·0)
18 304·4 
(10 992·8 to 
28 338·1)
38·4% 
(36·9 to 39·8)*
21·4% 
(20·5 to 22·3)*
−2·7% 
(−3·8 to −1·8)*
−1·3% 
(−2·0 to −0·6)*
Caries of deciduous teeth 531 801·7 
(443 844·0 to 622 463·7)
1 057 534·3 
(756 100·5 to 1 400 908·8)
138·9 
(59·4 to 278·1)
−4·5% 
(−6·2 to −2·9)*
4·9% 
(3·1 to 6·3)*
−7·0% 
(−8·6 to −5·6)*
−2·1% 
(−3·7 to −0·8)*
(Table 1 continues on next page)
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Prevalence (thousands) 
2017 counts
Incidence (thousands) 
2017 counts
YLDs (thousands)
2017 counts Percentage 
change in counts, 
1990–2007
Percentage 
change in counts, 
2007–17
Percentage change 
in age-standardised 
rates, 1990–2007
Percentage change 
in age-standardised 
rates, 2007–17
(Continued from previous page)
Caries of permanent teeth 2 301 999·2 
(2 104 931·2 to 
2 525 509·0)
2 452 124·9 
(2 233 639·1 to 
2 665 441·2)
1618·9 
(697·9 to 3087·7)
20·6% 
(18·9 to 22·5)*
9·4% 
(8·6 to 10·3)*
−8·2% 
(−9·3 to −7·0)*
−4·0% 
(−4·8 to −3·3)*
Periodontal disease 796 122·9 
(670 981·0 to 930 283·0)
71 483·7 
(61 593·0 to 81 227·2)
5185·6 
(2039·3 to 10 653·7)
50·2% 
(48·8 to 51·6)*
26·6% 
(25·1 to 27·9)*
3·2% 
(2·6 to 3·7)*
2·8% 
(2·3 to 3·2)*
Edentulism and severe 
tooth loss
267 457·5 
(235 214·4 to 300 011·3)
18 452·1 
(16 192·9 to 20 997·1)
7345·9 
(4894·2 to 
10 408·2)
40·8% 
(39·4 to 42·1)*
24·6% 
(23·7 to 25·5)*
−6·3% 
(−7·1 to −5·5)*
−4·1% 
(−4·7 to −3·4)*
Other oral disorders 139 086·3 
(133 117·0 to 145 643·0)
·· 4015·1 
(2507·7 to 5900·3)
32·7% 
(31·9 to 33·6)*
15·7% 
(15·0 to 16·3)*
0·0% 
(−0·3 to 0·4)
0·2% 
(−0·1 to 0·5)
Injuries 1 507 481·4 
(1 439 758·0 to 
1 587 209·4)
520 710·3 
(493 430·2 to 
547 988·6)
57 174·5 
(42 073·9 to 
75 427·0)
23·7% 
(22·1 to 25·3)*
23·4% 
(22·0 to 24·8)*
−10·4% 
(−11·2 to −9·5)*
2·9% 
(2·1 to 3·7)*
Transport injuries 226 305·6 
(209 529·5 to 244 291·1)
63 920·6 
(56 848·5 to 71 592·2)
13 394·4 
(9586·9 to 
17 861·0)
32·9% 
(30·5 to 35·3)*
21·6% 
(20·4 to 22·9)*
−4·0% 
(−5·4 to −2·7)*
1·2% 
(0·4 to 2·0)*
Road injuries 174 209·6 
(162 042·0 to 187 472·1)
54 192·3 
(47 381·6 to 61 645·9)
10 159·7 
(7272·0 to 13 618·8)
42·8% 
(41·0 to 44·8)*
21·7% 
(20·5 to 22·9)*
1·7% 
(0·6 to 2·8)*
0·5% 
(−0·3 to 1·3)
Pedestrian road injuries 46 000·9 
(39 776·2 to 54 538·8)
11 038·9 
(9097·7 to 13 168·8)
2710·1 
(1912·5 to 3722·5)
35·6% 
(32·3 to 38·5)*
18·1% 
(16·2 to 19·8)*
−3·1% 
(−4·8 to −1·5)*
−2·4% 
(−3·6 to −1·3)*
Cyclist road injuries 30 602·6 
(25 887·6 to 35 843·6)
11 912·9 
(9669·7 to 14 669·8)
1701·1 
(1203·1 to 2311·2)
49·1% 
(45·4 to 52·5)*
27·8% 
(25·6 to 29·8)*
6·6% 
(4·5 to 8·4)*
5·1% 
(3·9 to 6·4)*
Motorcyclist road injuries 43 911·6 
(37 802·2 to 50 950·2)
10 099·8 
(8264·3 to 12 257·1)
2563·7 
(1759·1 to 3510·3)
61·6% 
(58·6 to 64·8)*
22·5% 
(20·7 to 24·4)*
15·6% 
(14·0 to 17·3)*
2·0% 
(0·6 to 3·4)*
Motor vehicle road injuries 42 004·6 
(36 541·9 to 49 398·3)
16 209·2 
(13 485·6 to 19 383·3)
2568·1 
(1842·3 to 3439·8)
30·8% 
(29·3 to 32·4)*
16·3% 
(14·8 to 17·7)*
−7·7% 
(−8·5 to −6·9)*
−4·5% 
(−5·6 to −3·5)*
Other road injuries 11 689·9 
(9728·7 to 14 348·1)
4931·4 
(3777·3 to 6241·2)
616·6 
(438·2 to 853·2)
52·6% 
(49·6 to 55·3)*
45·4% 
(42·4 to 47·9)*
9·0% 
(7·4 to 10·5)*
20·3% 
(18·6 to 21·8)*
Other transport injuries 52 096·1 
(43 127·5 to 61 355·1)
9728·3 
(8120·6 to 11 627·0)
3234·7 
(2315·7 to 4345·0)
9·0% 
(6·9 to 11·4)*
21·4% 
(19·8 to 23·3)*
−18·5% 
(−19·8 to −17·2)*
3·5% 
(2·0 to 5·0)*
Unintentional injuries 935 298·2 
(876 022·5 to 
1 008 077·1)
415 410·3 
(390 092·6 to 
441 943·0)
36 509·7 
(26 384·7 to 
49 052·5)
19·8% 
(18·0 to 21·6)*
26·5% 
(25·2 to 27·7)*
−13·8% 
(−14·7 to −12·8)*
4·5% 
(3·7 to 5·3)*
Falls 411 712·0 
(366 391·0 to 465 355·0)
171 691·2 
(152 472·7 to 194 061·9)
19 252·7 
(13 725·4 to 
26 140·4)
23·1% 
(21·3 to 24·9)*
27·7% 
(26·5 to 29·0)*
−12·7% 
(−13·6 to −11·8)*
3·9% 
(3·0 to 4·6)*
Drowning 2207·3 
(1940·6 to 2531·3)
357·5 
(311·4 to 411·9)
131·6 
(94·3 to 175·8)
−11·2% 
(−14·0 to −8·2)*
14·2% 
(10·4 to 17·9)*
−33·1% 
(−34·9 to −31·2)*
−3·8% 
(−6·6 to −1·3)*
Fire, heat, and hot substances 99 746·8 
(85 298·5 to 115 988·1)
8991·5 
(7481·2 to 10 740·9)
3177·0 
(2210·4 to 4396·7)
0·8% 
(−4·4 to 6·2)
17·8% 
(13·9 to 21·7)*
−25·3% 
(−28·5 to −22·0)*
1·1% 
(−1·6 to 3·7)
Poisonings 4556·0 
(3808·4 to 5352·3)
4079·6 
(3287·6 to 4973·7)
467·4 
(308·0 to 663·8)
8·6% 
(7·2 to 10·0)*
29·9% 
(28·3 to 31·8)*
−18·1% 
(−19·0 to −17·1)*
12·2% 
(10·8 to 13·9)*
Poisoning by carbon 
monoxide
854·2 
(717·2 to 1034·9)
1043·5 
(770·9 to 1392·2)
75·5 
(50·4 to 109·9)
16·0% 
(14·1 to 18·0)*
33·4% 
(30·2 to 36·5)*
−13·1% 
(−14·4 to −11·9)*
14·7% 
(12·0 to 17·5)*
Poisoning by other means 3701·8 
(2951·6 to 4490·9)
3036·0 
(2379·5 to 3782·1)
391·9 
(252·7 to 576·0)
7·3% 
(5·8 to 8·8)*
29·3% 
(27·2 to 31·4)*
−19·0% 
(−19·9 to −18·0)*
11·8% 
(9·9 to 13·7)*
Exposure to mechanical forces 194 479·9 
(169 045·7 to 225 589·9)
72 503·4 
(62 042·8 to 84 320·6)
4959·6 
(3445·4 to 6978·5)
16·5% 
(14·3 to 18·6)*
29·0% 
(27·6 to 30·5)*
−16·0% 
(−17·2 to −14·9)*
7·4% 
(6·5 to 8·4)*
Unintentional firearm 
injuries
8469·2 
(6941·4 to 9838·8)
1911·8 
(1390·6 to 2544·6)
320·1 
(224·6 to 436·7)
13·7% 
(12·2 to 15·2)*
28·0% 
(26·5 to 29·5)*
−16·5% 
(−17·4 to −15·7)*
8·6% 
(7·7 to 9·6)*
Other exposure to 
mechanical forces
186 010·7 
(159 749·5 to 216 401·4)
70 591·6 
(60 734·7 to 82 371·3)
4639·5 
(3204·1 to 6560·6)
16·7% 
(14·4 to 18·9)*
29·1% 
(27·7 to 30·6)*
−16·0% 
(−17·2 to −14·8)*
7·3% 
(6·3 to 8·4)*
Adverse effects of medical 
treatment
2673·1 
(2059·9 to 3308·5)
34 975·0 
(29 997·9 to 40 308·2)
356·5 
(223·9 to 533·8)
60·5% 
(55·4 to 65·6)*
48·0% 
(41·2 to 54·5)*
18·5% 
(16·0 to 21·0)*
19·6% 
(15·3 to 24·0)*
(Table 1 continues on next page)
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Prevalence (thousands) 
2017 counts
Incidence (thousands) 
2017 counts
YLDs (thousands)
2017 counts Percentage 
change in counts, 
1990–2007
Percentage 
change in counts, 
2007–17
Percentage change 
in age-standardised 
rates, 1990–2007
Percentage change 
in age-standardised 
rates, 2007–17
(Continued from previous page)
Animal contact 38 403·6 
(34 169·0 to 43 179·8)
43 844·6 
(37 631·9 to 51 149·2)
1075·6 
(732·1 to 1484·0)
11·3% 
(9·7 to 12·9)*
17·9% 
(16·1 to 19·6)*
−17·0% 
(−17·9 to −16·2)*
1·1% 
(−0·2 to 2·3)
Venomous animal contact 15 812·1 
(13 211·3 to 18 557·7)
21 097·9 
(17 255·4 to 25 592·6)
717·2 
(487·1 to 1004·2)
14·7% 
(12·7 to 17·1)*
18·2% 
(16·2 to 20·3)*
−13·6% 
(−14·8 to −12·2)*
2·7% 
(1·1 to 4·3)*
Non-venomous animal 
contact
22 591·5 
(19 045·6 to 26 729·8)
22 746·6 
(18 607·8 to 27 654·5)
358·4 
(224·3 to 555·6)
5·0% 
(2·4 to 7·6)*
17·2% 
(14·8 to 19·1)*
−22·9% 
(−24·3 to −21·8)*
−1·8% 
(−3·5 to −0·5)*
Foreign body 19 350·9 
(16 787·2 to 22 108·8)
23 101·7 
(19 925·9 to 26 454·1)
949·3 
(683·3 to 1285·0)
16·3% 
(13·6 to 19·1)*
21·5% 
(20·3 to 22·9)*
−13·0% 
(−15·0 to −11·0)*
3·4% 
(2·4 to 4·5)*
Pulmonary aspiration and 
foreign body in airway
3008·1 
(2442·0 to 3662·4)
1346·3 
(1115·6 to 1607·1)
150·4 
(103·1 to 204·4)
12·2% 
(6·2 to 19·3)*
23·8% 
(20·7 to 26·9)*
−14·1% 
(−17·9 to −9·5)*
5·8% 
(3·6 to 8·2)*
Foreign body in eyes 3190·4 
(1644·6 to 4857·3)
17 672·8 
(14 633·0 to 20 947·8)
201·6 
(104·6 to 334·5)
20·3% 
(17·7 to 23·1)*
20·3% 
(18·8 to 22·1)*
−9·4% 
(−12·1 to −7·4)*
2·7% 
(1·3 to 3·6)*
Foreign body in other body 
part
13 152·5 
(10 991·9 to 15 298·2)
4082·5 
(3342·2 to 5009·6)
597·3 
(427·3 to 783·4)
16·0% 
(13·3 to 19·2)*
21·4% 
(20·0 to 22·9)*
−13·9% 
(−15·6 to −11·9)*
3·1% 
(1·8 to 4·3)*
Environmental heat and cold 
exposure
34 896·7 
(29 946·9 to 40 886·4)
8769·0 
(7357·0 to 10 370·5)
1509·5 
(1072·5 to 2023·8)
13·6% 
(11·0 to 16·4)*
24·5% 
(22·3 to 26·6)*
−16·7% 
(−18·2 to −15·1)*
4·9% 
(3·4 to 6·4)*
Exposure to forces of nature 15 757·0 
(11 656·5 to 20 853·3)
689·2 
(587·4 to 817·5)
725·5 
(524·9 to 975·9)
220·3% 
(200·7 to 238·8)*
22·6% 
(19·0 to 26·1)*
156·4% 
(140·2 to 171·7)*
7·8% 
(5·0 to 10·4)*
Other unintentional injuries 115 519·2 
(98 844·3 to 134 764·7)
46 407·6 
(39 513·5 to 53 786·8)
3904·9 
(2715·6 to 5485·4)
20·4% 
(18·4 to 22·2)*
28·4% 
(27·0 to 29·7)*
−13·9% 
(−14·9 to −13·0)*
5·7% 
(4·9 to 6·6)*
Self-harm and interpersonal 
violence
351 859·6 
(316 749·7 to 390 321·7)
41 379·4 
(37 344·5 to 45 834·4)
7270·4 
(5637·2 to 9008·3)
27·2% 
(24·7 to 30·0)*
13·0% 
(10·8 to 15·0)*
−3·5% 
(−5·4 to −1·3)*
−2·0% 
(−3·7 to −0·5)*
Self-harm 8502·0 
(7072·4 to 10 011·6)
3939·8 
(3338·1 to 4603·3)
435·3 
(306·0 to 574·8)
18·5% 
(15·2 to 21·9)*
6·3% 
(4·8 to 7·9)*
−16·0% 
(−18·2 to −13·9)*
−12·1% 
(−13·1 to −11·1)*
Self-harm by firearm 114·4 
(100·5 to 130·9)
41·6 
(26·1 to 63·2)
4·8 
(3·4 to 6·5)
13·5% 
(11·6 to 15·7)*
7·6% 
(5·3 to 9·9)*
−21·3% 
(−22·7 to −19·9)*
−12·9% 
(−14·7 to −11·1)*
Self-harm by other specified 
means
8387·6 
(6963·0 to 9894·9)
3898·2 
(3299·6 to 4570·6)
430·5 
(301·7 to 568·8)
18·6% 
(15·2 to 22·0)*
6·3% 
(4·8 to 7·9)*
−16·0% 
(−18·1 to −13·9)*
−12·1% 
(−13·1 to −11·1)*
Interpersonal violence 297 781·5 
(268 378·9 to 330 722·3)
22 919·4 
(19 569·3 to 26 696·3)
4561·8 
(3522·0 to 5756·8)
24·0% 
(21·7 to 26·3)*
14·6% 
(13·1 to 15·9)*
−7·4% 
(−8·7 to −5·9)*
−0·8% 
(−1·6 to −0·0)*
Assault by firearm 2599·6 
(2158·5 to 3151·0)
551·9 
(421·7 to 725·6)
116·9 
(83·8 to 159·3)
41·0% 
(38·7 to 43·5)*
20·2% 
(18·3 to 22·0)*
1·1% 
(−0·3 to 2·4)
0·5% 
(−0·9 to 1·9)
Assault by sharp object 14 754·5 
(12 033·6 to 20 359·8)
4233·0 
(3265·4 to 5366·7)
475·1 
(333·8 to 659·8)
21·0% 
(18·2 to 23·7)*
13·8% 
(12·1 to 15·7)*
−12·0% 
(−13·5 to −10·5)*
−3·4% 
(−4·9 to −1·9)*
Sexual violence 238 200·3 
(209 368·6 to 270 335·5)
·· 2142·0 
(1447·1 to 3106·7)
26·1% 
(22·5 to 30·1)*
12·4% 
(10·2 to 14·3)*
−1·9% 
(−3·5 to −0·1)*
0·6% 
(−0·6 to 1·6)
Assault by other means 42 227·1 
(35 479·3 to 50 750·5)
18 134·5 
(15 426·3 to 21 180·0)
1827·8 
(1295·0 to 2446·7)
21·3% 
(18·4 to 24·5)*
17·1% 
(15·7 to 18·6)*
−12·4% 
(−14·1 to −10·6)*
−1·9% 
(−3·0 to −0·7)*
Conflict and terrorism 41 912·3 
(28 964·3 to 59 365·8)
12 492·6 
(10 797·4 to 15 087·4)
2134·0 
(1438·2 to 3191·0)
35·1% 
(30·0 to 40·8)*
10·1% 
(4·9 to 15·5)*
8·2% 
(4·0 to 12·7)*
−3·2% 
(−7·6 to 1·4)
Executions and police conflict 3680·5 
(2459·9 to 5304·1)
2027·6 
(1683·1 to 2486·1)
139·3 
(99·1 to 197·0)
59·4% 
(45·9 to 74·0)*
32·9% 
(27·9 to 51·1)*
22·3% 
(11·9 to 33·5)*
14·6% 
(9·9 to 31·1)*
Nature of injury aggregates
Amputations 371 422·5 
(343 523·2 to 407 748·4)
9847·8 
(8414·6 to 11 519·6)
6409·0 
(4283·7 to 9318·6)
17·4% 
(12·9 to 21·9)*
19·6% 
(15·7 to 23·2)*
−15·5% 
(−18·6 to −12·2)*
−0·4% 
(−3·5 to 2·4)
Burns 208 679·9 
(192 327·8 to 227 204·0)
14 307·6 
(12 437·8 to 16 359·2)
6720·1 
(4841·1 to 9083·9)
5·8% 
(0·9 to 11·2)*
14·3% 
(10·1 to 18·6)*
−21·0% 
(−24·2 to −17·8)*
−1·5% 
(−4·3 to 1·2)
Fractures 360 136·5 
(338 070·9 to 385 693·0)
139 646·3 
(128 305·0 to 152 504·8)
19 793·8 
(13 702·1 to 
27 655·9)
30·3% 
(29·1 to 31·5)*
27·3% 
(26·1 to 28·3)*
−8·6% 
(−9·3 to −7·8)*
3·0% 
(2·1 to 3·7)*
Head injuries 46 873·2 
(44 984·0 to 48 892·5)
21 652·5 
(19 206·0 to 24 416·0)
6898·0 
(4883·9 to 9277·6)
35·6% 
(34·5 to 36·8)*
27·9% 
(27·1 to 28·7)*
−2·5% 
(−3·2 to −1·8)*
6·2% 
(5·6 to 6·9)*
Spinal injuries 22 489·5 
(20 671·6 to 25 115·6)
775·8 
(643·3 to 957·7)
6633·4 
(4708·0 to 8639·5)
26·1% 
(23·4 to 28·9)*
25·0% 
(22·9 to 26·6)*
−6·6% 
(−8·7 to −4·1)*
6·3% 
(5·0 to 7·3)*
(Table 1 continues on next page)
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The most common Level 3 causes of YLD rates by 
country and subnational locations by sex are shown in 
appendix 2. In both females and males, low back pain 
was the leading Level 3 cause by country. In females, 
the second most commonly leading Level 3 cause 
was headache disorders, which was the leading cause in 
57 countries, followed by diabetes, which was the leading 
cause in 20 countries. In males, the second most 
commonly leading Level 3 cause was diabetes, highest in 
39 countries, followed by drug use disorders and conflict 
and terror, each leading in five countries.
Temporal YLD trends in causes and impairments by 
geographical regions and SDI quintiles
Figure 3 shows rankings and trends of the top causes of 
YLDs by SDI quintile and by sex. SDI-based patterns 
varied by sex: the top cause of YLD rates between 1990 
and 2017 in the lowest SDI quintile was dietary iron 
deficiency for females and low back pain for males, 
whereas in the highest SDI quintile it was low back pain 
for both females and males. In the lowest SDI quintile, 
for both sexes combined, the top three causes of YLD 
rates were low back pain, dietary iron deficiency, and 
headache disorders, while in the highest SDI quintile 
the top three causes were low back pain, headache 
disorders, and depressive disorders (appendix 2). The 
sup plementary results show these results for the leading 
six impairments estimated in GBD: anaemia, heart 
failure, vision loss, hearing loss, epilepsy, and infertility 
(appendix 2). The immense burden of anaemia is shown, 
particularly for females in low-SDI regions. The 
differences in the burden of impairments by sex are also 
provided (appendix 2).
Figure 4 shows the all-age and age-standardised YLD 
rates by SDI and GBD region between 1990 and 2017 for 
males and females combined for all causes and then 
separately for Level 1 causes. In general, many regions 
experienced decreases in all-cause age-standardised 
Prevalence (thousands) 
2017 counts
Incidence (thousands) 
2017 counts
YLDs (thousands)
2017 counts Percentage 
change in counts, 
1990–2007
Percentage 
change in counts, 
2007–17
Percentage change 
in age-standardised 
rates, 1990–2007
Percentage change 
in age-standardised 
rates, 2007–17
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Minor injuries 198 921·3 
(187 143·0 to 213 281·5)
181 177·5 
(167 026·3 to 195 833·2)
1752·5 
(831·1 to 3319·5)
25·5% 
(24·1 to 27·1)*
27·5% 
(26·8 to 28·4)*
−10·2% 
(−11·1 to −9·2)*
5·1% 
(4·6 to 5·8)*
Other injuries 71 339·1 
(67 479·1 to 75 358·0)
153 302·9 
(143 603·2 to 162 955·6)
6825·7 
(4830·6 to 9168·5)
20·4% 
(18·7 to 22·4)*
23·1% 
(21·0 to 24·8)*
−10·7% 
(−11·8 to −9·4)*
4·1% 
(2·6 to 5·4)*
Impairments
Anaemia 1 950 345·6 
(1 909 153·0 to 
1 990 086·8)
·· 58 197·1 
(39 535·4 to 
83 046·0)
−0·9% 
(−3·3 to 1·5)
−6·7% 
(−9·5 to −3·8)*
−17·1% 
(−18·9 to −15·2)*
−16·2% 
(−18·8 to −13·5)*
Epilepsy 63 783·6 
(55 496·5 to 73 199·5)
·· 25 957·3 
(20 369·4 to 
32 900·4)
34·1% 
(25·9 to 42·1)*
16·3% 
(10·6 to 22·1)*
8·8% 
(1·9 to 15·2)*
4·5% 
(−0·7 to 9·8)
Guillain-Barré syndrome 103·7 
(82·7 to 127·2)
·· 30·7 
(19·3 to 44·4)
29·4% 
(25·5 to 33·8)*
18·3% 
(15·9 to 21·0)*
2·7% 
(1·0 to 4·3)*
3·4% 
(2·2 to 4·5)*
Hearing loss 1 428 450·1 
(1 388 276·9 to 
1 465 389·9)
·· 39 454·3 
(27 100·6 to 
55 310·2)
40·0% 
(38·7 to 41·0)*
22·4% 
(21·4 to 23·3)*
0·0% 
(−0·7 to 0·6)
−0·5% 
(−1·2 to 0·1)
Heart failure 64 343·9 
(57 187·0 to 71 648·3)
·· 9906·9 
(7261·9 to 12 443·6)
55·4% 
(51·7 to 59·1)*
32·6% 
(30·3 to 34·6)*
−0·4% 
(−2·6 to 1·9)
−0·5% 
(−2·0 to 0·7)
Infertility 123 084·9 
(99 543·3 to 150 556·1)
·· 956·9 
(487·4 to 1791·9)
31·7% 
(28·0 to 34·8)*
17·3% 
(13·6 to 20·5)*
−0·7% 
(−3·0 to 1·0)
6·8% 
(3·5 to 9·8)*
Developmental intellectual 
disability
188 585·1 
(145 641·8 to 230 402·8)
·· 25 301·2 
(19 706·5 to 
31 400·2)
30·2% 
(25·9 to 35·0)*
12·9% 
(10·0 to 16·1)*
7·1% 
(3·7 to 11·0)*
2·1% 
(−0·5 to 5·1)
Pelvic inflammatory disease 1064·1 
(906·7 to 1249·0)
·· 141·0 
(94·8 to 197·2)
42·3% 
(39·0 to 45·9)*
16·0% 
(13·6 to 18·7)*
4·5% 
(2·5 to 6·7)*
2·5% 
(0·4 to 4·7)*
Vision loss 1 339 970·3 
(1 291 077·0 to 
1 393 811·0)
·· 34 125·4 
(23 206·6 to 
48 924·6)
38·3% 
(36·9 to 39·6)*
22·2% 
(21·2 to 23·3)*
−2·4% 
(−3·2 to −1·6)*
−1·5% 
(−2·3 to −0·7)*
Data in parentheses are 95% uncertainty intervals. We did not calculate incidence for the nine impairments and certain neglected tropical diseases. Blank cells mean that no estimate is available or that the estimate 
has a magnitude less than 50. G6PD=glucose-6-phosphate dehydrogenase. GFR=glomerular filtration rate. H influenzae=Haemophilus influenzae. NASH=non-alcoholic steatohepatitis. YLDs=years lived with 
disability. *Percentage changes that are statistically significant. †Incidence of HIV/AIDS represents new infections of HIV only and does not include new infections of tuberculosis in HIV positive cases. ‡Incidence 
estimates for stroke represent first-ever stroke only. 
Table 1: Global prevalence, incidence, and YLDs for 2017; percentage change of YLD counts; and percentage change of age-standardised YLD rates for 1990–2007 and 2007–17 for both 
sexes combined for all Level 5 causes, nature of injury aggregates, and nine impairments
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YLD rates as SDI increased (figure 4). However, there 
were important exceptions to this finding. First, some 
regions did not follow this trend consistently. Southern 
sub-Saharan Africa showed an increase in YLD rates for 
more than a decade before beginning a more precipitous 
decline coinciding with the apex of the HIV epidemic, 
whereas regions with a higher baseline SDI have generally 
experienced minimal changes or increases in age-
standardised YLD rates over the past decade despite 
advances in SDI. We found that trends also varied over 
time depending on cause. As SDI increased, age-
standardised and all-age YLDs improved for CMNN 
causes in most regions, but this relation was less reliable 
for NCDs. The NCD pattern also differed markedly 
between all-age and age-standardised rates for NCDs, with 
all-age rates increasing as SDI improved with relatively 
little change over time observed in age-standardised rates. 
For injuries, some regions initially experienced a declining 
burden as SDI increased, followed by an increasing 
burden as SDI continued to increase over time, as seen in 
Central Europe, for example.
Age-specific and sex-specific patterns in prevalence 
and YLDs
Table 2 shows global age-standardised prevalence for 
females and males for all Level 2 GBD causes as well as 
the relative difference between the sexes in 1990 and 2017. 
In both 1990 and 2017, the cause with the greatest relative 
difference between sexes was substance use disorders, 
which had a relative difference of 1·09 (95% UI 1·03–1·15) 
in 1990, which increased to 1·16 (1·09–1·23) in 2017. In 
1990, 302 million (226–388) YLDs were in females and 
260 million (195–336) were in males. The all-age YLD rate 
for females was 11 273·6 (8455·6–14 492·5) per 100 000 and 
the all-age YLD for males was 9571·4 (7160·9–12 356·1) per 
100 000 in 1990. Among the global sum of YLDs, 53·6% 
(53·3–53·9) or 457 million (344–587) YLDs were in 
females and 46·4% (46·1–46·7) or 396 million (297–510) 
YLDs were in males. In the subset of causes that occur in 
both males and females, there were 761 million (565–987) 
total YLDs, with 53·0% (52·8–53·2) or 444 million 
(334–571) YLDs in females and 47·0% (46·8–47·2) or 
395 million (296–510) YLDs in males. Between 1990 and 
2017, all-age YLD rates increased for females and males, 
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Figure 2: Leading Level 3 causes of age-standardised YLD rates by location for both sexes combined, 2017
ATG=Antigua and Barbuda. COPD=chronic obstructive pulmonary disease. FSM=Federated States of Micronesia. Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. 
VCT=Saint Vincent and the Grenadines. YLD=years lived with disability.
Figure 3: Trends of age-standardised YLD rates per 100 000 for the top eight 
Level 3 causes of non-fatal burden in 2017 for each sex by SDI quintile, 
1990–2017
Mean estimates are shown. SDI=Socio-demographic Index. YLDs=years lived 
with disability. *One legend is shown for females and males. Anxiety disorders 
are a top cause of non-fatal burden for females and other musculoskeletal 
disorders are a top cause of non-fatal burden for males.
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by 6·5% (5·4–7·7) to 12 007·7 (9036·7–15352·0) YLDs per 
100 000 females and by 7·9% (6·6–9·2) to 10 328·1 
(7744·1–13 306·9) YLDs per 100 000 males.
Figure 5A illustrates the differences in global prevalence 
for females and males for 2017 by age group for the 
22 Level 2 GBD causes of non-fatal health loss, calculated 
as the female-specific estimate subtracted from the male-
specific estimate such that causes on the left side of the 
chart are more prevalent in females while causes on the 
right side of the chart are more prevalent in males in a 
given age group. Females experience overall higher 
prevalence in every age group and the highest age-specific 
global prevalence differences for female-predominant 
causes occur between the ages of 20 years and 49 years. 
From birth to 4 years of age, females have higher prevalence 
of other NCDs, which continues through all age groups, 
and of neoplasms than males, whereas neurological 
disorders are female predominant in all ages, becoming 
notably evident from age 5–9 years and continuing 
through out all subsequent age groups. Similarly, 
HIV/AIDS and sexually transmitted infections are female 
predominant in all ages, a trend that becomes evident 
from age 10–14 years. Although nutritional deficiencies are 
more prevalent in males in the earliest age groups up to 
age 9 years, they are more prevalent in females in sub-
sequent age groups up to age 74 years, at which point they 
once again become more prevalent in males up to the 
oldest age group. Females also have higher prevalence of 
self-harm and interpersonal violence starting from age 
1–4 years and continuing until age 84 years, after which 
they become more prevalent in males. Digestive diseases 
are more prevalent in males in all age groups, whereas 
unintentional injuries emerge as a male-predominant 
cause from 5 years of age and remain as such until age 
89 years, after which they become female predominant. 
Transport injuries are male predominant in all age groups 
starting from age 1–4 years. Respiratory infections and 
tuberculosis are male pre dominant in all ages. Cardio-
vascular diseases are male predominant starting from age 
50–54 years, whereas chronic respiratory diseases emerge 
as a male-predominant cause from age 65–69 years.
Figure 5B shows the sex differences in the global 
burden of YLDs for 2017 by age group for the 
22 Level 2 GBD causes of non-fatal health loss. Before 
age 10–14 years, males have greater YLD rates than 
females, driven largely by higher rates of nutritional 
deficiencies. From age 10–14 years and older, females 
have greater overall YLD rates in every age group. Under 
the age of 1 year, females experience higher YLD rates 
due to neoplasms and maternal and neonatal disorders, 
whereas male infants experience higher YLD rates due to 
nutritional deficiencies and other NCDs. Starting at age 
10 years, females experience a higher YLD rate due to 
other NCDs (until age 50–54 years), musculoskeletal 
disorders, mental disorders, neurological disorders, and 
chronic respiratory diseases. Males experience higher 
YLD rates due to unintentional injuries, transport 
injuries, and substance use disorders for most of life, 
although females older than 80 years of age experience a 
higher rate of unintentional injuries than do males. For 
self-harm and interpersonal violence, females experience 
higher rates than males until age 30–34 years, at which 
point males experience higher YLD rates. Males also 
experience higher YLD rates from neoplasms, cardio-
vascular diseases, and other NCDs starting in older age 
groups (≥60 years), and from digestive diseases from age 
25–29 years.
Figure 6 shows the extent to which males and females 
in region–cause combinations have diverged in terms of 
achieving equal change over time between 1990 and 2017. 
Each region–cause combination shows which sex has 
performed better over time either by decreasing more or 
by increasing less in terms of age-standardised YLD rates. 
Among the 462 region–cause combinations (excluding 
any “Global” or “All causes” combinations), females had 
more favourable outcomes over time for 260 combinations 
(56·3%), and males had more favourable outcomes for 
202 combinations (43·7%). The Z score, that is, the 
number of SDs from equality, was 0·433 for the mean 
deviation of female-favourable causes and 0·313 for the 
mean deviation of male-favourable causes.
Figure 7 shows the leading 20 causes of prevalence 
and YLDs for females and males separately for 1990, 
2007, and 2017, with percentage change. In 1990, the 
most common causes for females were oral dis-
orders, headache disorders, and haemoglobinopathies 
and haemolytic anaemias, whereas for males, the most 
common causes were oral disorders, headache disorders, 
and tuberculosis including latent tuberculosis. The 
number of prevalent cases in the top three leading causes 
for females increased by 23·1% (95% UI 21·8 to 24·5) for 
oral disorders, 31·5% (30·2 to 32·8) for headache 
disorders, and 29·9% (29·6 to 30·1) for haemo globino-
pathies and haemolytic anaemias between 1990 and 2007. 
Between 2007 and 2017, the number of cases increased 
further by 13·5% (12·9 to 14·1), 14·5% (13·8 to 15·3), and 
13·4% (13·2 to 13·6), respectively (figure 7A). Between 
1990 and 2007, for males, the number of prevalent cases 
of oral disorders increased by 21·6% (20·1 to 23·1), 
the number of headache disorders increased by 31·3% 
(29·9 to 32·8), and the number of prevalent cases 
of tuberculosis including latent tuberculosis infection 
increased by 26·2% (21·7 to 30·3). Between 2007 and 
Figure 4: Co-evolution of all-age and age-standardised YLD rates with SDI 
globally and for GBD regions for Level 1 causes for both sexes combined, 
1990–2017
Coloured lines are global and region values for YLDs. Each point in a line 
represents 1 year, starting from 1990 and ending in 2017. In all regions, SDI has 
increased over time so progress in SDI is associated with points further to the 
right and later years for a given region, with a downwards gradient indicating a 
reduction in YLD rate. The black lines indicate the trajectories for each geography 
expected on the basis of SDI alone. SDI=Socio-demographic Index. 
YLDs=years lived with disability.
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2017, the number of prevalent cases for these three causes 
increased by 12·5% (11·9 to 13·1), 14·3% (13·6 to 15·2), 
and 1·1% (−0·67 to 3·01), respectively (figure 7B). The 
age-standardised prevalence of the top cause for females, 
oral disorders, decreased by 3·8% (3·3 to 4·3) between 
1990 and 2007, and decreased by 1·3% (1·0 to 1·7) 
between 2007 and 2017. For the second and third top 
causes for females, the age-standardised prevalence 
decreased by 0·4% (−1·0 to 0·3) for head ache disorders 
and increased by 4·2% (4·0 to 4·4) for haemo -
globinopathies and haemolytic anaemias between 1990 
and 2007 and increased by 0·3% (0·1 to 0·6) and 0·8% 
(0·6 to 1·0), respectively, between 2007 and 2017. In 2017, 
oral disorders, headache disorders, and haemo globin-
opathies and haemolytic anaemias remained the top 
three leading Level 3 causes of global age-standardised 
prevalence for females. Between 1990 and 2007, the age-
standardised prevalence for the top three leading causes 
Prevalence in thousands, 1990 Prevalence in thousands, 2017 Percentage change, 1990–2017
Males Females Sex difference Males Females Sex difference Males Females
Substance use disorders 3008 
(2773 to 3237)
1439 
(1319 to 1557)
1·09 
(1·03 to 1·15)
3018 
(2782 to 3252)
1400 
(1279 to 1524)
1·16 
(1·09 to 1·23)
0·3% 
(−1·2 to 2·0)
−2·7% 
(−4·1 to −1·2)
Unintentional injuries 14 678 
(13 770 to 15 758)
10 230 
(9589 to 10 981)
0·43 
(0·40 to 0·47)
13 773 
(12 888 to 14 884)
9747 
(9148 to 10 484)
0·41 
(0·38 to 0·45)
−6·2% 
(−6·8 to −5·4)
−4·7% 
(−5·6 to −3·8)
Self-harm and 
interpersonal violence
3193 
(2893 to 3529)
5637 
(5058 to 6278)
0·43 
(0·39 to 0·48)
3265 
(2943 to 3630)
5643 
(5057 to 6302)
0·42 
(0·37 to 0·47)
2·3% 
(−0·1 to 4·9)
0·1% 
(−1·5 to 1·7)
HIV/AIDS and sexually 
transmitted infections
11 433 
(10 355 to 12 703)
18 320 
(16 789 to 19 998)
0·38 
(0·36 to 0·39)
11 902 
(10 826 to 13 196)
18 936 
(17 366 to 20 631)
0·37 
(0·36 to 0·39)
4·1% 
(3·3 to 4·9)
3·4% 
(2·6 to 4·1)
Transport injuries 3150 
(2924 to 3384)
2367 
(2189 to 2576)
0·33 
(0·30 to 0·37)
3322 
(3082 to 3582)
2336 
(2154 to 2535)
0·42 
(0·39 to 0·47)
5·4% 
(4·1 to 7·2)
−1·3% 
(−2·6 to 0·0)
Neoplasms 917 
(871 to 938)
1191 
(1167 to 1219)
0·23 
(0·21 to 0·27)
1188 
(1146 to 1244)
1355 
(1318 to 1391)
0·12 
(0·07 to 0·16)
29·6% 
(26·4 to 34·9)
13·8% 
(9·4 to 17·7)
Other non-communicable 
diseases
57 424 
(55 351 to 59 629)
73 370 
(72 026 to 74 850)
0·22 
(0·20 to 0·23)
55 565 
(53 542 to 57 701)
72 470 
(71 183 to 73 891)
0·23 
(0·22 to 0·25)
−3·2% 
(−3·7 to −2·8)
−1·2% 
(−1·5 to −1·0)
Maternal and neonatal 
disorders
1435 
(1264 to 1629)
1820 
(1643 to 2018)
0·21 
(0·18 to 0·25)
1953 
(1712 to 2208)
2288 
(2027 to 2586)
0·15 
(0·11 to 0·18)
36·1% 
(29·3 to 43·0)
25·7% 
(18·9 to 32·2)
Digestive diseases 26 590 
(25 678 to 27 503)
22 435 
(21 585 to 23 377)
0·19 
(0·17 to 0·20)
28 165 
(27 283 to 29 064)
23 417 
(22 581 to 24 342)
0·20 
(0·19 to 0·21)
5·9% 
(5·1 to 6·8)
4·4% 
(3·7 to 5·1)
Neurological disorders 36 664 
(34 401 to 39 294)
42 703 
(40 642 to 45 164)
0·14 
(0·13 to 0·16)
36 952 
(34 695 to 39 469)
42 718 
(40 688 to 45 034)
0·14 
(0·12 to 0·15)
0·8% 
(−0·1 to 1·6)
0·0% 
(−0·6 to 0·7)
Musculoskeletal disorders 15 247 
(14 414 to 16 131)
17 770 
(16 882 to 18 766)
0·14 
(0·13 to 0·15)
14 918 
(14 143 to 15 761)
17 581 
(16 745 to 18 503)
0·15 
(0·14 to 0·16)
−2·2% 
(−3·0 to −1·4)
−1·1% 
(−2·0 to −0·2)
Nutritional deficiencies 28 066 
(27 246 to 28 935)
31 354 
(30 605 to 32 153)
0·11 
(0·09 to 0·12)
23 473 
(22 648 to 24 309)
26 059 
(25 332 to 26 864)
0·10 
(0·08 to 0·11)
−16·4% 
(−18·0 to −14·6)
−16·9% 
(−18·0 to −15·8)
Diabetes and kidney 
diseases
10 920 
(10 428 to 11 489)
12 120 
(11 558 to 12 743)
0·10 
(0·09 to 0·11)
12 036 
(11 453 to 12 688)
13 044 
(12 444 to 13 733)
0·08 
(0·07 to 0·09)
10·2% 
(8·1 to 12·5)
7·6% 
(5·6 to 9·6)
Enteric infections 1115 
(1043 to 1189)
1216 
(1141 to 1292)
0·08 
(0·07 to 0·09)
1180 
(1096 to 1261)
1313 
(1221 to 1405)
0·10 
(0·09 to 0·11)
5·8% 
(2·8 to 9·1)
8·0% 
(5·0 to 11·3)
Respiratory infections and 
tuberculosis
33 220 
(29 889 to 37 160)
31 051 
(27 950 to 34 713)
0·07 
(0·06 to 0·08)
29 021 
(26 238 to 32 454)
27 301 
(24 756 to 30 428)
0·06 
(0·06 to 0·07)
−12·6% 
(−14·2 to −11·0)
−12·1% 
(−13·5 to −10·7)
Mental disorders 12 264 
(11 533 to 13 003)
13 237 
(12 584 to 13 938)
0·07 
(0·05 to 0·10)
12 010 
(11 338 to 12 694)
12 834 
(12 214 to 13 494)
0·06 
(0·04 to 0·09)
−2·1% 
(−2·7 to −1·4)
−3·0% 
(−3·6 to −2·5)
Cardiovascular diseases 6496 
(6261 to 6744)
6149 
(5904 to 6414)
0·06 
(0·05 to 0·07)
6253 
(6031 to 6482)
5939 
(5716 to 6177)
0·05 
(0·04 to 0·06)
−3·8% 
(−4·4 to −3·1)
−3·4% 
(−4·1 to −2·7)
Chronic respiratory diseases 7926 
(7441 to 8420)
8411 
(7890 to 8935)
0·06 
(0·05 to 0·07)
6731 
(6248 to 7268)
7267 
(6742 to 7825)
0·07 
(0·06 to 0·09)
−15·1% 
(−17·7 to −12·5)
−13·6% 
(−16·0 to −11·3)
Skin and subcutaneous 
diseases
25 139 
(24 328 to 26 021)
26 565 
(25 776 to 27 407)
0·05 
(0·05 to 0·06)
25 221 
(24 454 to 26 042)
26 592 
(25 832 to 27 377)
0·05 
(0·05 to 0·06)
0·3% 
(−0·4 to 1·0)
0·1% 
(−0·5 to 0·6)
Other infectious diseases 1574 
(1497 to 1661)
1633 
(1563 to 1709)
0·04 
(0·01 to 0·07)
1336 
(1273 to 1404)
1381 
(1330 to 1437)
0·03 
(0·00 to 0·07)
−15·1% 
(−18·8 to −11·3)
−15·4% 
(−18·1 to −12·7)
Neglected tropical diseases 
and malaria
29 748 
(28 431 to 31 138)
28 954 
(27 613 to 30 320)
0·03 
(0·02 to 0·03)
17 001 
(16 259 to 17 864)
16 834 
(16 104 to 17 681)
0·01 
(0·00 to 0·02)
−42·8% 
(−46·3 to −38·7)
−41·9% 
(−45·5 to −37·6)
Sense organ diseases 25 031 
(24 477 to 25 581)
25 473 
(24 949 to 26 007)
0·02 
(0·01 to 0·02)
24 868 
(24 325 to 25 411)
25 892 
(25 375 to 26 438)
0·04 
(0·03 to 0·04)
−0·7% 
(−0·8 to −0·5)
1·6% 
(1·4 to 1·9)
Data in parentheses are 95% uncertainty intervals. The relative difference for each of the 22 Level 2 causes between sexes were calculated using the values for females as the denominator. The causes are ranked 
by the value of the sex difference in 1990. All changes are significant.
Table 2: Global age-standardised prevalence rates per 100 000 for males and females for Level 2 GBD causes with the relative difference between the sexes for 1990 and 2017
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Figure 5: Sex differences in global prevalence and YLD rates per 100 000 for 22 Level 2 causes by age, 2017
The figure represents the difference in prevalence (A) and YLD rates (B) between males and females as well as the cause composition of those differences for each GBD age group for the Level 2 causes 
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for males decreased by 4·3% (3·8 to 4·9) for oral 
disorders, increased by less than 0·1% (−0·85 to 0·85) 
for headache disorders, and decreased by 3·1% (0·8 to 5·4) 
for tuberculosis including latent tuberculosis infection. 
Between 2007 and 2017, the age-standardised prevalence 
for males for oral disorders and tuberculosis further 
decreased by 1·6% (1·2 to 2·0) and 11·5% (10·1 to 12·8), 
respectively, whereas the age-standardised prevalence 
for headache disorders increased by 0·7% (0·4 to 0·9). 
In 2017, oral disorders, headache disorders, and tubercu-
losis including latent tuberculosis remained the three 
Level 3 causes with greatest global age-standardised 
prevalence for males.
In terms of numbers of YLDs, in 1990, the leading 
causes for both females and males were low back pain, 
headache disorders, and dietary iron deficiency (figure 8). 
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Figure 6: Absolute difference in non-fatal trend equality for males and females in terms of age-standardised YLD rates, 1990–2017
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Figure 7: Leading 20 Level 3 causes of global prevalence for 1990, 2007, and 
2017, with percentage change in number of cases and all-age and 
age-standardised rates for each sex
Causes are connected by lines between time periods; solid lines are increases and 
dashed lines are decreases. For the time periods 1990–2007 and 2007–17, three 
measures of change are shown: percentage change in the number of cases, 
percentage change in the all-age prevalence rate, and percentage change in the 
age-standardised prevalence rate. Communicable, maternal, neonatal, and 
nutritional diseases are shown in red; non-communicable causes in blue; and 
injuries in green. Statistically significant changes are shown in bold. COPD=chronic 
obstructive pulmonary disease. STIs=sexually transmitted infections.
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Figure 8: Leading 20 Level 3 causes of global YLDs for 1990, 2007, and 2017, with percentage change in number of YLDs and all age and age-standardised rates for each sex
Causes are connected by lines between time periods; solid lines are increases and dashed lines are decreases. For the time periods 1990–2007 and 2007–17, three measures of change are shown: 
percentage change in the number of YLDs, percentage change in the all-age YLD rate, and percentage change in the age-standardised YLD rate. Communicable, maternal, neonatal, and nutritional 
diseases are shown in red; non-communicable causes in blue; and injuries in green. Statistically significant changes are shown in bold. COPD=chronic obstructive pulmonary disease. YLDs=years lived 
with disability.
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For both males and females, the top two leading causes 
of global YLDs remained consistent between both time 
periods, during which the total number of YLDs for each 
of these causes increased. The third top cause in 2017 
was depressive disorders for females and diabetes for 
males. From 1990 to 2007, for females, the number of 
YLDs attributable to low back pain increased by 
29·8% (95% UI 27·7–31·8) and headache disorders 
increased by 34·0% (32·8–35·3). From 1990 to 2007, for 
females, the number of YLDs attributable to depressive 
disorders increased by 32·2% (29·8–34·4), causing 
depressive disorders to become the third leading cause in 
2007. The number of YLDs for the three leading causes 
for females continued to increase from 2007 to 2017, by 
17·3% (15·8–18·8) for low back pain, 15·3% (14·4–16·2) 
for headache disorders, and 14·1% (12·8–15·5) for 
depressive disorders. From 1990 to 2007, for males, the 
number of YLDs attributable to the top two leading 
causes increased by 30·2% (28·1–32·2) for low back pain 
and 34·1% (32·7–35·4) for headache disorders. From 
1990 to 2007, for males, the number of YLDs attributable 
to diabetes increased by 79·0% (75·8–82·2), causing 
diabetes to become the third leading cause. The number 
of YLDs for the three leading causes continued to climb 
from 2007 to 2017, increasing by 17·8% (16·5–19·3) for 
low back pain, 15·5% (14·5–16·5) for headache disorders, 
and 30·1% (24·8–36·1) for diabetes.
Between 1990 and 2007, age-standardised YLD rates 
for females decreased for the three leading causes: low 
back pain (by 7·6%, 95% UI 6·2 to 8·9), headache 
disorders (by 0·1%, −0·80 to 0·69), and dietary iron 
deficiency (by 18·8%, 17·0 to 20·7). Between 1990 and 
2007, the YLD rate for depressive disorders decreased by 
3·0% (1·6 to 4·5) and became the third leading cause of 
YLDs in females in 2007 due to the simultaneous large 
decrease in dietary iron deficiency (figure 8A). Between 
1990 and 2017, YLD rates for females decreased for low 
back pain (by 10·1%, 95% UI 8·8 to 11·3), depressive 
disorders (by 6·0%, 5·0 to 7·1), and dietary iron 
deficiency (by 30·7%, 27·4 to 33·7), while headache 
disorders increased by 0·6% (−0·19 to 1·42). Between 
1990 and 2007, the YLD rates for males decreased for 
low back pain (6·8%, 5·6 to 7·8) and dietary iron 
deficiency (15·1%, 10·9 to 18·9), and increased for 
headache disorders (1·1%, 0·15 to 1·9). Between 1990 
and 2007, the YLD rate for diabetes increased by 21·9% 
(20·0 to 24·0) and became the third leading cause of 
YLDs in males in 2007. From 2007 to 2017, the YLD rate 
for headache disorders increased by 1·5% (0·8 to 2·3) 
and that for diabetes increased by 4·2% (0·0 to 8·7), 
whereas the YLD rate for low back pain decreased by 
1·3% (0·7 to 1·9). Between 1990 and 2017, the YLD rate 
for low back pain decreased by 8·0% (6·9 to 9·1) and 
that for dietary iron deficiency decreased by 26·7% 
(20·6 to 32·5), whereas the rates for headache disorders 
and diabetes increased by 2·6% (1·6–3·6) and 27·0% 
(22·2–32·4), respectively.
Discussion
Main findings
While age-standardised all-cause global YLD rates 
decreased by less than 4% over the nearly three-decade 
period from 1990 to 2017, the number of total YLDs has 
increased by more than 50% during this time. This 
pattern is concerning given the lack of substantial 
improvement in age-standardised rates over time as well 
as the increased magnitude of total health loss. These 
patterns are probably related to population growth and 
ageing as well as increasing numbers of YLDs from 
conditions such as type 2 diabetes and opioid use 
disorders, which were less common in 1990. YLD 
increases, even when age-standardised rates are slightly 
improving, might pose a burden to economies and 
health-care systems that have not expanded proportionally 
to population growth or in populations where economic 
improvements have not been equitably distributed.
Globally, over the 28-year period studied, three chronic 
NCDs (low back pain, headache disorders, and depressive 
disorders) have prevailed as three of the top four leading 
causes of YLDs, collectively causing 162 million (95% UI 
118–216) YLDs in 2017 and representing nearly one in 
five YLDs globally. This substantial portion of global 
YLDs might be amenable to treatment and care access, 
because headache disorders and depressive disorders 
can be treated with low-cost therapeutics. The persistence 
of depressive disorders and low back pain is also 
concerning given the former’s relation with self-harm 
and the latter’s relation with potential loss of functional 
status in the work force.
Emerging trends
For the first time in the GBD study, we estimated the 
burdens of type 1 and type 2 diabetes separately. Our 
estimates illustrate the emergence of diabetes as a leading 
cause of disability globally, ranking as the fourth leading 
cause of age-standardised YLDs in 2017. This increased 
burden was observed across all levels of development. 
Age-standardised YLDs increased for both females and 
males across all SDI quintiles between 1990 and 2017 
(figure 3). Diabetes poses complicated care challenges 
even in areas with reliable access to medical services. 
Preventive measures such as pre diabetes screening, 
lifestyle modification, and treatment with low-cost 
medications such as metformin could avert worsening 
incidence rates, but as prevalence increases, health-care 
systems will also need to provide access to services such as 
wound care, surgical resources, medications including 
insulin, care for diabetic retino pathy, and increased focus 
on heightened cardiovascular disease risk.
This is also the first year of GBD estimation for non-
alcoholic fatty liver disease (NAFLD) and cirrhosis and 
liver cancer caused by non-alcoholic steatohepatitis 
(NASH). For cirrhosis and liver cancer caused by NASH, 
we estimated 892 million (95% UI 859–928) global 
cases for cirrhosis due to NASH and 97 400 cases 
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(86 800–108 000) for liver cancer due to NASH, and an 
age-standardised prevalence of 11 061 cases (10 651–11 493) 
per 100 000 for cirrhosis due to NASH and 1·20 cases 
(1·07–1·33) per 100 000 for liver cancer due to NASH in 
2017 (appendix 2), identifying NASH as an increasingly 
important cause of liver disease. We observed that these 
cases were distributed across all GBD regions, although 
more commonly in North Africa and the Middle East 
and in Oceania in terms of age-standardised rates. 
This expansion of NAFLD and liver disease due to 
NASH reflects the worsening burden of metabolic 
conditions globally. Given the complexity of chronic liver 
disease and the difficulty of effectively treating obesity, 
efforts to prevent obesity and to develop therapeutics for 
NAFLD will be increasingly important.
After initial steep reductions in HIV incidence between 
1998 and 2005, the global rate of decline in new HIV 
infections continues, although it has slowed in recent 
years and global prevalence has increased slightly since 
2010, a trend which is probably driven by rapid expansion 
of antiretroviral therapy in high-prevalence countries and 
extended life expectancy of people living with HIV. These 
longer lifespans call for increased resources for treatment 
and continued prevention and treatment interventions to 
maintain declines in incidence.27 For tuberculosis, it is a 
notable success that drug-susceptible tuberculosis has 
declined in terms of age-standardised incidence since 
1990. The burden of malaria has also declined since the 
mid-2000s in terms of age-standardised incidence rates. 
High age-standardised incidence rates of acute viral 
hepatitis have persisted, however, with age-standardised 
incidence rates of hepatitis A and B combined exceeding 
malaria incidence in 2017 despite availability of vaccines. 
The age-standardised incidence rate of acute hepatitis 
did not significantly change from 1990 to 2007, from 2007 
to 2017, or from 1990 to 2017, suggesting that more 
proactive global initiatives are important, particularly 
with respect to vaccine coverage28 and cost-effective 
access to hepatitis C curative treatments.29–31
Incidence rates of lower respiratory infections (LRIs) 
declined among children younger than 5 years by 
32·4% (95% UI 27·2–37·5) since 1990 and caused 
83·0 million (66·4–101) episodes in children younger 
than 5 years in 2017, while the age-standardised incidence 
rate decreased by 5·8% (1·5–10·0) between 1990 and 
2017 (appendix 1). Among all ages, pneumococcal 
pneumonia has prevailed as the leading aetiological 
subtype of LRI, accounting for more than five times 
more YLDs than the second leading cause (influenza). 
Diarrhoeal episodes have persisted as the second most 
common incident cause of health loss after upper 
respiratory infection among all ages, with 6·29 billion 
(5·81–6·82) total episodes in 2017, with rotavirus pre-
vailing as the leading aetiology. The age-standardised 
incidence of diarrhoea varied nine-fold across GBD 
regions, with the lowest rates in Australasia and the 
highest rates in Oceania (appendix 2). The burdens 
of pneumococcal pneumonia and rotavirus diarrhoea 
are notable given the availability of vaccines for these 
pathogens, highlighting the need for continued expan-
sion of vaccine coverage and delivery systems.
While the burden of musculoskeletal disorders, vision 
loss, and hearing loss in older ages has been a consistent 
theme in past GBD studies due to their substantial 
contribution to non-fatal health loss, the burden of 
medically complex, high-resource conditions has also 
become increasingly concerning. Cardiovascular disease, 
chronic respiratory conditions, and neurological disorders 
sum to form more than 15% of age-standardised YLDs in 
every GBD region except two (southern Latin America 
and eastern sub-Saharan Africa; appendix 2). GBD risk 
factor estimates show that the drivers for atherosclerotic 
cardiovascular diseases—high systolic blood pressure,32–34 
high cholesterol, poor diet,35 high fasting plasma glucose,35 
and low physical activity36—prevail in many geographies, 
indicating that this burden can be expected to persist and 
possibly expand as populations age. While the efforts of 
primary prevention approaches such as statin therapy and 
smoking cessation are evident in the gradual declines in 
age-standardised prevalence in high-income countries 
over the past 28 years, the prevalence of cardiovascular 
disease in these popu lations still remains high, which 
might also reflect improved survival from acute events 
due to improved response systems and interventions such 
as percutaneous coronary intervention, coronary artery 
bypass grafting, and rapid stroke treatment guidelines,37–40 
as well as secondary prevention with statins, anti-
hypertensives, and smoking cessation.41–46 As developing 
economies increas ingly experience cardio vascular disease 
burden, investing in health system infrastructure to 
ensure access to these interventions as well as to primary 
prevention therapeutics could help to mitigate disability 
and improve survival into older ages.40,47,48 Chronic 
respiratory conditions also inflict considerable health loss 
in older people, contributing to more than 5% of YLDs 
starting in the 50–54 year age group, globally, who were 
exposed to risk factors such as smoking and indoor air 
pollution and similarly pose challenges to health systems 
with ageing populations, given the importance of oxygen 
therapy,49–52 access to medical care,53–55 and the risk of 
respiratory infections among these patient populations.56,57 
Neurological con ditions continue to show large numbers 
of prevalent cases and YLDs, with consistent increases in 
recent years. We anticipate that this burden will also 
expand as populations age, creating challenges for health-
care systems given the lack of modifiable risk factors for 
some neurological conditions and effective treatments 
for conditions such as Alzheimer’s disease. Given the 
extensive care requirements these conditions—in iso-
lation or as comorbidities—demand from both health 
systems and social and familial supports, their morbidity 
can reflect not only diminished health for an individual 
and population but also lost capital in an economy and 
among caretakers.58–63
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Opioid use disorders including opioid dependence 
have become an era-defining epidemic in the USA with 
more than 4 million prevalent cases in 2017. Outside the 
USA, opioid dependence was estimated to cause more 
than 1% of age-standardised YLDs in 135 countries in 
2017, whereas in 12 out of 21 GBD regions, more than 
5% of YLDs in the 15–49 year age group were caused by 
substance use disorders overall (appendix 2). Cumu-
latively, these results show pervasive health loss from 
substance use, which might also cause lost human 
capital given the concentration of the burden in working 
ages. The burden of mental disorders is present in 
both sexes and across all age groups after emerging 
in childhood with idiopathic intellectual disability 
and autism spectrum disorders and continuing into 
older ages with depressive disorders, anxiety disorders, 
and schizo phrenia. Mental disorders have consistently 
formed more than 14% of age-standardised YLDs 
for nearly three decades, and have greater than 
10% prevalence in all 21 GBD regions. These findings 
substantiate a global need for increased mental health 
and substance abuse treatment re sources, improved 
judiciousness of opioid prescribing patterns particu-
larly for chronic pain, and expanded harm-reduction 
strategies such as opioid substitution therapy and 
needle programmes.
Cross-cutting themes
Among the 22 causes in the Level 2 GBD cause hierarchy, 
14 causes had a relative difference between males and 
females greater than or equal to 10% in terms of prevalent 
cases in 2017, while 12 causes had a relative difference 
greater than 10% in terms of age-standardised prevalence. 
Notably, females had significantly higher prevalence of 
HIV/AIDS and sexually transmitted infections (driven 
primarily by higher burden from sexually transmitted 
infections) and self-harm and interpersonal violence, 
among other causes, whereas males had significantly 
higher prevalence of substance use disorders and trans-
port injuries, among other causes. Figure 6 illustrates 
how divergent trends were nearly evenly distributed 
between males and females, despite the overall higher 
numbers of YLDs experienced by females. As indicated 
by the higher Z score in female-favourable causes, the 
cause-regions where females did better over time tended 
to have greater improvements in age-standardised YLD 
rates than did the cause-regions where males did better 
over time. There were important exceptions, however: 
for example, with HIV/AIDS and sexually trans mitted 
infections in central sub-Saharan Africa, the age-
standardised YLD rates for females increased by 30·0% 
(95% UI 6·8–68·1), while rates for males decreased 
by 43·0% (23·2–58·5) between 1990 and 2017. This 
particular trend reveals a striking lapse in health equity 
given the extensive knowledge of treatment and 
prevention methods for HIV/AIDS and many sexually 
transmitted infections.
These observations imply that health systems might 
have achieved improvements in non-fatal burden that 
have not been shared across sexes. The underlying 
reasons for these imbalances are likely to be complex. 
For causes that are inherently more common in males 
or females, improvements in one sex over the other 
might reflect these causes differing in susceptibility to 
prevention, intervention, and treatment. For example, 
autoimmune conditions such as rheumatoid arthritis 
can affect both males and females but are ordinarily 
more common in females.64,65 However, such a cause still 
leads to increased disability that might also have 
ramifications not captured in a health study, such as 
income loss due either to disability at young ages or to 
the cost of modern immunotherapies. Similarly, females 
of childbearing age experience risk of pregnancy-related 
and maternal conditions, risks that could be pronounced 
in lower-resource settings without sufficient access to 
modern obstetric facilities and follow-up care.66,67 Other 
causes have firmly established causal risk factors such as 
smoking and chronic obstructive pulmonary disease 
(COPD), where the higher COPD rates in males are 
probably due to historically higher rates of smoking 
compared with females. Additionally, some causes 
may be susceptible to systematic misdiagnosis due to 
conventional clinical heuristics based on flawed or non-
existent evidence. For example, in some areas, females 
presenting with acute coronary syndrome are more 
commonly misdiagnosed,68 whereas other causes, such 
as autism spectrum disorders, might be systematically 
underdiagnosed in females compared with males.69–71 
These biases in sex-specific misdiagnosis emphasise the 
need for continued refinement in sex-specific burden 
estimation.
While YLD rates are highest in older ages, globally, 
YLD counts are heavily concentrated in working-age 
males and females (ie, from 20–54 years), a pattern which 
is particularly evident among causes such as mental 
disorders, neurological disorders, and musculoskeletal 
disorders, which sum to more than 45% of all YLDs in 
these age groups. This finding is notable for two main 
reasons. First, these age groups have a considerable 
number of years to live that would otherwise be in full 
health, emphasising how conditions at these ages, even 
if having lower disability weights, can still contribute 
substantially to the non-fatal burden. Second, a disabling 
condition that occurs during this period of life could 
represent lost human capital. This loss will be 
increasingly important to characterise with human 
capital emerging as an important area of focus at the 
World Bank.72,73
In GBD 2017, anaemia is classified as an impairment, 
with aetiologies ranging from rare genetic haemo globino-
pathies to iron deficiency. Because these aetiologies 
alone could cause a relatively small proportion of all 
anaemia cases, the magnitude of anaemia’s burden 
would be obscured by the granularity of these aetiologies 
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if it was not also estimated in aggregate. In 2017, the sum 
of YLDs across all causes of anaemia was 58·2 million 
(95% UI 39·5–83·0), with a global age-standardised rate 
of 783·9 YLDs (531·3–1117·8) per 100 000 for both sexes, 
with sex-specific rates of 1012·8 YLDs (689·4–1436·5) per 
100 000 females, and 555·9 YLDs (370·4–801·8) per 
100 000 males. Globally, in terms of YLD rates in 2017, 
anaemia is the leading impairment for females, males, 
and both sexes combined. If anaemia were treated as a 
cause, it would rank as the fourth leading Level 2 cause 
and as the first leading Level 3 cause in terms of age-
standardised YLD rates globally for females in 2017. The 
third leading impairment for males, females, and both 
sexes combined was blindness and vision impairment 
(1·34 billion [1·29–1·39] cases in 2017), which is notable 
given the economic consequences of vision loss,74,75 the 
relative treatability of many vision loss conditions, and 
the increased risk of injury that stems from visual 
impairment.76,77 Summed together, the impairments 
included in the GBD cause hierarchy comprise a total of 
more than 5 billion prevalent cases worldwide in 2017, 
making it evident that health-care systems and policy 
makers should evaluate non-fatal burden not only for 
diseases and injuries but also for impairments and their 
aetiologies.
Important changes in GBD 2017 compared with 
GBD 2016
Overview
Overall, the most important systemic change to this year’s 
study is the estimation of population and fertility in the 
GBD framework. In addition, we made changes to the 
GBD cause hierarchy (for example adding an aggregate 
Level 3 headache disorders cause), which limits certain 
cause-specific comparisons with past GBD cycles; this is 
discussed in more detail in the Limitations section below. 
Other notable cause-specific considerations, comparisons, 
and limitations that are new as of GBD 2017 are as 
follows. More details for each cause can be found in the 
supplementary methods (appendix 1 section 4).
Cause-specific considerations, comparisons, and limitations
In GBD 2017, we added the Malnutrition and Enteric 
Disease (MAL-ED) study to our existing use of the Global 
Enteric Multicenter Study (GEMS)78–80 to measure diar-
rhoeal aetiologies, which affected our aetiological 
distributions with increased norovirus and rotavirus 
attributions. Our overall diarrhoea incidence estimates 
were not affected. The Walker and colleagues’ study81 
estimated 1·7 billion episodes of diarrhoea among 
children younger than 5 years in 2010, a value that is 
greater than the GBD 2017 estimate in the same year 
(1·16 billion, 95% UI 1·00–1·34). For pneumonia, a study 
by Rudan and colleagues82 estimated a global pneumonia 
incidence of 0·22 episodes (IQR 0·11–0·51) per child-
year among children younger than 5 years in 2010, 
accounting for 122·6 million episodes, a value that is 
greater than the GBD 2017 estimate of 94·5 million 
(79·5–112). These two studies are part of the Maternal 
and Child Epidemiology Estimation (MCEE). The MCEE 
methodology for diarrhoea and pneumonia incidence 
differs from GBD in that MCEE uses only community-
based studies. By contrast, the GBD uses a greater 
volume of data including Demographic and Health 
Surveys, Multiple Indicator Cluster Surveys, and clinical 
data records. We also used diarrhoea-specific and LRI-
specific summary exposure values as covariates in our 
models, which include location-specific and year-specific 
estimates of risk factors associated with diarrhoea or LRI. 
We observed that these covariates had significant 
relationships with diarrhoea and LRI incidence rates and 
therefore strengthened our estimates, particularly in 
data-sparse areas. Further modelling details are described 
in the supplementary methods (appendix 1 section 4).
For HIV/AIDS, we used new methods to adjust for 
representativeness bias in ANC surveillance data,83 which 
led to our models predicting a lower peak and flatter 
trend of the epidemic in southern sub-Saharan Africa 
compared with GBD 2016. We updated our inputs of 
antiretroviral therapy coverage distribution informed by 
data from the International Epidemiology Databases to 
Evaluate AIDS and CD4+ progression parameters for 
children.84,85 We also improved our sex-specific modelling 
strategy in Spectrum by sex-splitting incidence based on 
a model fit to the sex ratio of prevalence observed in 
countries with representative surveys. Our estimated 
global prevalence results are similar to UNAIDS 2017 
values, with some variation at the national level. 
Estimates in recent years are expected to be less stable 
due to improvements in HIV treatment coverage and 
prevention. Further modelling details are described in 
the supplementary methods (appendix 1 section 4).
The hepatitis estimation process has changed to 
improve internal consistency between mortality and non-
fatal estimates for GBD 2017. First, we included case-
fatality rates from clinical data in our mortality models to 
improve the distribution of hepatitis deaths by virus. 
Second, we developed a time series of hepatitis B 
virus vaccine coverage in infants to use as a covariate. 
Third, the aggregate cause-specific mortality rate of acute 
hepatitis, cirrhosis, and liver cancer due to hepatitis B 
and hepatitis C was combined with virus-specific sero-
prevalence data to ensure internal consistency among 
incidence, prevalence, remission, and excess mortality 
rates. Fourth, the prevalence of chronic hepatitis B and C 
are now captured in the cirrhosis and other chronic liver 
diseases cause group rather than in the prevalence 
estimates for acute hepatitis B and acute hepatitis C. 
Overall, this caused prevalent cases of hepatitis B and C to 
be shifted from the acute hepatitis B and C causes to 
the cirrhosis and other chronic liver diseases cause. 
Specifically, in terms of global age-standardised prevalence 
rates for both sexes in 2016, acute hepatitis B decreased 
from 6295 cases (95% UI 5349–7436) per 100 000 in GBD 
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2016 to 219 cases (193–248) per 100 000 in GBD 2017, while 
its corres ponding chronic cause, cirrhosis and other 
chronic liver diseases due to hepatitis B, increased from 
170 cases (159–184) to 5625 cases (5159–6118) per 100 000. 
Similarly, acute hepatitis C decreased from 2152 cases 
(1927–2382) per 100 000 in GBD 2016 to 8·11 cases 
(7·37–8·98) per 100 000, while its corresponding chronic 
cause, cirrhosis and other chronic liver diseases due to 
hepatitis C, increased from 149 cases (136–164) to 
1723 cases (1517–1969) per 100 000 (appendix 2).
Maternal, neonatal, and child health
Several changes were adopted for GBD 2017. Adding 
clinical and claims records from outside the USA to 
our models affected congenital birth defects, haemo-
globinopathies, and maternal disorders. Updating our 
inpatient admission per-capita estimates to include in-
facility deliveries as a newborn admission affected neonatal 
disorders and congenital birth defects. Adopting in-facility 
delivery estimates for processing clinical data for maternal 
disorders led to lower estimates of pregnancy compli-
cations, especially in high-utilisation settings. We refined 
our method for estimating age-specific preterm birth and 
its complications to be consistent with GBD risk factor 
analysis, which resulted in preterm birth prevalence being 
higher than in previous GBD estimates. We enforced 
internal consistency among our estimates such that, for 
example, the sum of all specific types of congenital heart 
disease must equal the total number of cases of congenital 
heart disease. These methodological changes have lowered 
global estimates for many of the specific causes of birth 
defects, enforced the internal consistency of mortality and 
non-fatal estimates, narrowed the unexplained geo-
graphical variation in disease incidence, and strengthened 
the empirical re lationship with known environmental, 
nutritional, and behavioural deter minants of these con-
ditions. For nutri tional deficiencies, we extended our 
analysis of protein-energy malnutrition past age 5 years, 
incorporated cause-specific mortality rates, and included 
the prevalent cases of moderate wasting without oedema. 
Although the net result might seem to be an increase in 
the number of protein-energy malnutrition cases, it 
instead reflects a more comprehensive assessment of 
acute malnutrition than was estimated previously.
Diabetes
Diabetes has been estimated in previous GBD studies, 
but this is the first year that type 1 and type 2 diabetes 
were estimated and reported separately. The estimation 
strategy for diabetes is provided in more detail in the 
supplementary methods (appendix 1 section 4), but in 
summary, we measured overall diabetes and type 1 
diabetes. We subtracted estimates of type 1 from overall 
diabetes to produce estimates for type 2 diabetes. One of 
the main limitations to measuring type 2 diabetes is that 
surveys of diabetes in adults do not make a distinction 
between cases of type 1 and type 2 diabetes.
NASH and NAFLD
In GBD 2017, for the first time we estimated NASH as a 
cause of liver cancer and cirrhosis and NAFLD as an 
asymptomatic health state. Our global age-standardised 
prevalence estimate of NAFLD and NASH that leads 
to cirrhosis or liver cancer was 10 935 cases (95% UI 
10 522–11 365) per 100 000 in 2017, which was lower than 
a study by Younossi and colleagues,86 which estimated a 
global prevalence of 24%. This difference is due to how 
we adjust for alcohol use in the population, which helps 
to distinguish these conditions from alcohol-driven liver 
disease. Our study shows a similar geographical pattern 
to the Younossi study, with higher rates in North America 
and the Middle East, corresponding to higher rates 
of obesity.
Cardiovascular diseases
We split haemorrhagic stroke into subarachnoid 
haemor rhage and intracerebral haemorrhage as sub-
types of stroke and added non-rheumatic valve disease 
as an additional cause and aetiology of heart failure. The 
overarching limitation in cardiovascular estimation is 
that low-income and middle-income locations are less 
likely to have diagnostic tests such as treadmill tests, 
ankle-brachial index measurement, and other modern 
diagnostics. This also limits the identification of 
preclinical atherosclerotic disease for individuals who 
have not had clinical events but who might have 
ischaemic changes with provocative cardiac testing. For 
stroke, there were few sources of incidence data in 
many low-income and middle-income countries, and 
many clinical records used the ICD code for “acute, 
unspecified stroke”, which does not differentiate 
between ischaemic stroke, intracerebral haemorrhage, 
and subarachnoid haemorrhage. Future incorporation 
of more clinical record data might help to address these 
limitations by providing more diagnostic detail for 
cause subtypes.
Chronic respiratory diseases
We added several data sources that had lower estimates 
than the International Study of Asthma and Allergies in 
Childhood studies, which were the main source of 
asthma prevalence previously. Additionally, the adjust-
ment factor for studies reporting on physician-diagnosed 
asthma without an additional question on wheezing 
changed between GBD 2016 and GBD 2017 after new 
data sources were added.
Neurological conditions
For dementia, we added covariates for whether studies 
had common features present in their diagnostic protocol, 
such as a review of clinical records or a diagnosis by a 
clinician to try to correct for some of the heterogeneity 
between studies, because only a very small fraction of 
studies used the same methods. We do not have reliable 
covariates for prevalence or incidence of dementia and 
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other neurological disorders, although in future studies, 
estimates of neurological disorders will benefit from the 
increased use of clinical and claims records.
Cancer
For GBD 2017, we added the new cause “myelodysplastic, 
myeloproliferative, and other haemopoietic neoplasms”, 
which were previously estimated as part of the “other 
neoplasms” group. In addition, we added new causes 
for three categories of benign and in-situ neoplasms: 
intestinal, cervical and uterine, and other.
Mental and substance use disorders
We estimated burden for a combined group of autism 
spectrum disorders consistent with the Diagnostic and 
Statistical Manual of Mental Disorders 5 designations in 
GBD 2017 as opposed to separately estimating autism 
and Asperger’s syndrome and other autism disorders.87 
Modelling improvements were made for opioid use 
disorders by incorporating new country-level covariates, 
including a measure of opioid analgesic consumption by 
country and the prevalence of injection drug use. 
Enhancements in the fatal modelling of opioid use 
disorders also contributed to these improved estimates. 
Improvements were also made in terms of data additions, 
particularly for cocaine and amphetamine dependence, 
where new data showed greater subnational variation in 
Mexico and Brazil.
Injuries
For GBD 2017, improvements were made to the com-
putational framework required for injuries non-fatal 
measurement. These updates included incorporating 
GBD 2017 age groups and updating the differential 
equation solver for converting incidence to prevalence. 
Poisoning was divided into the two subcauses of 
poisoning by carbon monoxide and poisoning by other 
agents. Our estimate of 172 million (95% UI 152–194) 
falls per year resulting in any short-term or long-
term disability was higher than those of WHO, which 
estimated 37 million falls88 that required medical 
attention per year—a difference that might be explained 
by GBD’s inclusion of a wide spectrum of injury 
severities including minor injuries that result from falls. 
The WHO and GBD estimates on road injuries were 
more similar, with WHO estimating 20–50 million 
people experiencing non-fatal road injuries per year89 and 
GBD 2017 estimating 54·2 million (47·4–61·6) road 
injuries in 2017. For fires, WHO and GBD 2017 had 
similar estimates when comparisons were available—for 
example, in the USA, WHO reported 410 000 burn 
injuries90 in 2008 and GBD 2017 reported 360 000 
(313 000–380 000) fire, heat, and hot substance injuries.
Limitations
As is evidenced in figure 1 and the supplementary 
methods, there is considerable heterogeneity in terms of 
data density for each Level 1 location-cause combination 
in the GBD study. Data availability does not consistently 
correlate with burden—that is, high-burden causes and 
locations can have relatively sparse data for non-fatal 
outcomes. This will also be increasingly problematic 
as more countries start to experience greater burden 
from NCDs.
Currently, we inform most of the severity distributions 
that affect YLD calculation using the Medical Expenditure 
Panel Survey from the USA. This poses a limitation as 
the severities experienced in this population probably do 
not reflect global severity distributions or reflect that 
severity distributions are likely to vary over time, location, 
age, and by treatment access. As such, YLDs estimated 
might not reflect improvements in disability over time as 
SDI increases. Even for the limited diseases such as 
COPD, epilepsy, and stroke for which data from epi-
demiological studies allow us to differentiate severity by 
age, time, and location, the underlying data sources are 
still extremely limited in coverage by age, time, and 
location. Relying on published data on severity is unlikely 
to provide improved estimates in the near future. We also 
plan to access linked data between administrative records 
with diagnostic information and health surveys using 
health status measures to quantify severity of disease and 
how this changes over time and by age and sex.
Comorbidity adjustment in GBD 2017 assumes inde-
pendent distributions of comorbid conditions. This is a 
limitation because comorbidity distributions are known 
to vary by cause, age, sex, location, and time. For example, 
diabetes and cardiovascular disease are more likely to be 
comorbid than asthma and gynaecological disorders but 
currently our comorbidity adjustment does not capture 
these correlations.
Clinical data records have known selection bias for 
subsets of the population that have access to health care. 
Some GBD causes rely heavily on clinical data given the 
lack of other sources, with efforts made to correct for this 
bias by using representative studies as a reference group. 
In recent years, the GBD study has used USA claims 
records to inform hospital data adjustments and various 
other elements of GBD estimation. Relying on data from 
a privately insured cohort in a high-income country 
poses limitations to the generalisability of these adjust-
ments. This year, we also used tabulated claims records 
from Taiwan (province of China) for the first time in the 
GBD study, and in future publications we plan to 
continue incorporating claims data from additional 
countries to address this limitation. Acquiring further 
health insurance claims data will not only inform 
estimates in terms of incidence and prevalence measures 
but will also help to develop more accurate parameters 
that affect GBD estimates in other modelling steps.
With regard to age-time patterns, in DisMod-MR 2.1, 
we start by estimating a global model that uses all the 
available data and covariates with hierarchical random 
effects for geographies to estimate a prior distribution 
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that is passed down the geographical cascade. Time 
trends in our estimates result from where the covariates 
are changing over time, when year is included as a 
covariate or when data in different time periods lead 
to variation in the posterior estimates. This frame-
work, however, does not capture true cohort effects. 
For example, we do not directly take into consideration 
prevalence in 30-year-olds in 1990 when estimating 
prevalence in 50-year-olds in 2010. This is a limitation for 
some diseases with known cohort effects such as the 
high incidence of hepatitis C in the USA in younger 
adults in the 1970s. We are continuing to develop a 
version of DisMod that explicitly incorporates a full age-
time-period model in a Bayesian framework that will 
help to address this issue.
While our cause list currently specifies 354 diseases 
and injuries, there is great interest in incorporating a 
greater level of detail. Going forward, we intend to 
become more granular in our cause list, but every new 
disease requires a substantial amount of new reviews 
and model building. In consultation with our Scientific 
Council, we will need to balance our available resources 
with this growing list of priorities for new additions.
Similar to the cause reporting list, the hierarchy of the 
cause list and the method by which conditions are 
classified and grouped is a complex component of the 
GBD framework that has undergone nearly continuous 
improvement and refinement in years past. Grouping 
GBD causes into broad cause groups is a necessary part 
of the study’s estimation and reporting process, but it 
can also cause limitations and challenges in the absence 
of broad consensus on objective frameworks for 
organising cause hierarchies. Other studies that measure 
burden of disease exemplify how disease groupings can 
affect a study’s implications and interpretation. A recent 
study91 cited medical errors as the third leading cause 
of death in the USA but grouped all heart disease and 
all cancer as the first and second leading causes, 
respectively. A different aggregation or level of detail in 
terms of the disease grouping in such a study could 
change these rankings, which become important in the 
realm of health policy and resource allocation as well as 
popular and political perception of what causes death 
and disability in a population. In the GBD study, we have 
strived to retain as much detail as is methodologically 
possible given available data, and additionally we have 
incorporated input from the GBD collaborator network 
in terms of refining our cause hierarchy to represent a 
heterogeneous mix of medical specialties, research 
expertise, and location-specific knowledge. In addition, 
our framework allows us to revise the cause hierarchy 
for specific specialties such as the burden of neurological 
disorders.92
Future directions
The methods and data that inform YLD estimation in the 
GBD study will continue to evolve. Several specific 
improvements have been suggested by the GBD collab-
orator network and the global research community, and 
the following future directions are planned to be 
incorporated in the coming cycles.
Because the GBD cycle continues to be published on 
an annual basis, it will be important to incorporate 
updated data sources for older estimation years but also 
to add sources for the most recent estimation year. This 
necessitates data inclusion immediately after the end of 
the calendar year in order to be incorporated for the 
following year’s estimation. This is challenging because 
some surveys, surveillance systems, and literature 
studies have a lag period between data collection and 
publication. One solution to this challenge would be 
adding, updating, and incorporating clinical data records 
from inpatient and outpatient visits from hospitals 
and clinics from more locations. Clinical data provide a 
level of detail, demographic information, and diagnostic 
accuracy that enhances the GBD study’s ability to 
produce accurate estimates in the more recent estimation 
years. Relying more heavily on clinical data will require 
improved methods for adjusting for known repre-
sentativeness biases. In the future, we plan to link 
medical records to representative survey results, which is 
possible with certain claims databases such as the 
Medicare Current Beneficiary Survey in the USA.93
In the next iteration of the GBD study, we plan to 
incorporate improved age-time estimation using a new 
tool, DisMod-AT, that simultaneously quantifies the 
relationships over time, by age, and by age cohorts. 
DisMod-AT will address the age-time measurement 
limitation described above.
We plan to continue updating and refining our cause 
and location hierarchies including the causes described 
above. This is the first year that estimates for a non-geo-
graphical subnational grouping (ie, Māori and non-Māori 
populations in New Zealand) were modelled, and in 
future GBD studies it would be compelling to similarly 
estimate disease burden in groups within a location not 
strictly determined by geographies—for example, race 
groups within the USA or refugee populations in host 
countries.
Conclusion
The global burden of non-fatal health loss in 2017 
represents a complex culmination of nearly three decades 
of evolving disease patterns and risk factor profiles, 
improving health care, and dynamic populations. This 
study provides comprehensive updates from prior GBD 
studies and identifies topical themes that can be used to 
guide future research and discussion in the arena of non-
fatal health loss. Continuing a trend from throughout 
the history of the GBD study, we show how YLDs 
continue to increase as countries improve along the 
develop ment spectrum and emphasise how economies 
should anticipate difficulties in caring for older popu-
lations suffering from complex conditions such as 
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diabetes, respiratory and cardiovascular diseases, and 
neuro logical conditions. Additionally, we report hetero-
geneity in outcomes experienced across different sexes, 
geo graphies, and income levels, and identify regions and 
causes where sexes have had divergent health trends over 
time. These findings should help to focus prevention 
and treatment efforts on groups and areas that have 
experienced inequitable health outcomes. Continuing 
the theme of health equity, we highlight the extensive 
amount of health loss experienced globally for conditions 
that are treatable or preventable such as viral hepatitis, 
emphasising the profound impact that health-care 
systems can produce with increasing investment in and 
access to health-care resources. Finally, we emphasise 
the burden of non-fatal health loss in younger and 
middle ages, where it is speculated that non-fatal health 
loss could ultimately lead to loss in human capital.
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